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Decision making in a healthcare system 
Decision making in any healthcare system potentially has both immediate and long-
term impacts on public health outcomes, patient quality of life, and healthcare budgets. 
It is an important process that helps policymakers choose appropriate new healthcare 
programs, interventions, or services by guiding them to consider the available resources 
in order to achieve the objectives of good healthcare governance. Reimbursement 
decision making is an outstanding example of governance in a healthcare system as it 
plays an essential role in the efficient allocation of resources.  
Reimbursement decision making 
The main objective of decisions regarding reimbursement (insurance coverage) of new 
health technologies is to provide patient access to various healthcare services in an 
affordable manner. There are a wide variety of policies throughout the world for 
reimbursement of services in a healthcare system. It would not be a far-fetched 
assumption to say that in all of these policy frameworks, the decision makers inherently 
would like to provide the best patient access along with affordable healthcare services. 
However, the final outcomes of different decisions cannot always be exactly what the 
policymakers had expected to achieve due to uncertainties about the decisions that 
were made.[1] Positive or negative consequences of reimbursement decision making 
are derived from the level of uncertainties that policymakers are facing in decision 
making based on their initial knowledge. 
Health technology assessment (HTA) techniques are widely used in high-income 
countries (HICs) in order to improve predictability and reduce the uncertainties in 
reimbursement decision making. HTA helps policymakers make a more reliable decision 
by providing different types of studies such as: 
- Cost-effectiveness studies to assess health gains relative to the costs of different 
health interventions.[2] 
- Budget impact studies to estimate the financial consequences of approving a 
new intervention.[3] 
- Health equity studies to investigate the unfair and preventable or remediable 
disparities in health services and outcomes among groups of people.[4] 
- Burden of disease studies to measure population morbidity and mortality.[5] 
- Evidence-based medicine studies to improve decisions by individual doctors 
about individual patients.[6] 
One important aspect of the knowledge based decision making is the cost-effectiveness 
of a new technology compared to the current routine practice [2]. In fact, a cost-
effectiveness analysis (CEA) is the core of an HTA study. In one outer layer of this core, 
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different types of knowledge such as budget impact, burden of disease, and equity 
analyses are included. These all help policymakers estimate the necessary financial 
resources and set priorities for new interventions. Subsequently, in an ideal situation, 
this knowledge should be applied in a framework called a multiple criteria decision 
analysis (MCDA) to make a reimbursement decision considering the relative importance 
of criteria obtained from the previously defined knowledge.[7] Conducting systematic 
approach for reimbursement decision making is expected to mostly result in better 
consequences corresponding with the goals of decision making.  
Overall goals of a reimbursement decision-making system 
The goals of a reimbursement decision-making system can be variously defined, 
depending on the differing perspectives of patients, healthcare professionals, and 
policymakers. What is clear is that the ultimate goals should include the rational 
expectations of all involved parties. However, there are always issues such as limited 
financial resources that cause decision making to be more complex. Actually, the art of 
decision making is a constant balancing act between various expectations and available 
resources. This means that proper reimbursement decision making happens when it 
can concurrently pursue these three main goals: [8] 
1- Quality of care, focusing on patient centralization, reliability, accessibility, and 
safety. 
2- Population health, applying proven interventions to address behavioral, social, 
and environmental determinants of health in addition to delivering higher 
quality care. 
3- Affordability of healthcare services, reducing the cost of quality healthcare for 
patients, families, employers, and governments. 
Therefore, the best decision is reached when decision making focuses on reaching all 
these three goals (Figure 1.1), and this is what is referred to as the art of decision 
making. In this case, changes made in the healthcare system are sustainable and all 
stakeholders will benefit from its advantages. In other cases, the outcomes of decision-
making cannot cover all of the expectations of the different parties and, therefore, the 
sustainability of the decision would be under question. The fact is that goal setting is 
always easy, but achieving the goals requires information. In other words, policymakers 
need to have enough knowledge regarding the possible consequences of their 
decisions. 
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Knowledge production for reimbursement decision making in middle-income 
countries 
Various studies have shown that HTA-based decision-making systems are not 
coherently implemented in many middle-income countries (MICs), although HTA 
studies are increasing in these countries [9,10]. For example, a published study showed 
that despite the establishment of specific pharmacoeconomic agencies, the drug 
reimbursement decision-making procedures in Thailand, China, and South Korea face 
issues such as a low number of pharmacoeconomic researchers, lack of  reliable 
information.[11] In fact, policymakers cannot make effective decisions due to limited 
evidence or poor quality research. For example, a review that assessed the quality of 24 
economic evaluations of breast cancer control originating from low and middle-income 
countries reported that the majority of the studies were of poor quality, particularly in 
terms of examining costs. [12] 
Reimbursement decision making in Iran 
There is a very complex process in Iran to decide whether a technology should be 
reimbursed or not. The rationale behind this process is partly based on a healthcare law 
entitled Iran Universal Health Insurance Coverage adopted by the Iranian Parliament in 
1994.[13] According to this regulation, the Iran Supreme Council of Health Insurance is 
responsible to assess new technologies that have been registered for reimbursement 
 
Quality of 
care 
Population 
health 
Affordability 
 
Best decision 
Poor decisions 
Figure 1.1: The main goals from a reimbursement decision-making system. Adapted 
from a report to the USA congress entitled “The national strategy for quality 
improvement in healthcare”. [8]  
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decision making. The Iran Supreme Council of Health Insurance encourages applicants 
for reimbursement of a new technology to submit their application along with a CEA.  
Drug reimbursement decision making in Iran 
The drug reimbursement process in Iran can be described as a shared responsibility 
process, since the decision-making process is distributed between two ministries with 
different interests: the Ministry of Health and Medical Education and the Ministry of 
Welfare and Social Security. Ultimately, it is the Iranian Cabinet that approves a drug 
and recommends its use to all health insurance organizations. The details of the 
decision process will be explained in the second chapter; however, it is worth noting 
here that this structure causes some problems that affect the process of decision 
making. For example, new drugs are officially launched on the market before that the 
Iranian Cabinet make reimbursement decision. Patients have to pay the whole public 
price of non-reimbursement medications. The Ministry of Health, which is responsible 
for drug pricing, use the external reference pricing method for imported drugs that are 
mostly expensive [14]. None of performance-based and finance-based risk sharing 
agreements are not implemented and also price negotiation has not efficiently affected 
drug prices in Iran. 
A case study on drug reimbursement decision making in Iran 
This thesis is focused on the drug reimbursement decision-making system in Iran as an 
MIC. It also examines the use of trastuzumab in the treatment of breast cancer as a case 
study to investigate possible solutions for improving the current reimbursement 
decision-making process in Iran and other MICs with the same healthcare system.  
Breast cancer 
Breast cancer is the most frequent cancer in women worldwide with an estimated 1.67 
million new cancer cases diagnosed in 2012 (25% of all cancers).[15,16] Breast cancer 
is increasing, particularly in MICs, where most cases are diagnosed in the late 
stages.[16] In MICs like Iran, this increased frequency will lead to greater dilemmas 
because of their more limited financial resources and the subsequent impact of breast 
cancer on the healthcare budget due to existence of effective but costly treatments. An 
additional reason to expect increasing numbers of breast cancer patients is the 
increased use of better diagnostic strategies.[17] 
- An epidemiological perspective on breast cancer in Iran 
The most recent study showed that the age-standardized incidence rate of breast 
cancer per 100,000 people increased from 16 in 2003 to 28 in 2009 in Iran.[18] The 
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increasing breast cancer incidence rate has made it one of the most frequent 
malignancies among Iranian women.[19] Two other studies have shown that the 
mortality rate due to breast cancer is increasing among Iranian females. The age-
standardized mortality rate of breast cancer per 100,000 people increased from 3.69 in 
2003 to 4.92 in 2010 (Figure 1.2).[20,21]  
 
- An economic perspective on breast cancer in Iran 
To date, two studies have investigated the direct medical costs and economic burden 
of breast cancer in Iran. The first study studied the direct medical costs of breast cancer 
patients in one hospital in Isfahan and found that the costs of different therapies in 
2010 per patient varied from $1,670 ($=USD) at stage I to $22,133 at stage IV.[22] In 
the second study, researchers reported the total economic burden of breast cancer in 
Iran as $947,374,468 in 2010.[23] According to the results of this study, a significant 
proportion of the cost of breast cancer (77%) was productivity loss due to the breast 
cancer mortality rate. The direct medical costs accounted for 19% of the total estimated 
costs.[23] Treatment of breast cancer is the most expensive therapy among the 
different types of cancer in Iran, due to the use of monoclonal antibodies. Based on the 
annual reports of Iran’s Social Security Organization (SSO), a health insurer which covers 
approximately 50% of all Iranians (~40 million), trastuzumab (a monoclonal antibody) 
alone accounted for almost 20% of all chemotherapy costs in 2015.[24] 
- Using monoclonal antibodies in breast cancer 
Monoclonal antibodies have been established as one of the most successful therapeutic 
strategies for both hematologic malignancies and solid tumors in the last 25 years.[25] 
To date, 14 monoclonal antibodies have been approved by the U.S. Food and Drug 
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Figure 1.2: Age-standardized breast cancer mortality [18,19] and 
incidence [17] rates per 100,000 persons 
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Administration and there are several more monoclonal antibodies in the late stages of 
clinical trials.[26] Trastuzumab (Herceptin) is used widely in the treatment of 
overexpressed human epidermal growth factor receptor 2 (HER2-positive) breast 
cancer.[27] It is estimated that 25%−30% of patients suffering from breast cancer have 
HER2-positive breast cancer.[27] Various studies have investigated the safety and 
efficacy of trastuzumab.[28] As a consequence, trastuzumab is widely use in different 
stages of breast cancer in many countries. Different durations of trastuzumab use in the 
early stages of breast cancer were tested to address its safety and efficacy. These 
durations varied from 9 weeks [29] to 2 years [30]. However, the most common 
duration of trastuzumab use, which is also recommended in many clinical guidelines, is 
one year (52 weeks).[30] Subsequently, various studies were conducted to investigate 
the cost-effectiveness of trastuzumab. The results of these CEAs showed that this 
duration of trastuzumab is cost-effective in many HICs due to their high threshold of 
willingness to pay. [31,32] 
Current recommendations of one-year trastuzumab use for HICs have a huge impact on 
the healthcare budgets in MICs. Therefore, as an expensive drug, trastuzumab has 
continued to be a topic of conversation in many healthcare systems since its launch into 
the pharmaceutical markets. Trastuzumab’s huge share of total drug expenditure, 
particularly in MICs, has raised policymakers’ concerns regarding efficient resource 
allocation in their countries.  
The overall goals of a reimbursement decision-making system and current system in 
Iran  
An overview of the consequences of the current reimbursement decision-making 
system in Iran shows that the process of decision making could not provide a pervasive 
improvement on the overall goals of a reimbursement decision-making system. In 
general, to understand the consequences of the current reimbursement decision 
making in Iran, it would be appropriate to look at the amounts of patient out-of-pocket 
payments, life expectancy, and disease-caused mortality rate as the indicators for 
affordability of healthcare services, population health, and quality of care respectively. 
According to data from the World Health Organization (WHO), the share of total health 
expenditure of Iran’s GDP increased during past two decades.[33] Figure 1.3A shows 
that this rate of increase (184%) over 19 years (1995−2014) was much greater than the 
average growth rate of two groups of countries at the same socio-economic level, the 
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Middle East and North Africa (125%), and upper middle-income countries (118%). This 
means that Iran spent a larger share of its GDP in the healthcare sector than other 
countries. This is, however, were not desirable. For example, it is expected that out-of-
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Figure 1.3: Iran’s total health expenditure (% of GDP) (A), out-of-pocket health expenditure (% 
of total expenditure on health (THE) (B), and life expectancy at birth (C) compared with two 
groups of countries (Middle-East & North Africa and upper middle-income countries) 1995-
2014.  
(Source: The World Health Organization Global Health Expenditure database)  
*Total health expenditure  
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C 
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pocket payments decline when total health expenditure growths. As Figure 1.3B shows, 
despite Iran’s allocation of greater financial resources, their amount of out-of-pocket 
payment did not significantly change (R2 = 0.024), while in upper middle-income 
countries, a slight increase in total health expenditure meant that out-of-pocket 
payment significantly declined (R2 = 0.521).  
On the other hand, as Figure 1.3C shows, more investment in the healthcare sector may 
causes an improvement in life expectancy at birth in Iran over the same time period. 
Iranian life expectancy at birth has significantly grown compared to the average life 
expectancy at birth in Middle East and North Africa (p=0.525). However, as Figure 1.2 
shows, the mortality rate of breast cancer is increasing while the total health 
expenditure is also growing. Therefore, from the perspective of the overall goals, the 
current process has not successfully improved the affordability of healthcare services 
and quality of breast cancer care even though the overall population health has 
improved in Iran. This interpretation is compatible with a report from the World Bank 
that provides an explanation regarding Iranian healthcare sector [34]. It describes that 
Iran achieved a significant improvement in total population health and implemented a 
basic but strong primary health care system while some necessary restructuring across 
some key strategic interventions was necessary to improve efficiency and equity such 
as governance, patients access to healthcare services, and financing [34].  
Consequently, a realization of the principle of concurrently improving the overall goals 
is likely unattainable within this current framework. As a matter of fact, the weakness 
in the knowledge production infrastructure may be one of the most important causes 
for this shortcoming of the current process. 
Thesis aims and research questions 
The overall aim of this thesis is to investigate how an MIC (in this case, focusing on Iran) 
can improve its drug reimbursement decision-making system. This thesis, therefore, 
tries to answer the following research questions for Iran considering the above 
mentioned content:  
- What is the current structure of the drug reimbursement decision-making 
system, who are the key stakeholders, and what are the main issues regarding 
the current drug reimbursement decision-making system?  
- How consistent are the national guidelines with the medical literature? And 
what do Iranian doctors do in daily practice with the recommendations found 
in the current national guideline for treating HER2-positive breast cancer?  
- What are the possible solutions to overcoming the lack of patient registry 
data?  
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- What are the main real-world cost components of the treatment of HER2-
positive breast cancer?  
- What is the cost-effectiveness of trastuzumab in the treatment of early HER2-
positive breast cancer? What is the optimal trastuzumab therapy in terms of 
duration of trastuzumab use?  
- Can the transfer of economic evaluation results from HICs help policymakers 
in MICs to make better reimbursement decisions?  
- Is external reference pricing a threat to internationally equal affordability and 
does it help MICs in terms of pharmaceutical pricing? 
- What are the prerequisites for improving pharmaceutical pricing and 
reimbursement decision making to enhance the capacity of performance-
based and finance-based risk-sharing arrangements? 
Thesis outline 
This thesis includes three parts and each of these provides an answer to one or more 
research questions. 
In the first part (chapters 2 and 3), the current situation and subsequent consequences 
of the drug reimbursement decision-making system in Iran are discussed. 
- Chapter 2 explains the current process of drug reimbursement decision 
making, introduces the key stakeholders, and investigates the strengths and 
weaknesses of this process. It also describes how the process is split between 
two ministries and why the process is time-consuming. 
- Chapter 3 explains that the national guideline published by the Iranian Ministry 
of Health recommends a 9-week regimen for trastuzumab to treat HER2-
positive breast cancer instead of the 52-week regimen currently 
recommended in many other countries. It investigates the degree of clinician 
adherence to this national guideline in Iran.  
The second part focuses on knowledge production in MICs. As already mentioned, 
obtaining information is not an easy task in MICs and researchers have to find solutions 
to overcome this shortage of information. Therefore, this part provides some solutions 
for this problem. In addition, it describes some economic evaluations and a scenario 
analysis for efficient and affordable treatment. This part has three chapters (4−6). 
- Chapter 4 provides a solution for MICs dealing with issues of obtaining real-
world evidence of the cost-effectiveness of treatments. It is obvious that 
patient registries play an important role in this; however, implementation is 
costly and sometimes infeasible in many MICs. This chapter discusses how 
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patients can be classified into different stages of HER2-positive breast cancer 
in the absence of a comprehensive patient registry. Then, it would be possible 
to estimate the direct medical costs of HER2-positive breast cancer treatment 
in Iran. This study uses validated data-mining algorithms applied to a huge 
claims database from the Iran SSO. 
- Chapter 5 provides a cost-effectiveness analysis from the Iranian healthcare 
perspective and investigates an optimal duration of trastuzumab use in Iran. It 
also explains why the implementation of clinical guidelines around the world, 
which have recommended a one-year trastuzumab regimen as standard care 
for early HER2-positive breast cancer, could have a remarkable impact on total 
drug expenditures in MICs if trastuzumab were to be reimbursed.  
- Chapter 6 investigates the compatibility between the results of a model-based 
cost-effectiveness analysis in Iran with the transferred results of studies 
performed in some HICs. It provides some recommendations about how 
policymakers can use the results of these two methods for reimbursement 
decision making. 
The third part provides recommendations to improve the system. It describes how MICs 
can benefit from HTA studies and knowledge production in order to achieve the overall 
goals of a reimbursement decision-making system. This part has two chapters, which 
are chapter 7 and 8. 
- Chapter 7 investigates feasibility of internationally drug affordability and the 
importance of price differentiation in enhancing drug affordability and 
accessibility in MICs. Using prices of 10mg trastuzumab across 14 HICs and 5 
MICs. The inability to purchase across countries were estimated in two 
different scenarios. This chapter also provides some recommendations to 
improve pricing systems in MICs. 
- Chapter 8 examines the prerequisites for improving pharmaceutical pricing 
and reimbursement in Iran. Using an analysis of strengths, weaknesses, 
opportunities, and threats (SWOT), the current pharmaceutical pricing and 
reimbursement decision-making system in Iran is compared with the 
pharmaceutical governance and infrastructures in six reference countries 
(England, Germany, Hungary, Italy, Poland, and Turkey) that have 
implemented performance-based and finance-based risk-sharing policies. 
Subsequently, it provides recommendations for policymakers in Iran and other 
MICs who are considering the implementation of innovative pricing and 
reimbursement policies. 
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Finally, Chapter 9 presents a general discussion of the main findings of this thesis and 
provides policy recommendations for improvement of the current process of decision 
making in Iran. This chapter also explains the limitations faced while doing the research 
for this thesis. 
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Abstract 
Objective: Previous studies of health policies in Iran have not focused exclusively on the 
drug reimbursement process. The aim of this study is to describe the entire drug 
reimbursement process and the stakeholders, and discuss issues faced by policy 
makers. 
Methods: Review of documents describing the administrative rules and directives of 
stakeholders, supplemented by published statistics and interviews with experts and 
policymakers. 
Results: Iran has a systematic process for the assessment, appraisal and judgment of 
drug reimbursements. The two most important organizations in this process are the 
Food and Drug Organization, which considers clinical effectiveness, safety and 
economic issues, and the Supreme Council of Health Insurance, which considers various 
criteria, including budget impact and cost-effectiveness. Ultimately, the Iranian Cabinet 
approves a drug and recommends its use to all health insurance organizations. 
Reimbursed drugs account for about 53.5% of all available drugs and 77.3% of drug 
expenditures. Despite its strengths, the system faces various issues, including 
conflicting stakeholder aims, lengthy decision-making duration, limited access to 
decision-making details and rigidity in the assessment process. 
Conclusion: The Iranian drug reimbursement system uses decision-making criteria and 
a structured approach similar to those in other countries. Important shortcomings in 
the system include out-of-pocket contributions due to lengthy decision-making, lack of 
transparency, and conflicting interests amongst stakeholders. Iranian policymakers 
should consider a number of ways to remedy these problems, such as case studies of 
individual drugs and closer examination of experiences in other countries. 
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Introduction  
Expenditures in Iran on pharmaceuticals (inpatient and outpatient) accounted for more 
than 23% of all health care costs incurred by the Social Security Organization in 2011 
(Social Security Organization, internal annual reports). Previous studies have shown 
that the Iranian pharmaceutical sector is complex and that the process of decision-
making about drug reimbursement is complicated [35]. Beyhaghi and Basmenji 
concluded that the current system suffers from a lack of integration and clarity, and 
emphasized the need to implement a more transparent and consistent system [36]. 
Delgoshaei et al attempted to describe major problems in the drug reimbursement 
process in Iran and pointed to undefined and unreliable mechanisms, a reliance on 
traditional price setting methods, and a disregard for insurer capacity to actively 
negotiate prices with suppliers. Other weaknesses mentioned by them included 
insufficient support for the vulnerable classes (e.g. the retired) and indigent groups, and 
inadequate measures to promote rational prescribing and dispensing of low-price 
alternatives at the pharmacy level [37].  
A study of the drug reimbursement process in Iran is an important step to ensuring that 
the budget is used optimally. However, studies to date have not performed a detailed 
examination of the drug reimbursement process. The aim of this study was to describe 
the decision-making process regarding drug reimbursement in Iran. This paper covers 
the current reimbursement process relating to drugs in Iran up to the end of July 2012, 
and we describe the role of the two main stakeholders (the Ministry of Health and 
Medical Education (MoHME) and Ministry of Welfare and Social Security (MoWSS)) and 
other important actors and stakeholders in this process. 
Methods 
Three different methods were used in this study. To investigate and describe the 
administrative rules and the directives of stakeholders involved in the drug 
reimbursement process, we examined formal government documents, including the 
latest laws enacted by the Iranian parliament, legislative documents and published 
internal regulations of various stakeholders [13,38-44]. Interviews were conducted with 
three policymakers and experts in Ministry of Welfare and Social Security (MoWSS), 
Food and Drug Organization (FDO) and the Medical Services Insurance Organization 
(MSIO) enabled us to add some details about the reimbursement process. Finally, we 
used periodically released and publicly available statistics, especially drug sale statistics 
published by the Food and Drug Organization (FDO).  The numbers and costs of drugs 
sold by drug distribution companies to pharmacies are available in these publications 
[38], which enabled us to generate an overview of the current situation in Iran. 
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Health Insurance Systems 
Major changes in the Iranian national health insurance system began in 1994 with the 
introduction of universal health insurance [13]. This policy contained a description of 
the role of each stakeholder in the health care sector, the financing of health insurance 
organizations (HIOs), the health services tariff policy, and the minimum health service 
package to be adopted by all HIOs. Since the introduction of this policy, Iran has had 
four major health insurers: the Social Security Organization (SSO), the Medical Services 
Insurance Organization (MSIO), the Armed Forces Health Insurance Organization 
(AFHIO) and the Imam Khomeini Relief Foundation (IKRF) [13].  
The SSO, established in 1953, is a non-governmental organization which covers about 
43% of the population. The insurees comprise wage-earners and salaried workers, many 
self-employed personnel in different businesses, and many civil servants [39]. SSO 
provides two kinds of health care schemes: direct and indirect health care. Direct health 
care is provided to SSO beneficiaries through 69 hospitals (8550 hospital beds) and 275 
clinics [40]. Beneficiaries can also receive indirect health care from other providers, 
including health centers (privately, government-owned, army) and charity 
organizations. SSO beneficiaries who referred to direct health care do not have to make 
any payments or copayments (unless they receive indirect health care) [40]. Besides 
health care services, the SSO provides other social services relating to pension 
payments, disability compensation, and unemployment insurance services. These long-
term services account for two-thirds of annual SSO expenditures. 
The MSIO is a governmental organization established in 1994 which insures about 41% 
of the population, comprising mainly civil servants, the self-employed and rural 
populations. The MSIO provides only health insurance services and has variable 
financing. The activities of MSIO are similar to the indirect health care provided through 
the SSO. 
The two other health insurance organizations, the Armed Forces Health Insurance 
Organization (AFHIO) and the Imam Khomeini Relief Foundation (IKRF) respectively 
cover almost 6% and 2.5% of the population. AFHIO beneficiaries include armed forces 
personnel and their families while IKRF beneficiaries include people with physical 
disabilities and people with economic or social crises that are so severe that they are 
not self-sufficient [41]. 
 In addition, there are an additional 30 or so smaller health financing schemes for 
privileged members of society or large organizations (e.g., government ministries, 
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municipalities, banks and cooperatives), which provide coverage to their employees 
and their families [45,45]. 
Key points about the Iranian health insurance organizations are as follows: 
1- Governmental organizations involved in the health care system are supervised by 
different ministries in the government. The SSO and the MSIO are supervised by 
the Minister of Welfare and Social Security, the AFHIO is supervised by the 
Minister of Defense, while the IKRF falls under the direct supervision of the Iranian 
president.  
2- The occupation held by the head of household is the most important factor that 
determines HIO enrollment, insurance premiums and level of commitment of HIO 
to reimburse healthcare services. In fact, most people cannot select their health 
insurer and insurance premiums are paid monthly by their employers. Only self-
employed people can choose between the SSO and the MSIO.  
3- According to some experts, some people may benefit through coverage by multiple 
health insurers while others may have no health insurance coverage at all. The 
number of people without any coverage is estimated to be up to 10 percent of the 
population. Although the socioeconomic proportions of non-insured people have 
not been investigated, the experts argue they are mostly young and poor people, 
who are not eligible to register by the SSO, MSIO and AFHIO and do not need health 
care services (because of being young). Moreover, some rich people would not be 
insured since they can easily afford to pay for health care services in the private 
sector. 
4- The contents of the minimum benefit package of the four main health insurers are 
determined by the Supreme Council of Health Insurance (SCoHI) and all insurers 
are obliged to provide whatever is included in the package. By law, patients must 
make copayments of 10% and 30% of the costs of inpatient and outpatient services, 
respectively. Insurers make direct payments to pharmacies on a monthly basis and 
patients have to pay both copayments and a dispensing fee. The dispensing fee 
(about 0.70 Euro in 2011) is a fixed-rate fee for labeling and repackaging that is 
generally paid out of pocket for every prescription received. In addition to the 
minimum benefit package and copayment rules, organizations can provide excess 
services to prevent catastrophic household health expenditures. They may cover 
some non-reimbursed drugs or decrease the patient's share of financial 
contribution. The ratios of cost-sharing in drug services provided by HIOs for 
diseases are shown in Table 2.1. Cancer patients treated with non-reimbursed 
drugs receive financial support from HIOs using different approaches. For example,   
30 | Chapter 2 
 
Ta
b
le
 2
.1
: T
h
e 
fi
n
an
ci
al
 c
o
n
tr
ib
u
ti
o
n
 o
f 
d
ru
g 
re
im
b
u
rs
em
en
t 
se
rv
ic
es
 b
y 
m
ai
n
 Ir
an
 h
ea
lt
h
 in
su
ra
n
ce
 o
rg
an
iz
at
io
n
s.
 
D
is
e
as
es
 o
r 
in
d
ic
at
io
n
s 
D
B
C
1  
O
u
tp
at
ie
n
ts
 
In
p
at
ie
n
ts
 
SS
O
 
M
IS
O
 
A
FH
IO
2  
IK
R
F 
SS
O
 
M
IS
O
 
A
FH
IO
2  
IK
R
F 
D
H
C
 
IH
C
 
D
H
C
 
IH
C
 
C
an
ce
rs
 
1
4
.8
 
1
0
0 
8
5
 
9
0
 
1
0
0 
1
0
0 
1
0
0 
9
0
 
9
0
 
1
0
0 
1
0
0 
D
ia
ly
si
s 
(A
ll 
d
ru
gs
) 
3
.4
 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
9
0
 
1
0
0 
1
0
0 
H
em
o
p
h
ili
a 
(A
ll 
d
ru
gs
) 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
9
0
 
1
0
0 
1
0
0 
Th
al
as
se
m
ia
 
(A
ll 
d
ru
gs
) 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
9
0
 
1
0
0 
1
0
0 
K
id
n
ey
 t
ra
n
sp
la
n
t 
1
.3
 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
9
0
 
1
0
0 
1
0
0 
O
th
er
 o
rg
an
 t
ra
n
sp
la
n
ts
 
(I
m
m
u
n
o
su
p
p
re
ss
iv
es
) 
 
0
.9
 
1
0
0 
1
0
0
3  
7
0
 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
9
0
 
1
0
0 
1
0
0 
M
u
lt
ip
le
 s
cl
e
ro
si
s 
(I
n
te
rf
er
o
n
 
d
ru
gs
) 
9
.4
 
1
0
0 
9
0
 
9
0
 
1
0
0 
1
0
0 
1
0
0 
1
0
0 
9
0
 
1
0
0 
1
0
0 
O
th
er
 d
is
ea
se
s 
7
0
.2
 
1
0
0 
7
0
 
7
0
 
7
0
 
7
0
 
1
0
0 
9
0
 
9
0
 
1
0
0 
1
0
0 
1
- 
D
ru
g 
b
u
d
ge
t 
co
n
tr
ib
u
ti
o
n
 p
e
rc
en
ta
ge
 b
as
ed
 o
n
 IH
C
 o
f 
SS
O
 a
n
n
u
al
 r
ep
o
rt
s 
fo
r 
o
u
tp
at
ie
n
ts
 in
 2
.1
0
.2
0
1
1
-2
.1
0
.2
01
2
. 
2
 A
FH
IO
, p
ro
vi
d
e 
th
e 
b
as
ic
 a
n
d
 s
u
p
p
le
m
en
ta
ry
 h
ea
lt
h
 in
su
ra
n
ce
 t
o
ge
th
er
. 
3
 In
 a
d
d
it
io
n
 t
o
 im
m
u
n
o
su
p
p
re
ss
iv
es
, o
th
er
 n
ec
es
sa
ry
 d
ru
gs
 b
as
ed
 o
n
 k
in
d
 o
f 
tr
an
sp
la
n
ta
ti
o
n
 a
ls
o
 c
o
ve
re
d
 b
y 
th
e 
SS
O
. 
A
b
b
re
vi
a
ti
o
n
s:
 A
FH
IO
: A
rm
ed
 F
o
rc
es
 H
ea
lt
h
 In
su
ra
n
ce
 O
rg
a
n
iz
a
ti
o
n
, D
B
C
: 
D
ru
g
 B
u
d
g
et
 C
o
n
tr
ib
u
ti
o
n
, D
H
C
: D
ir
ec
t 
H
ea
lt
h
 C
a
re
 s
ch
em
e 
a
t 
SS
O
, I
H
C
: I
n
d
ir
ec
t 
H
ea
lt
h
 C
a
re
 s
ch
em
e 
a
t 
SS
O
, I
K
R
F:
 Im
am
 K
h
o
m
ei
n
i R
el
ie
f 
Fo
u
n
d
a
ti
o
n
, M
IS
O
: M
ed
ic
a
l I
n
su
ra
n
ce
 S
er
vi
ce
s 
O
rg
a
n
iz
a
ti
o
n
, S
SO
: S
o
ci
a
l S
ec
u
ri
ty
 O
rg
a
n
iz
a
ti
o
n
 
The drug reimbursement system in Iran | 31 
2 
the SSO pays a limited yearly grant directly to patients. The MSIO compensates 
patients for the costs of the drug, the maximum amount being equal to the costs 
of pharmacologically similar drugs that are reimbursed. The AFHIO covers all drug 
costs through obligatory supplementary insurance. Lastly, the IKRF covers 50% of 
the costs of all non-reimbursed drugs. 
Drug registration process in Iran 
All new drugs (except orphan drugs, with a disease prevalence of 1 in 200.000 people 
or less) [46] must be registered by the Council to Consider and Compile Drugs (CCCD) 
before they can become available in Iran. This council is part of the FDO that is 
responsible for drug policy, which in turn is supervised by the minister of Health and 
Medical Education. All CCCD members are MoHME employees and most of them are 
clinicians or pharmacists. The first step in the registration of any new drug that is 
produced or imported is the completion of 3-4 drug registry forms (Figure 2.1). The 
applicant (e.g., pharmaceutical firm, group of physicians, specialist society) must 
prepare documents that address the following items: efficacy, safety and adverse 
events, comparative efficacy with similar drugs, approval history, contraindications – 
CCCD: preparation of the assessment 
CCCD: Final assessment and decision 
The end of drug registry by getting unique 
national code, entrance to the Iran 
Pharmacopeia and Iran Pharmaceutical 
market 
Manufacturer or importer of drug 
New molecule New dosage form 
New salts or new 
dose 
Economic 
appraisement 
Outer 
consultation 
The applicant submit an application to FDO 
Applicant 
Non-registered 
drugs 
Y N 
Figure 2.1: Overview of drug registration process in Iran. 
Abbreviations: CCCD: Council to Consider and Compilation Drugs, FDO: Food 
and Drug Organization, Y: Yes, N: NO 
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warnings – precautions – monitoring parameters, pharmacokinetics, patient 
compliance and pharmacoeconomic studies [42]. However, the CCCD may exclude one 
or more of these items based on the kind of drug and the availability of data. 
Applications fall into three categories: 1) new molecules; 2) new dosage forms; and 3) 
new salts or new doses of any drug if the base has already been approved by CCCD. 
Suppose the drug erythromycin, with stearate as a salt in its formulation, are available 
on the market and approved by CCCD. If a new application of erythromycin contains a 
different salt (e.g., ethyl succinate), it will fall in the third category. 
 If the application involves a new molecule, consultation will be sought from the heads 
of medical and pharmaceutical societies, national research centers and medical 
universities. Approval of the drug by other organizations (such as the FDA, EMA, and 
TGA) and its use in at least five countries (including the USA, EU countries or other 
countries with a GDP similar to Iran’s) have an important role in the evaluation. Once a 
drug is approved, it is given a unique national code and can be distributed, prescribed 
and used throughout the entire country. However, patients using the drug will have to 
pay 100% of the drug costs until the drug is added to the reimbursement list.  
Drug reimbursement process in Iran 
The SCoHI is the organization that deals with drug reimbursement decisions in Iran. The 
Drug Benefit Package Review Committee (DBPRC) is part of the SCoHI and is responsible 
for drug assessment. All members and stakeholders of SCoHI have a representative in 
Figure 2.2: Overview of drug reimbursement system in Iran (Stakeholders roles map) 
 
The documentation route 
Consultation route  
Drug reimbursement order 
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this committee. Based on Iran’s rules, all of the health services covered by health 
insurance organizations should complete the reimbursement process. The main rule, as 
previously mentioned, is universal health insurance and one of the most important 
parts of this law is the appointment of the Supreme Council of Health Insurance as an 
important health insurance policy center. The members of this council are the minister 
of MoWSS (who is also the chairman of the council), minister of MoHME, minister of 
Economic Affairs and Finance, vice president on Strategic Planning and Control, CEO of 
SSO, CEO of MSIO, CEO of AFHIO, president of the Islamic Republic of Iran Medical 
Council chief of IKRF and two members of the Iranian Islamic Parliament (Health 
Commission and Budget Commission). The process of reimbursement of health services 
is described in section 10 of the Iran universal health insurance for health care law. 
Figure 2.2 shows the roles of the stakeholders in the assessment of a drug’s eligibility 
for reimbursement. Only drugs that have completed the registration process at FDO 
and received a national code can enter the SCoHI process (Figure 2.3); otherwise the 
application is rejected. Applicants (drug companies, physicians, physician specialist 
societies, etc.) must complete a formal application and submit all of the necessary 
documents. These documents contain information about the drug and its 
characteristics, the proposed price, the cost in each treatment period, a list of 
alternative drug therapies with an analysis of their advantages and disadvantages, and 
documentation of the clinical and economic aspects of the drug. This information is 
categorized into items, each of which contributes a certain number of points towards 
the application. The maximum possible score is 100 points. If the total score based on 
an initial evaluation performed by SCoHI’s experts is less than 50 points, the application 
is rejected. However, if the total score is 50 points or more, the application will be sent 
to all DBPRC members, who will be asked to provide comments on the new drug, 
including the probable effect that it will have on their budget. Once these comments 
are received, the DBPRC will start the assessment process. If a drug application receives 
more than 80 points and no significant objections from the council, it will be sent to the 
SCoHI with a positive vote. The final DBPRC decision will also consider the budget impact 
for the country as well as cost-effectiveness results from other countries. If they find 
that rich countries have concluded that a drug is not cost-effective, then this new drug 
will be considered unlikely to be cost-effective in Iran.All documents are then sent to all 
stakeholders two weeks before a general meeting is held where all stakeholders gather 
to discuss the application. The documents contain the following information: 
- Comparison of effectiveness with other drugs in the Iranian pharmacopeia that 
have the similar therapeutic effects. 
- Estimated impact on the use of other drugs, which can help to estimate the overall 
impact of a drug on a health insurer's budget. 
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- Cost modelling for one therapeutic course in outpatient care and comparison with 
other drugs with the same therapeutic effects.  
- Average monthly increase in sales in the 6-month period prior to the 
reimbursement application. 
- Drug price in other countries with a GDP similar to that of Iran’s. 
- Opinions and comments of certain departments of major medical universities (the 
choice of department is based on the kind of drug). 
All stakeholders will have two weeks to examine the information, after which a general 
meeting will be held. The first goal in the meeting is to reach consensus about whether 
or not to reimburse the drug. If consensus is not achieved, the members will vote for or 
against reimbursement. A negative reimbursement decision brings the process to an 
end since there is no opportunity to reapply for reimbursement. However, if the 
reimbursement decision is positive, a meeting is arranged with the drug company to 
negotiate the drug price. If the drug company is able to agree with the DBPRC about the 
price, the application for reimbursement will be accepted, otherwise it will be rejected. 
The applicant submit a reimbursement file to SCoHI 
Manufacturer or importer of drug 
Applicant 
DBPRC: preparation of the assessment, pre-evaluation and 
stakeholders consultation  
Stakeholders: preparation of comments and budget impact 
DBPRC: Summarized data and assessment 
Rejected drugs 
Accepted drugs 
DBPRC: negotiates the price with applicant 
SCoHI: Final decision making 
Governmental cabinet: Final approval 
The drug is added on the imbursement list, decision 
published in the government official journal 
Y 
N 
N 
Y 
Figure 2.3: Overview of drug reimbursement process in Iran.  
Abbreviations: DBPRC: Drug Benefit Package Review Committee, SCoHI: 
Supreme Council of Health Insurance, Y: Yes, N: NO 
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Once the price has been set, the DBPRC will release a document containing the 
following information: 
1- Conditions of reimbursement (e.g., which specialists can prescribe the drug, 
which indication(s) the drug can be used for and location of production (Iran 
or other country)). For example, rituximab is only reimbursed if it is prescribed 
by an oncologist to treat non-Hodgkin’s lymphoma and will not be reimbursed 
for other purposes (e.g., rheumatic disorders).  
2- Dosage forms under reimbursement.  
3- Whether or not health insurance organizations need to set up a patient registry 
for the specific drug.  
4- Assessment of reimbursement eligibility by a health insurance organization 
before a patient purchases the drug. 
The DBPRC will then send the positive results of their decision with the agreed prices to 
the chairman of the SCoHI (Minister of Welfare and Social Security), who will then 
provide a final summary of comments made during a meeting with the SCoHI. After this 
process of deliberation is completed, a report with SCoHI conclusions is sent to the 
Iranian Cabinet, which makes the final official decision. According to experts, the 
Cabinet has never rejected a drug approved by SCoHI. Following Cabinet approval, the 
drug is added to the reimbursement list and the decision is published in the 
Government’s official journal. 
Patients can receive the drug with different copayments based on disease category 
(Table 2.1). Once an international nonproprietary name (INN) in a specific dosage form 
is added to the reimbursement list, all brand names with a similar dosage form are also 
added. However, HIOs will be required to reimburse only the lowest price of all available 
brands. For instance, assume that three brands of ranitidine 300 mg were available on 
the market with three different prices (95, 100, and 110 Rials). If ranitidine is covered, 
all three brands are covered but the health insurer will only reimburse 95 Rials (the 
price of the cheapest brand) and patients wanting a more expensive brand will have to 
pay the extra costs themselves. 
Overview of the current situation 
Currently, there are 3530 INN national codes in Iran’s drug pharmacopeia [43] and 1800 
INN national codes and 90 raw materials for some drugs produced by pharmacies are 
reimbursed [44]. Most vitamins, nutritional supplements, infertility drugs and herbal 
extracts are not on the reimbursement list. Based on statistics provided by the FDO [38],   
36 | Chapter 2 
Table 2.2: The top twenty non-reimbursement drugs based on sales in the period between 
2.10.2011 and 2.9.2012 (1 Euro  16000 Rials in 2011) 
Drug Major indication 
Drug sales of total 
non-reimbursement 
sales 
FDO 
approval 
date2 
What is clear 
decision from 
SCoHI? 
% € 
Trastuzumab 440mg vial Certain breast cancers 3.0 18,269,992 Before 
2008 
No (4/2010) 
Follitropin 75iu amp Infertility 2.5 15,233,374 Before 
2008 
No Application 
Orlistat 120mg cap Obesity 2.4 14,492,096 Before 
2008 
No Application 
Ibuprofen 400mg pearl1 Moderate pain 2.3 13,498,195 Before 
2011 
No Application 
Pantoprazole 40mg tab1 Gastroesophageal reflux 2.2 13,050,840 Before 
2008 
No (4/2009) 
Tamsulosin 0.4mg cap Benign prostatic 
hyperplasia 
2.2 12,907,345 Before 
2008 
No (6/2010) 
Sildenafil citrate 100mg tab Erectile dysfunction 1.9 11,239,538 Before 
2008 
No Application 
Menotropins 75 iu fsh+75iu lh 
amp 
Fertility disturbances 1.8 10,809,738 Before 
2011 
No Application 
Vaccine-influenza virus killed  Protect against 
influenza virus 
1.7 10,437,869 Before 
2008 
No Application 
Drospirenone/Estradiol 
3/0.03mg tab 
Hormonal contraceptive 1.5 8,928,217 Before 
2011 
No Application 
Bevastizumab 400mg/16ml 
vial 
Various cancers, 
colorectal, lung, breast, 
glioblastoma kidney and 
ovarian. 
1.4 8,303,165 Before 
2011 
No Application 
Salbutamol 100mcg/dose 
200dose inhaler1 
Relief of bronchospasm 1.3 7,900,956 20/11/2009 No Application 
Buprenorphine 2mg sl tab1 Moderate to severe 
chronic pain 
1.3 7,624,896 Before 
2005 
Under study 
Celecoxib 100mg cap Osteoarthritis, 
rheumatoid arthritis, 
acute pain 
1.2 7,245,080 Before 
2000 
No (4/2002) 
Zoledronic acid 4mg vial Osteoporosis 1.1 6,707,129 Before 
2008 
Yes (Wait for 
Government 
Cabinet) 
Pantoprazole 20mg tab1 Gastroesophageal reflux 1.1 6,565,955 Before 
2008 
No (4/2009) 
Celecoxib 200mg cap Osteoarthritis, 
rheumatoid arthritis,  
1.0 5,891,905 Before 
2000 
No (4/2002) 
Prospan 1 syrup Expectorant 0.9 5,678,314 Before 
2011 
No Application3  
Acetaminophen/ Caffeine/ 
Ibuprofen 325/40/200mg cap1 
Moderate pain 0.9 5,566,815 26/09/2011 No Application 
Tramadol 100mg tab Moderate to severe 
pain 
0.9 5,431,981 Before 
2002 
No Application 
  Sum 32.6  195,783,400   
  Total  100 600,562,577   
1- There are some others dosage forms in Iran reimbursement list. Background color is changed to gray in 
this group of drugs. 
2- When the exact dates were not accessible, we looked at the Iran pharmaceutical market and if drug was 
been accessible in each year, we used “Before that year” to describe the FDO approval date. 
3- Other internal products are reimbursed. 
Abbreviations: FDO: Food and Drug Organization, SCoHI: Supreme Council of Health Insurance 
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over a one-year period (2.10.2011-2.9.2012), the expenditures of the drugs found on 
the reimbursement list is approximately 77.3% of the total expenditures of all drugs 
sold to pharmacies by distribution companies. The rest is paid by patients or 
supplemental insurance. Since no reliable report about expenditures of non-
reimbursed drugs is available, we used sale reports to describe the results of the 
reimbursement process. The top twenty non-reimbursed drugs (based on the results of 
the previous report) are shown in Table 2.2. This list of drugs includes both essential 
and non-essential drugs, where drugs are considered non-essential if therapeutically 
equivalent drugs are already available on the market.  
Although sales statistics cannot accurately describe overall drug use over long periods 
of time, it can at least help to estimate the costs of non-reimbursed patient expenses in 
various groups of diseases and changes in the use of non-reimbursed drugs. As seen in 
Table 2.2, since the exact date of presentation of application to SCoHI is unknown, it is 
not possible to estimate the mean duration of the application process. However, it is 
known that some applicants received a decision a couple of years after submitting their 
reimbursement application. This delay appears to be due to the SCoHI screening of 
drugs. Many controversial drugs seem to have been held back by bureaucratic barriers 
while less controversial ones easily passed this bureaucratic filter. On the other hand, 
there are twelve drugs with a “No Application” status, which usually reflects a situation 
where the applicant is not entirely confident about gaining approval from SCoHI 
because of incompatibility properties of their drugs and SCoHI expectations. However, 
in other cases, it is likely that some companies choose not to apply for reimbursement 
since they are sure their drugs will sell well in Iran without it. 
Discussion 
Drug reimbursement decision-making is an important process in the health care sector 
and has an essential role in the efficient allocation of resources. Moreover, the 
expansion of health insurance schemes with affordable and comprehensive packages 
of basic services is a great aid in achieving health equity. While Iran is a developing 
country with an economy that is transforming into a market-based economy, the 
Iranian state still plays a key role in the economy, since it owns large public and quasi-
public enterprises which partially dominate the manufacturing and commercial sectors. 
The Iranian pharmaceutical market has undergone great growth in comparison with 
developing countries and the market is expanding quickly while a major share goes for 
biotechnology drugs during 1977-2010 [47]. Therfore, as a middle-income country with 
a total health expenditure in 2011 of 6.0% of the GDP [48], evidence-based decision-
making and the appropriate use of available resources are of paramount importance. 
While there is a process now in place to assess whether or not a new drug is eligible for 
reimbursement in Iran, previous studies have found that this process lacks efficiency in 
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making quick and sound reimbursement decisions. This paper's approach was to go one 
step further by providing a more comprehensive view of the current situation, which 
enabled us to identify both the strengths and the shortcomings of the review process.  
Our study revealed some strengths of the current process. The drug registration and 
reimbursement system in Iran basically uses the same decision-making criteria that are 
applied in many other countries, which include efficacy, safety, and economic 
considerations. SCoHI has managed to eliminate some of the problems arising from a 
lack of therapeutic guidelines by drawing up restriction rules on the consumption of 
some reimbursed drugs based on their indications (see rituximab example above). HIOs 
can not only provide an appropriate financial contribution, especially for high risk 
patients, but they can also provide extended universal coverage in Iran. Improved 
planning in the area of reimbursement would help to improve this strength even 
further. Price negotiation, budget impact and priority for drug coverage are important 
activities in the process of drug reimbursement. 
The drug reimbursement process in Iran can be described as a shared responsibility 
process, since decision-making process is distributed between two ministries with 
different interests. The Ministry of Health and Medical Education is expected to ensure 
patient access to useful drugs, while the Ministry of Welfare and Social Security must 
try to maximize health insurance coverage with a limited budget. The two ministries 
therefore have goals which can conflict with each other. In addition, the SCoHI must 
consider the recommendations of many stakeholders when making reimbursement 
decisions. These two factors of conflicting aims and many decision-makers may 
complicate the goal of independent decision-making. This not only might challenge the 
societal goals of drug reimbursement but also cause other problems like prolonged 
decisions. One consequence of a prolonged reimbursement process is an increase in 
out-of-pocket payments by patients, who will have to pay for a drug until it is deemed 
reimbursable. Some HIOs may therefore use supplemental insurance or decrease other 
services to help patients needing expensive non-reimbursed drugs.  
One issue in the current system is that periodical reports by SCoHI and FDO are not 
publicly available. The reasons for approving or disapproving drug registration and 
reimbursements, and the average durations of the registry and reimbursement 
processes are therefore unknown. This can be viewed as evidence of lack of 
transparency in the process, which could easily be resolved if information from the 
SCoHI and FDO were published. In addition, the repetition of some activities during the 
evaluation process likely means redundancy, inefficiency and delays in decision-making. 
A good example of this is the requirement by the applicant to supply various economic 
documents to both the CCCD and the DBPRC.  
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The drug reimbursement process uses the same approach in dealing with different 
applications regarding required documents, evaluation and decision-making process, 
regardless of the budget impact and whether or not the drug is essential. On the other 
hand, modern HTA methods are not evident in this process. One consequence of these 
issues is reduction in process dynamicity and accumulation of different applications 
with different degrees of importance in patient safety. Although standardization of the 
required documents and assessment protocol of the applications is a strength of the 
reimbursement system in Iran, it does have its limitations. That is, process dynamicity 
could be improved by developing different approaches to assess drugs in different 
categories based on their medical and economic characteristics. Policymakers could 
then apply a set of criteria to prioritize drug reimbursement reviews. For example, a 
drug with great budget-saving potential might receive a higher priority. In contrast, a 
drug could be given a lower priority if another drug (with a similar safety and 
effectiveness profile) is already available on the market. 
Improvements in the drug reimbursement system may not resolve all of the problems 
that patients have with the if the total drug expenditure in health care would not be 
matched with the real needs. Moreover, it will be difficult to find a better functioning 
system which is able to satisfy all stakeholders. If the number of new and expensive 
drugs continues to be high, this can lead to delays in decision-making and various 
problems such as distrust between the public and policymakers and  an increased 
numbers and expenditures of non-reimbursed drugs, which can in turn lead to  
insurance fraud by patients and physicians.  
Since sharing of expertise and experience in middle income countries would be helpful 
for HTA developers and policy makers in these countries [9]. Iran because of its 
geopolitical properties, market size and the relative superiority in health indicators 
[34,47,48] is an important country for HTA researchers in the region and the west part 
of Asia. 
Conclusion 
The Iranian drug reimbursement system is a shared process between two different 
ministries and has an important role in the efficient allocation of resources. Some issues 
that have been discussed cause reduced functionality of this system. Therefore, Iranian 
policymakers need to make changes and reevaluate the admission process of new drugs 
to the reimbursement lists under a new set of guidelines and possibly a more efficient 
regulatory body. In this new set of guidelines, one important step to improving decision-
making is greater transparency (e.g., by publishing reimbursement and registry 
decisions) on details. More transparency will help to improve other key performance 
indicators of new decision-making process like: independence, timeliness, and 
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dynamicity. Benchmarking studies on the Iranian drug reimbursement decision making 
process versus other countries’ processes are needed to highlight Iran's procedural 
difficulties. Other studies, especially case studies, should evaluate the exact drug 
reimbursement decision-making in Iran. These studies and the experiences of other 
countries can serve as a framework to find the best solutions to improve the drug 
reimbursement decision making process.  
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Abstract 
Introduction: Most national standard therapeutic guidelines in the world recommend 
a 52-week trastuzumab regimen for breast cancer treatment. In contrast, the national 
guideline published by the Iranian Ministry of Health recommends a nine-week 
regimen. Since guidelines are not necessarily followed in daily practice, we assessed the 
extent to which current routine practice in Iran as a middle-income country matches 
the recommendations found in these guidelines. 
Methods: 128 Iranian oncologists were asked to complete an online anonymous 
questionnaire. Concurrently, a 3-year retrospective claims database analysis was 
conducted using data from the Social Security Organization, a health insurer which 
covers approximately 50% of the Iranian population, to enable comparisons with the 
questionnaire results.  
Results: With a 41% (52/128) response rate, doctors reported a relatively high absolute 
adherence (86%) to the guideline for HER2 receptor testing but a low rate of absolute 
adherence (6%) to the guideline for duration of trastuzumab treatment. Doctors 
indicated that the planned duration was 9 weeks in only 33% of patients; in most cases, 
the plan was 52-week treatment. Patients with a 9-week treatment plan received 
trastuzumab for 8.6 weeks on average while patients with 52-week plans received 
treatment for 29.2 weeks. The general trends found in the survey were confirmed in 
the claims database analysis of 1295 HER2-positive patients. 
Conclusions: Resource-sensitive guidelines may be beneficial in middle-income 
countries where limited budgets cannot accommodate all innovative technologies. 
However, Iranian physicians appear to rely more on the medical literature than on 
national guidelines regarding trastuzumab use. Policymakers, doctors and other 
stakeholders need to reach some consensus about the optimal way to treat patients. A 
national guideline needs to be accompanied with country-specific economic 
evaluations.   
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Introduction 
A standard treatment guideline (STG) is “a systematically developed statement 
designed to assist doctors and patients in making decisions about appropriate health 
care for specific clinical circumstances” [49]. STGs are also one of the measures used by 
policymakers to provide standardized guidance to practitioners and promote efficient 
use of funds [49], especially when they decide to reimburse a new and expensive 
intervention.  
If the sustainable reimbursement of innovative but expensive medical technologies 
presents an important challenge to policymakers in high-income countries, it is a near 
impossibility for policymakers in middle-income countries (MICs). Policymakers in these 
countries need to take particular care in reimbursement decisions when the total 
budget impact of reimbursing a drug may be exceptionally high. If the aim of 
reimbursement is to address the goal of maximizing health given limited available 
resources, then STGs may help in this endeavor [49]. For example, Iran has attempted 
to manage the use of monoclonal antibodies like trastuzumab by using national 
guidelines [50]. Trastuzumab for breast cancer was probably chosen by Iranian 
policymakers as one of the treatments to be assigned its own guideline because of its 
high costs per individual and the high probability of a substantial budget impact. In fact, 
budget concerns probably explain why trastuzumab was not reimbursed when it first 
entered the Iranian pharmaceutical market in 2007 [51]. The standpoint of the Ministry 
of Health and Medical Education (MoHME) appears to have changed five years later 
when it published the first version of the guideline for trastuzumab use in 2012 [52]; 
trastuzumab was reimbursed one year later [53]. The main recommendation in this STG 
is a 9-week treatment regimen in women with human epidermal growth factor receptor 
2 (HER2) positive breast cancer, which was based mostly on expert opinion and 
literature reviews. However, since national STGs may represent the culmination of 
compromises between policymakers and clinicians, they may not reflect how clinicians 
actually treat their patients. In fact, informal discussions with Iranian clinicians had 
suggested that trastuzumab use in daily practice deviates substantially from what the 
guideline recommends. 
The aim of this study was to investigate clinician adherence to the Iranian guideline for 
treating HER2-positive breast cancer. Specifically, we compared what Iranian doctors 
do in daily practice with the recommendations found in the current guideline for 
treating HER2-positive breast cancer and explored the degree of association between 
socioeconomic parameters and trastuzumab consumption.  
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Methods 
General study design 
Two different approaches were used to assess clinician adherence. The first approach 
was to conduct a clinician survey to determine how much clinicians adhere to the 
guidelines for trastuzumab and the second approach was a claims database analysis. 
Details regarding these two approaches are provided below. 
Clinician survey 
- Study population 
The target population in this survey comprised the specialists working in the areas of 
oncology, the specialists who are eligible to manage breast cancer in Iran (total number: 
approximately 264). They can work in the public (e.g., Ministry of Health, Social Security 
Organization and state hospitals and clinics), private (e.g., private hospitals, clinics, and 
doctors’ offices) or both sectors.  
An invitation to participate in the survey, including an internet address link to the 
questionnaire, was emailed to all specialists in the target population with a known email 
address (n=128). Specialists who preferred to receive the questionnaire by mail were 
sent a copy in a sealed envelope. 
- Questionnaire  
An online anonymous questionnaire was created on the SurveyMonkey website 
(https://www.surveymonkey.net). This questionnaire examined treatment preferences 
in four stages of breast cancer: breast cancer without local or distant recurrence 
symptoms, contralateral breast cancer or new primary non-breast cancer, ipsilateral 
loco-regional recurrence and distant recurrence. 
Feedback from four oncologists was used to develop and refine the questionnaire. A 
pilot study of the questionnaire was then performed by sending the questionnaire to 
10 respondents, five of whom responded within two weeks. The final version of the 
questionnaire containing 30 main questions was then sent out to all oncologists. 
Database analysis 
A retrospective claims database analysis was conducted using the Social Security 
Organization (SSO) database. The SSO insures almost 50 percent of the Iranian 
population (~38 million) [54]. The database, however, does not contain some clinical 
information such as disease stage or diagnosis coding (e.g., ICD-10). The HER2-positive 
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patients were therefore identified based on the national health services coding by 
applying four filters to the database: cancer patient, woman, history of a 
mammography, and trastuzumab use in the past two years. The combination of these 
filters yielded a total of 1,298 patients. Data cleaning and exploratory data analysis were 
then conducted, followed by data extraction. The data analysis was performed at both 
the national and provincial levels; an additional analysis compared trastuzumab use 
between the provinces. 
Statistical analysis  
Microsoft Excel, Access 2013 and R (version 3.1.0) software was used to perform the 
analyses. Results from the survey and database analysis were compared and the 
differences between them were tested for statistical significance using Pearson's χ2 
tests for categorical variables and t-tests for interval variables (including variables with 
a nonnormal distribution given the central limit theorem). Finally, multiple linear 
regression analysis was used to examine the relationship between the independent 
variables and trastuzumab use among different provinces. An alpha=0.05 was used to 
assess statistical significance. 
Results 
Clinician survey 
Of the 128 clinicians invited to participate in the survey, 52 (41%) responded and 48 
(38%) completed the entire questionnaire. A description of the respondents is shown 
in Table 3.1. The respondents were divided into two main groups of university 
instructors and other specialists. 
Table 3.1: The profile of responders 
 
Health care sectors Number of participants (%) Total (%) 
University 
instructors 
Public sector only  10 (19) 
36 (69) Private sector only 2 (4) 
Both public and private sectors 24 (46) 
Others 
Public sector only 6 (12) 
16 (31) Private sector only 4 (8) 
Both public and private sectors 6 (12) 
Total 52 52 (100) 
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HER2 test  
The first part of the questionnaire focused on how doctors determine if a patient has 
HER-2 positive breast cancer. Most respondents (84%) reported that they first use the 
immunohistochemistry (IHC) test and then, depending on the IHC test result, order a 
fluorescence in situ hybridization (FISH) test. The remaining respondents stated that 
they only examine the IHC results (12%), immediately order a FISH test (4%) or never 
order a test. Based on the respondents’ answers, 91% of all patients underwent at least 
one type of HER2 test (IHC or FISH). The database analysis yielded somewhat lower 
percentages, since it showed that 75% of the patients underwent the IHC (74%) and 
FISH (1%) tests before chemotherapy.  
Trastuzumab treatment plan 
When clinicians were asked how many of their patients are initially started on a 9-week 
regimen versus a 52-week regimen, their responses varied widely. At one end of the 
spectrum, some doctors planned a 9-week regimen for all of their patients while at the 
other end, some doctors planed a 52-week regimen for all of their patients. The different 
plans for trastuzumab therapy are shown in Figure 3.1. These results showed that only 
6% of respondents stated that they use a 9-week regimen (i.e., the treatment strategy 
recommended in the national guidelines) with all of their patients, while 39% of 
respondents had a plan to use a 52-week regimen with all of their patients. When the 
responses of the clinicians were combined with the frequency of their use of a 52-week 
vs 9-week plan, the results suggested that two-thirds (67%) of the patients were started 
on a 52-week regime and one-third (33%) were started on a 9-week plan. There was no 
significant difference between two specialist groups of university instructors and others 
(p=0.849) regarding these results. 
Figure 3.1: Distribution of the proportion of patients receiving the 52-week and 9-
week trastuzumab regimens based on the survey results. 
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The respondents mentioned that patients on average complete only 67% of their 
trastuzumab regimen. However, the actual percentage depended on the planned 
treatment duration. Patients who were supposed to undergo a 9-week trastuzumab 
regimen received trastuzumab for an average of 8.6 weeks while the patients who 
started their treatment with a 52-week plan received trastuzumab therapy for an 
average of 29.2 weeks. The database results were slightly lower than the survey results. 
The average duration of trastuzumab use found in the database was 6 (SD=2, range:1-
9) weeks for patients who received trastuzumab for a period of 9 weeks or less (n=196) 
and 23 (SD=12) (range:9-51) weeks for patients who received trastuzumab for a period 
longer than 9 weeks (n=303). Overall, patients received trastuzumab for an average 
duration of 21 weeks regardless of disease stage and completion or continuation of 
trastuzumab use, which was estimated by assuming that patients who did not use 
trastuzumab for more than 90 days had stopped using it. There was no significant 
difference between the survey results and the results from the database analysis 
(Pearson's chi-squared test, p=0.358) (Figure 3.2). 
When respondents were asked to provide the reasons to discontinue trastuzumab, they 
gave not only clinical reasons but also three non-clinical reasons: 1) inability of the 
patient to pay for trastuzumab and its administration; 2) lack of trastuzumab access in 
the region where the patient lived; and 3) lack of access to a specialist in the region 
where the patient lived.  
The database analysis revealed wide variation in the duration of trastuzumab treatment 
among the different Iranian provinces (Figure 3.3). As the map in Figure 3.3 shows, the 
average treatment duration ranged from 12 weeks in Semnan to 32 weeks in Ilam.  
Figure 3.2: The overall average of the proportion of patients receiving the 52-
week and 9-week trastuzumab regimens based on the results of the 
questionnaire and database analysis (difference between questionnaire and 
database, p = 0.358). 
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Factors affecting assessment on trastuzumab consumption 
We examined the correlation between average duration of trastuzumab treatment per 
province and several province-level parameters that might affect trastuzumab use, 
including the number of oncologists and pharmacies, geographical size of the province, 
average premium per beneficiary (2013), average age of patients in the database and 
female beneficiaries (n=16,392,192) among different provinces (Figure 3.3). Average 
premium was used as a proxy for household income, which was not available due to 
confidentiality reasons. The associations seen between trastuzumab use and the 
various parameters were small and suggested that these parameters do not adequately 
explain the variation in trastuzumab use.  
 
  Coefficients Standard Error P-value 
Number of oncologists* 0.182 0.140 0.207 
Number of pharmacies* -0.230 0.163 0.171 
Vastness of province* -0.023 0.060 0.702 
Premium earned by SSO per beneficiaries (2013)* 0.148 0.139 0.295 
Patients average age  -0.020 0.015 0.207 
Female beneficiaries average age  0.012 0.030 0.689 
*Natural Logarithm (LN)  R2=0.248 
  
Figure 3.3: The average of trastuzumab continuation (n = 1295) and correlation between the 
important independent variables and duration of trastuzumab use based on a multiple linear 
regression analysis among the different provinces in Iran (n = 31). 
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Discussion 
Policymakers with inherently limited healthcare budgets must contemplate the total 
financial impact of providing an expensive drug when deciding whether to reimburse it. 
HER2-positive breast cancer is a costly disease due to the use of expensive drugs like 
trastuzumab and costs will likely continue to increase as new treatment options 
emerge, such as pertuzumab in combination with trastuzumab. Though indicated for a 
fairly narrow group of patients (0.07-0.09% of the whole population in Iran), 
trastuzumab is very expensive compared with many other medications and can 
therefore have an important impact on healthcare budgets.  
If the healthcare budget cannot accommodate the total costs of a specific new drug 
(including related costs such as administration), policymakers could consider two 
divergent approaches that will not increase the overall healthcare budget: a benefit 
package modification (where some services are cut to make room for a new 
intervention) and a full-payment patient scheme (where patients must pay for all of the 
costs of the new intervention themselves). These two choices represent the two ends 
of a reimbursement decision-making spectrum. Policymakers choosing to cut services 
would face some very tough decisions since many services might have to be omitted 
from the benefit package to offset the total costs of trastuzumab; these omissions may 
even lead to more health loss than the health gains from trastuzumab [55]. The other 
extreme of asking patients to cover all of the costs of trastuzumab could be viewed as 
ethically inappropriate since trastuzumab is prohibitively expensive for many patients. 
If these two extremes are excluded as options, the resource-sensitive guideline chosen 
by Iranian policymakers may be seen as one of the unsatisfying but reasonable solutions 
for trastuzumab.  
Iranian policymakers tried to implement a resource-sensitive guideline with a 
recommendation of 9 weeks regimen for trastuzumab use [50]. And interestingly 
enough, the 9-week treatment regimen was recommended despite the explicit 
admission that it is not as effective as the 52-week regimen [56]. In fact, the only reason 
to support a 9-week regimen seems to be the high budget impact of trastuzumab, even 
though the extra budget required to finance a 52-week regimen versus a 9-week 
regimen might seem limited given a 0.024% annual incidence in women age 30+ years. 
However, this amounts to a total of almost 9,120 new early breast cancer cases per year 
[57]. In monetary terms, if we assume an average weight of 70 kg and include 
administration and cardiac monitoring costs, an extra 40-75 million euros (1 
euro=35,500 rials, 2014) would need to be spent to finance an increase in 
recommended duration from 9 weeks to 52 weeks. Relative to the total annual 
outpatient health care costs of 1,021 million euros in 2013 [58] for the SSO, this would 
mean an increase in expenditures of 2-4%.  
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Guideline adherence is an important indicator of the influence of recommended 
practices on the behavior of healthcare professionals. Recent studies have shown that 
there is a wide range in adherence to national guidelines in the treatment of HER2-
positive breast cancer. For example, a large observational study on adherence to French 
prescription guidelines showed fairly low clinican adherence to French post-licensing 
guidelines, which contrasts with the high level of adherence to the regional clinical 
guidelines on the treatment of metastatic HER2-positive breast cancer [59]. To our 
knowledge, no other study has examined physician adherence to guidelines for 
trastuzumab therapy in early HER2-positive breast cancer. Our results suggest that the 
use of HER2 authentication methods in daily practice largely reflects what is 
recommended in the STG. In contrast, the results suggest a poor adherence to the STG 
regarding trastuzumab use.  
Iranian health insurers initially reimbursed a 9-week trastuzumab regimen, in line with 
the national guideline. Any patients receiving the 52-week regimen therefore had to 
pay for the remaining costs themselves. Since the cost difference between 9 and 52 
weeks is two times the average urban gross annual household income (7,800 euro/year) 
[60], longer treatment could increase the risk of catastrophic health expenditures, 
increased inequity and treatment failure. Interestingly, after the first year of 
reimbursement, insurers decided to reimburse a 52-week regimen due to pressure from 
physician and patient organizations. Phrases like “Mothers are going to die due to lack 
of funding” were used to influence the reimbursement policy [61,62]. While this 
extension of trastuzumab reimbursement satisfied patients and doctors, it also means 
that money needed to fund trastuzumab treatment will be shunted away from other 
treatments, which may cause health and efficiency loss elsewhere in the healthcare 
system [55].  
Since STGs in different countries for a particular treatment rely on a common evidence 
base and local circumstances, it is not surprising to see both similarities and differences 
between them. Table 3.2 provides an overview of various STGs in different countries 
for trastuzumab. While the recommendation for the pre-treatment diagnostic 
assessment is almost the same in many countries, differences between countries can 
be observed in the duration of trastuzumab therapy. It is worth noting that the 9-week 
trastuzumab regimen was once recommended in other countries besides Iran. 
Specifically, PHARMAC (The Pharmaceutical Management Agency) in New Zealand 
initially funded nine weeks of trastuzumab from 2007 [63], just like the Turkish Ministry 
of Health before 2010, along with a reimbursement plan [64]. This raises the question 
of why policymakers in these countries did not recommend the 52-week guideline right 
from the very start.  
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Table 3.2: A summary of current trastuzumab guidelines in different countries 
Country 
Year of 
publication 
Trastuzumab 
therapy intervals 
(weeks) 
Trastuzumab 
therapy duration 
(weeks) 
Cardiac 
monitoring 
intervals 
(months) 
Ref 
Sweden 2014 3 52 - [65] 
USA (NCCN) 2014 1 & 3 52 Every 3 [66] 
Belgium 2013 3 52 Every 3 [65] 
Finland 2013 3 52 Every 3 or 6 [67] 
Scotland 2013 1 & 3 52 Months 4 and 8 [68] 
Brazil 2012 - 52 - [69] 
Iran 2012 1 9 Every 3 [50] 
Netherlands 2012 3 52 Every 3 [70] 
Turkey 2010 1 & 3 52 Every 3 [71] 
New Zealand 2009 3 52 Every 3 [72] 
Australia 2007 1 & 3 52 Every 3 [73] 
UK 2007 3 52 Every 3 [74] 
Abbreviations: IHC: Immunohistochemistry, FISH: Fluorescence in Situ Hybridization, CISH: Chromogenic in 
Situ Hybridization, SISH: Silver in Situ Hybridization. 
 
There are two study limitations worth noting. First, the 41% response rate in our 
physician survey could suggest possible selection bias and it is possible that some 
physicians provided inaccurate or socially desirable answers in the survey. However, it 
is unlikely that these factors had a dramatic effect on the overall conclusions of this 
study since the survey results corresponded reasonably well with the claims database 
analysis using data on 50% of the Iranian population and almost whole Iranian 
oncologists. Second, the lack of access to some patient-level information necessitated 
analyses using province-level data, which are prone to ecological fallacy. This means 
that even though we found no significant associations between trastuzumab use and 
various parameters, it is still possible that important associations could be seen if 
patient-level data were to be used.  
Policymakers in MICs must admit that a resource-sensitive guideline can be an 
ineffective way to constrain costs if guideline adherence is poor. Policymakers in 
different MICs should share their strategies and experiences like the impact of drug 
price nego-tiations with manufacturers on the healthcare budget. Within a country, 
better collaboration between doctors and policymakers is necessary to promote mutual 
awareness about policymaking criteria and the socioeconomic impact of their decisions. 
In addition, stakeholders (including policymakers, doctors, patients, health insurers and 
the general public) need to reach a consensus about the optimal way to treat patients. 
Efforts to promote cooperation amongst stakeholders could be enhanced by some 
changes in reimbursement decision-making system [51]. For example, if applicants 
were required to submit the results of a country-specific cost-effectiveness analysis, 
knowledge about the cost-effectiveness of an expensive drug like trastuzumab could be 
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used to facilitate dialogue among the stakeholders, support drug price negotiation with 
producers, guide rational decision-making and help to improve guideline adherence.  
Conclusions 
In MICs, budget limitations represent a huge challenge for policymakers when they 
decide whether or not to reimburse an expensive intervention like trastuzumab. While 
price negotiations can be effective in containing overall costs, the design and 
implementation of a suitable resource-sensitive guideline may be another strategy to 
achieve that goal. However, the functionality of this strategy is totally dependent on 
physician adherence to STGs. Based on our findings regarding the use of trastuzumab, 
Iranian doctors appear to rely more on the medical literature than on national 
guidelines developed by the Ministry of Health. The stark contrast between the STG for 
trastuzumab and the preferences of doctors can be viewed as a sign that the system is 
not working as well as it should. It is therefore clear that additional efforts are necessary 
in the implementation of resource-sensitive guidelines. Policymakers choosing to 
implement resource-sensitive guidelines must consider ways to improve physician 
adherence. 
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Abstract 
Introduction: Expensive treatments like trastuzumab for HER2-positive breast cancer 
(BC) have placed a heavy burden on middle-income countries (MICs), which require a 
good understanding of real-world healthcare costs to make better reimbursement and 
implementation decisions. The two aims of this study were to estimate direct medical 
costs of treatment HER2-positive BC in Iran and to examine the fraction of total costs 
related to trastuzumab use into three disease stages. Since no patient registries existed, 
we used claims data and data mining to achieve these aims. 
Method: We performed a retrospective analysis of claims data from the Iran Social 
Security Organization, a health insurer which covers approximately 50% (~40 million) of 
the Iranian population. A data-mining algorithm using R software, validated using 
patient dossiers in the Cancer Research Center, identified 1295 patients and divided 
them into the three main HER2-positive breast cancer stages (early, loco-regional and 
advanced). Payers perspective was used to calculate the absolute and relative direct 
costs of medical services associated with the treatment of HER2-positive breast cancer 
in the public and private healthcare systems. 
Results: The number of women totaled 802 (early), 125 loco-regional and 218 
(advanced). Mean age was 45, 46 and 48 years, respectively, while mean follow-up in 
all stages was approximately one year. Average costs of direct medical care in early, 
loco-regional and advanced stages were €11,796 (95%CI: €9,356-€12,498), €8,253 
(95%CI: €6,843-€10,002) and €17,742 (95%CI: €15,720-€19,505), respectively. 
Trastuzumab accounted for the largest share of total costs in all three stages (range: 53-
76%). 
Conclusion: Stage-specific cost estimates derived from this study can be used to 
perform real-world cost-effectiveness analyses of therapies for HER2-positive BC and 
support healthcare financing decisions. Moreover, wherever comprehensive patient 
registries are infeasible or costly, real-world costs can be estimated through claims 
databases and data-mining strategies. 
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Introduction 
Breast cancer (BC) is the most frequent cancer in women worldwide with an estimated 
1.67 million new cancer cases diagnosed in 2012 (25% of all cancers) [15,16,75]. BC is 
also a costly illness throughout the world. For example, the US National Institutes of 
Health has estimated that medical expenditures for cancer will increase by 27% in 2020 
compared to 2010 due to growth and aging of the U.S. population, and estimated that 
BC will be responsible for a major share of $158 billion in 2020 [17]. 
BC has become one of the most frequent malignancies among Iranian women [19], 
which has led to increased efforts to find ways to reduce its burden through prevention 
or treatment. However, the impact of treating these patients on the overall healthcare 
budget can be dramatic because of the costs of medications such as targeted therapy 
with monoclonal antibodies (trastuzumab), even though the proportion of BC patients 
with HER2-positive is approximately 20-25%, [76]. Consequently, the decisions about 
financing and reimbursement regarding treatments for HER2-positive BC can be a 
serious issue for policymakers in Iran and other MICs [76-81].  
Cost-effectiveness studies are used to ensure value for money in treatment of BC by 
any expensive interventions. These studies need stage-specific patient level 
information both in costs and quality adjusted life years (QALYs) [82]. As far as we know, 
there is no country-specific cost analysis in Iran that has reported results representing 
the general Iranian population. 
Patient registries play an important role in providing patient level data that can be used 
to estimate the real-world effectiveness and effectiveness of treatments. However, 
their implementation is costly and sometimes infeasible in many MICs. Therefore, there 
is an important knowledge gap for cost estimation in these countries. On the other 
hand, claims databases are one of the possible sources to investigate resource use and 
costs in these countries. These sources of data can be used to estimate stage-specific 
costs, if patients were classified based on their disease stages. In this study, we used a 
tool to predict some important and necessary information that we normally obtain from 
patient registries. 
The first aim of our study was to estimate a real-world direct medical costs of HER2-
positive BC treatment in Iran. The second aim was to examine the fraction of stage-
specific total costs related to different stages of HER2-positive BC. These aims were 
achieved by using data-mining techniques applied to claims databases.  
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Methods 
General study design 
In sum, data from a claims database of the largest health insurance database in Iran 
were processed using data mining, combined with data from other sources, and then 
analyzed to estimate the direct medical costs of HER2-positive BC in each disease stage 
from payers perspective. The results of the data-mining process were verified using 
patient registry data. The following sections describe the main parts of the study. Figure 
4.1 shows an overview of the different steps of the study. 
Data sources for healthcare resource use 
Three sources were used to estimate healthcare resource use. Most data on outpatient 
services and costs were drawn from a major claims database of the Social Security 
Organization (SSO), a social and health insurance organization that covers more than 
50% (~40 million insurees) of the whole Iranian population [54]. Due to absence of an 
integrated country level database, data on inpatient services came from two general 
referral hospitals (Fayazbakhsh and Alborz), which operate under the supervision of the 
SSO [51]. Outpatient and inpatient data were received anonymously. Lastly, we used 
the results of a survey of 52 oncologists [76] to estimate some minor outpatient costs 
in those rare cases where health care services were not covered by the SSO (e.g., 
services provided by doctors in their private offices). Using all these available data, this 
study conducted in three steps.  
Step 1: Data-mining (Identification and categorization of patients and treatment 
regimens)  
This step comprised several sub-steps which are as follows: 
- Step 1.1: Design of patient classification algorithm 
The results of a survey of oncologists [6] and other sources such as clinical guidelines 
[1,9,10] were used to design a strategy for patient classification. The strategy was 
assessed by two academic oncologists and modified based on their feedback. The final 
patient classification algorithm was based on medication pattern (combination and/or 
sequence of drug administration) seen between three index dates. 
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- Step1.2: Data requirements 
Since different types of data were needed to classify patients and estimate stage-
specific costs, we prepared a list of necessary data in each category and then defined 
our data extraction strategy. 
- Step 1.3: Data extraction 
Four filters were used to select patients with HER2-positive BC in the main SSO 
database: diagnosis of cancer, female, history of a mammography and trastuzumab use 
in the past two years. The Iranian national health services coding system was used to 
identify women who underwent a mammography and received trastuzumab. After 
identifying patients, all cost data associated with BC in various healthcare services (e.g. 
medication, diagnosis tests, medical imaging, radiotherapy and hospitalization) were 
then extracted from different databases.  
- Step 1.4: Data cleaning 
This step involved a check for duplications, completeness of data, and consistency of 
chemotherapy approaches. Any duplicated records were removed from the database. 
Then, to improve completeness and uniformity of data, two exclusion criteria were 
applied. Firstly, we excluded patients who did not receive more than five 
“prescriptions” (or requests for a healthcare service) for a period longer than 2 months 
since the date of the first prescription containing chemotherapy. Secondly, patients 
were also excluded if they had a treatment regimen that was different than our 
previously defined treatment strategies. 
- Step 1.5: Applying classification algorithm  
Classification algorithm was used to categorize patients into three different stages 
(“early BC”, “loco-regional BC” and “advanced BC”) based on medication patterns over 
a 3-year observation period (21.3.2011-20.3.2014). A decision tree induction using a 
divide-and-conquer approach [83] was used to predict disease stages. We also used 
distance matrix analysis [84,85] to obtain possible medication combinations (Figure 
4.2). In the divide phase, we divided outpatient records into three main groups 
(radiotherapy, chemotherapy, and other medications). The main groups were 
continually divided into a number of subgroups of the same (or related) type until these 
subgroups became simple enough to find possible combination by using distance 
matrix. Then, in the conquer phase we found possible combinations of medication and 
radiotherapy over the observation period. Based on the results of the survey and 
guidelines we combined these different combinations to find the possible medication 
patterns. Afterwards, we calculated the probability that a particular woman had early 
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BC, loco-regional BC or advanced BC. The probability that a woman was in a given health 
state was based on the ‘confidence’ about the association between our previously 
defined patterns and discovered patterns. Therefore, the confidence was calculated by 
the number of discovered medication patterns representing any specific health state 
divided by the number of all discovered medication patterns in all health states [84]. 
For example, if data-mining found one medication pattern that represents early BC and 
there were three discovered medication patterns (regardless of the disease stage), then 
the value of confidence for early BC would be 33.3%. We also defined a minimum 
threshold of 70% for stage-specific confidence. If the confidence of one of the three 
stages was higher than 70%, the patient was categorized into that stage. Otherwise, we 
examined the possibility of overlap between the groups. In other words, the possibility 
that patients progressed during the observational period (e.g. from early BC to loco-
regional or advanced BC). In this case, we looked at the difference between index dates 
of each health state. If the difference between two or three index dates was more than 
3 months, patients were categorized into multiple stages with different index dates, 
otherwise the health state with the highest confidence was selected. For patients with 
early BC, an index date was set for each patient according to the first date of 
chemotherapy or radiotherapy (whichever happened earlier) according to possible drug 
combinations for early BC treatment. The loco-regional BC index date was defined as 
the first date when the patient received vinorelbine or capecitabine use or single-agent 
chemotherapy by taxols (docetaxel or paclitaxel). Finally, the index date for advanced 
BC patients was the first date of gemcitabine, zoledronic acid or temozolomide use. 
Patients who could not be classified into one of the three stages due to lack of 
chemotherapy records were categorized as unclassifiable.  
Figure 4.2: The processes of patient classification 
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In general, data-mining resulted in the classification of patients into three health states, 
including a patient-specific time interval representing the start and end dates of 
treatments at any particular health state.  
Step 2: Verification of patient classification algorithm   
Patient-level data from the Cancer Research Center (CRC) were used to verify the results 
of the patient classification algorithms. We included all patients at this center who were 
HER2-positive and SSO beneficiaries (n=51); patients were considered to have HER2-
positive BC if their IHC result showed two or more pluses or their FISH test was positive. 
Verification involved comparing the results of the algorithm results with the clinical 
results based on the tumor, node, and metastases (TNM) classification system. We 
examined if patients categorized as having early stage BC by the classification algorithm 
were in stages I or II of BC, if patients with loco-regional BC had stage III BC and if 
patients with advanced BC had stage IV BC. 
Step 3: Cost calculations 
Firstly, ‘service-based treatment costs’ were estimated using the national coding 
system for health care services. All outpatient and inpatient services costs are classified 
based on national coding system for healthcare services. Outpatient care costs were 
calculated focusing on prevalent healthcare services (e.g. chemotherapy, hormone 
therapy, radiotherapy, diagnostic tests and medical imaging). Inpatient costs were 
estimated by extracting data from two hospitals on the surgical procedures used in BC 
management (e.g., lumpectomy, mastectomy and oophorectomy); this data were 
extracted from the same period as the outpatient data (21.3.2011-20.3.2014).  
Afterwards, we used the results of data-mining to calculate ‘stage-specific treatment 
costs’. As mentioned earlier, data-mining was used to categorize patients into three 
health states. Moreover, data-mining helped us to determine the duration of time that 
individual patients spent in each health state (stage-specific time interval). Therefore, 
stage-specific costs over time were estimated as follows. Various outpatient healthcare 
services costs (e.g. medications, radiotherapy, diagnostic tests, medical imaging) were 
calculated based on the individual stage-specific time interval. For those patients whose 
outpatient and inpatient data were available, inpatient costs were categorized based 
on their stage-specific time interval obtained from data-mining on outpatient data. 
In both service-based and stage-based costs, we also included treatment costs in the 
private sector, since the unit costs can differ between the public and private sector and 
patients are free to choose their healthcare provider [51]. Therefore, to estimate the 
treatment costs of patients in the private sector, the prices of medical services in the 
public sector were first converted to private prices based on the official private tariffs 
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in the period of 2011-2014 [86]. Treatment costs in the private sector were then 
calculated based on amount of resources used and converted prices. In certain rare 
instances, this conversion was also based on the results of a survey of Iranian 
oncologists [76]. In all above steps, costs unassociated with BC as well as the costs of 
uncompleted treatment regimens were excluded from the analysis. 
Analysis 
The claims data were analyzed to determine the mean and distribution of resource use 
and costs of different medical treatment regimens, including chemotherapy, hormone 
therapy, radiotherapy, laboratory tests, medical imaging services and surgery in the 
different BC stages. 95% confidence intervals (CIs) were calculated using non-
parametric bootstrapping. The number of iterations was 2000 times in all cases. All 
data-mining process and calculations were made using R software (version 3.2.2) for 
Windows.  
Results  
Data extraction, cleaning and patient classification 
The data extraction process yielded 1,295 patients with an average age of 44 years 
(Table 4.1). 54 patients were excluded from the study due to small number of 
prescriptions or inconsistency between their chemotherapy approach and our 
previously defined drug combinations. Of the 1,241 patients, 802, 125 and 218 patients 
were categorized into early BC, loco-regional BC and advanced BC, respectively. The 
mean ages of women in the different health stages ranged from 45-48 years and 
average follow-up durations per patient was 425 days. Furthermore, on average, the 
follow-up duration per stage were 397 (early BC), 349 (loco-regional BC) and 357 
(advanced BC) days. During the follow-up period, 158 patients with early BC progressed 
to loco-regional (n=41) or advanced BC (n=106), 19 patients progressed from loco-
regional to advanced BC, and 11 patients progressed through all three BC stages. Finally, 
284 patients were not classifiable due to lack of chemotherapy records.  
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Table 4.1: Age characteristics of study patients with HER2-positive BC 
Stages Before analysis Early BC Loco-regional BC Advanced BC 
Number of 
patients 
1295 802 125 218 
Age  at start date 
 (2011-03-21) 
at index date  at index date  at index date  
Average [SD] 44 [10]  45 [10] 46 [10] 48 [10] 
Age range (%)     
≤34 222 (17) 120 (15) 15 (12) 21 (10) 
35-44 447 (35) 261 (33) 46 (37) 54 (25) 
45-54 409 (32) 267 (33) 38 (30) 84 (39) 
55-64 172 (13) 124 (15) 22 (18) 47 (22) 
≥65 45 (3) 30 (4) 4 (3) 12 (6) 
Abbreviation: SD: Standard Deviation 
Patient classification verification 
Patient-level data, obtained from CRC, represents a group of patients who were 65% 
(n=33) in early BC, 10%(n=5) in loco-regional BC and 25%(n=13) in advanced BC. 
Verification of the classifications based on data-mining revealed an 84% (n=43) accuracy 
rate. Specifically, 49% (n=25) of early BC, 12% (n=6) of loco-regional BC and 27% (n=14) 
of advanced BC patients were correctly categorized. Two (4%) patients had both loco-
regional and advanced BC in the observation period. Some patients with loco-regional 
and advanced BC were incorrectly categorized as having early stage BC (14% (n=7) of 
patients in the loco-regional stage and 2% (n=1) of patients with advanced BC). In 
contrast, data-mining was able to categorize patients in loco-regional or advanced BC 
with 100% accuracy. 
Service-based treatment costs - Outpatient costs 
The different outpatient costs are shown in Table 4.2. The costs were weighted based 
on proportion of resource use between public and private sectors; medication costs 
required no weighting because there are no price differences between the two sectors. 
The average costs also include the costs of drugs used as concomitant drugs in 
chemotherapies like antiemetics. The most common chemotherapy regimen among 
early BC patients consisted of a taxane (docetaxel or paclitaxel) along with doxorubicin 
and cyclophosphamide (66%). The more expensive medications in early BC comprised 
different combinations of chemotherapy including docetaxel. Patients with loco-
regional BC were almost uniformly distributed among different treatment regimens. 
Vinorelbine was used in the treatment of almost half (45%) of the advanced BC patients. 
Tamoxifen and letrozole were the two most common types of hormone therapy.  
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Table 4.2: A verage costs of outpatient services 
 Continued   n=1,241 
 Costs as of 20.03.2014 (1€=34,000 rials) 
Provided 
by public 
sector* 
Treated (%) Mean [SD] € Range € 
Medications      
 Chemotherapy (Early BC) 
    
All NA 802 (65) 11,865 [8,247] 623-45,275 
trastuzumab NA 757 (61) 10,565 [7,668] 332-40,447 
doxorubicin + cyclophosphamide + 
docetaxel 
NA 314 (25) 2,480 [1,335] 105-6,925 
doxorubicin + cyclophosphamide + 
paclitaxel 
NA 236 (23) 1,164 [433] 249-2,444 
epirubicin + cyclophosphamide + docetaxel NA 100 (8) 2,507 [1,016] 703-5,459 
fluorouracil + epirubicin + 
cyclophosphamide + docetaxel 
NA 65 (5) 2,108 [988] 372-4,737 
epirubicin + cyclophosphamide + paclitaxel NA 39 (3) 1,321 [390] 638-2,249 
fluorouracil + doxorubicin + 
cyclophosphamide + docetaxel 
NA 19 (2) 1,747 [802] 713-3,474 
paclitaxel OR docetaxel + carboplatin NA 14 (1) 1,953 [1,081] 297-3,721 
fluorouracil + epirubicin + 
cyclophosphamide + paclitaxel 
NA 12 (1) 940 [235] 604-1,337 
fluorouracil + doxorubicin + 
cyclophosphamide + paclitaxel 
NA 7 (1) 1,293 [560] 402-2,196 
 Chemotherapy (Loco-regional BC) 
    
 All NA 125 (10) 7,776 [6,768] 75-34,363 
 trastuzumab NA 90 (9) 8,346 [6,420] 820-29,700 
 capecitabine NA 42 (3) 604 [472] 140-2,165 
 vinorelbine NA 26 (3) 1,129 [1,124] 26-4,929 
 paclitaxel NA 19 (2) 750 [612] 188-2,846 
paclitaxel OR docetaxel + capecitabine NA 18 (2) 1,881 [1,415] 151-4,884 
 docetaxel NA 18 (2) 1,741 [884] 392-3,697 
paclitaxel OR docetaxel + carboplatin NA 5 (0) 1,597 [1,415] 446-4,047 
 Chemotherapy (Advanced BC) 
    
 All NA 218 (18) 14,191 [12,045] 108-49,453 
 trastuzumab NA 198 (16) 11,471 [8,793] 756-42,560 
 vinorelbine NA 72 (6) 1,967 [1,769] 41-8,845 
 capecitabine NA 63 (5) 1,277 [845] 159-3,579 
 
paclitaxel OR docetaxel + 
capecitabine 
NA 29 (2) 1,347 [1,080] 93-2,665 
 
paclitaxel OR docetaxel + 
carboplatin 
NA 15 (1) 1,672 [1,380] 236-5,627 
 docetaxel NA 16 (1) 1,039 [830] 265-2,690 
 paclitaxel NA 13 (1) 2,021 [1,918] 155-6,217 
doxorubicin + cyclophosphamide + 
docetaxel 
NA 3 (0) 1,656 [839] 693-2,227 
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 Continued   n=1,241 
 Costs as of 20.03.2014 (1€=34,000 rials) 
Provided 
by public 
sector* 
Treated (%) Mean [SD] € Range € 
doxorubicin + cyclophosphamide + 
paclitaxel 
NA 3 (0) 1,207 [685] 542-1,910 
fluorouracil + epirubicin + 
cyclophosphamide + paclitaxel 
NA 3 (0) 1,839 [640] 1,223-2,501 
epirubicin + cyclophosphamide + docetaxel NA 1 (0) 713 [NA] NA 
fluorouracil + epirubicin + 
cyclophosphamide + docetaxel 
NA 1 (0) 1,683 [NA] NA 
fluorouracil + doxorubicin + 
cyclophosphamide + paclitaxel 
NA 1 (0) 2,529 [NA] NA 
epirubicin + cyclophosphamide + paclitaxel NA 0 (0) 0 0-0 
fluorouracil + doxorubicin + 
cyclophosphamide + docetaxel 
NA 0 (0) 0 0-0 
lapatinib + capecitabine NA 0 (0) 0 0-0 
 Hormone therapy 
    
 All NA 662 (53) 168 [241] 1-1,257 
 tamoxifen NA 272 (22) 11 [8] 0-42 
 tamoxifen + triptorelin NA 135 (11) 407 [245] 51-1,145 
 letrozole NA 115 (9) 67 [48] 8-327 
 triptorelin NA 56 (5) 259 [206] 41-812 
 tamoxifen + letrozole + triptorelin NA 27 (2) 475 [329] 69-1,257 
 tamoxifen + letrozole NA 26 (2) 75 [44] 22-169 
 exemestan NA 9 (1) 436 [178] 164-777 
 letrozole + triptorelin NA 7 (1) 553 [356] 229-1,187 
 tamoxifen + exemestan NA 2 (0) 553 [232] 389-717 
 goserelin NA 0 (0) 0 0-0 
Visit and administration     
 Oncologist visits per session 0.54# 1,241 (100) 4+ [2] 2Y-7 Y 
Chemotherapy administration per session  0.61# 1,241 (100) 28# [23] 4#-103# 
Cardiac monitoring services     
 Cardiac drugs NA 676 (55) 8 [15] 1-156 
 Internist or Cardiologist visits 0.45 715 (70) 16 [21] 3-206 
 Cardiology services 0.63 115 (9) 518 [457] 136-1,989 
Radiotherapy 0.31 231 (19) 2,426 [1,313] 110-8,530 
Laboratory tests     
 All 0.21 1,180 (97) 112 [88] 2-1,308 
 Sampling fees 0.26 1,151 (93) 5 [4] 0-33 
 Hematology 0.25 1,129 (91) 10 [7] 1-50 
 Clinical chemistry 0.23 1,060 (85) 24 [24] 1-226 
 Cytopathology 0.19 786 (63) 6 [8] 2-56 
 Descriptive pathology 0.19 741 (60) 53 [34] 5-352 
 Tumor marker 0.16 693 (56) 32 [28] 0-263 
 Urinalysis 0.22 582 (47) 1 [1] 0-13 
 Hormones 0.15 549 (44) 13 [12] 3-105 
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 Continued   n=1,241 
 Costs as of 20.03.2014 (1€=34,000 rials) 
Provided 
by public 
sector* 
Treated (%) Mean [SD] € Range € 
 Serology and immunology 0.17 403 (32) 10 [15] 1-208 
  Microbiology 0.27 332 (27) 2 [2] 0-24 
 pecific clinical chemistry 0.17 320 (26) 8 [6] 1-43 
 Coagulation 0.17 241 (19) 3 [3] 1-36 
 Cytogenetics 0.17 24 (2) 162 [114] 2-400 
 Molecular genetics 0.06 21 (2) 87 [244]  16-1,140 
Medical imaging     
 All 0.19 1,157(93) 612 [1,158] 3-8,697 
 Ultrasound 0.14 833 (67) 29 [26] 4-197 
 X-ray 0.22 787 (63) 25 [18] 3-115 
 CT Scan 0.24 666 (54) 73 [58] 12-443 
 Nuclear medicine 0.15 476 (38) 73 [66] 15-1,347 
 MRI 0.22 313 (25) 80 [67] 30-715 
 Other services  0.25 26 (2) 83 [27] 21-115 
NA Not Applicable     
* This column shows the proportions of healthcare utilization in the public sector (Number of services in 
public sector/Total number of services (private + public)). 
# The data obtained from the results of a questionnaire survey. [76] 
Y The unit costs obtained from the national health care services tariff 2014 [87] 
+ The unit cost obtained from the SSO yearly report (2014) [58] 
Abbreviation: SD: Standard Deviation, CT-Scan: Computed Tomography Scan, MRI: Magnetic Resonance 
Imaging 
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In all three BC stages, there is a rapid increase in outpatient-related costs during the 
first year after the index date (Figure 4.3) followed by a gradual increase and a plateau.  
 
Figure 4.3: Cumulative outpatient costs in different health states 
of HER2-positive breast cancer in Iran, over a 3-year follow-up 
period (21.3.2011-20.3.2014). 
Service-based treatment costs - Inpatient costs 
Table 4.3 shows the inpatient costs based on the two main surgical operations 
(mastectomy and oophorectomy), which were based on information from two hospitals 
and 710 patients. The mean costs were calculated using all components of 
hospitalization costs, including procedure, nursing, accommodation, medication, 
laboratory tests, medical imaging, pathology, medical equipment and physiotherapy. 
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The mean costs of mastectomy and oophorectomy were 293 and 261 euros 
respectively.  
Table 4.3: Average costs of mastectomy and oophorectomy.  
(Costs as of 20.03.2014; 1€=34,000 rials) 
Inpatient services 
Number 
of 
patients 
Mean 
admission 
days[SD]  
Mean 
cost[SD] € 
Range € 
Mastectomy 141 3.57 [3.09] 293 [178] 31-1,242 
Partial 42 1.93 [1.47] 125 [138] 38-718 
Partial with axillary lymphadenectomy 7 3.29 [1.11] 179 [63] 103-254 
Simple, complete 20 1.60 [1.43] 103 [65] 53-350 
Radical, including pectoral muscles and axillary 
lymph nodes 
7 4.57 [3.26] 190 [90] 68-324 
Radical, including internal mammary lymph 
nodes, unilateral 
41 5.49 [3.52] 261 [174] 111-1,144 
Modified radical, including axillary lymph 
nodes but leaving pectoral muscles 
24 4.63 [2.90] 309 [247] 31-1,242 
Oophorectomy 569 3.38 [4.68] 261 [172] 62-2,550 
Partial resection of ovary (unilateral or 
bilateral) 
145 3.60 [3.62] 161 [102] 62-756 
Wedge resection or bisection of ovary 
(unilateral or bilateral) 
14 6.14 [7.90] 209 [111] 113-547 
Ovarian cystectomy (unilateral or bilateral) 374 3.24 [4.83] 200 [196] 66-2,550 
Oophorectomy, Unilateral or bilateral, partial 
or total 
36 2.92 [1.42] 166 [104] 83-570 
Abbreviation: SD: Standard Deviation 
Stage-specific direct medical healthcare costs 
As Table 4.4 shows, trastuzumab accounted for the largest share of total direct medical 
costs; its share was almost 76% for early BC, 73% for loco-regional BC and 56% for 
advanced BC. The relative costs of other medications (including chemotherapy, 
cardiovascular drugs, analgesics and hormone therapies) were similar in early BC and 
loco-regional BC but much greater in advanced BC (Figure 4.3). Other cost components 
comprised a limited share of the total costs. 
The average cumulative direct medical costs for early BC were €11,796 (95% CI: €9,356-
€12,498) over the follow-up period. The treatment costs for loco-regional BC averaged 
€8,253 (95%CI: €6,843-€10,002). In contrast, the mean costs for advanced BC (95% CI) 
was 17,742 (€15,720-€19,505), which was roughly 50% higher than the costs for early 
stage BC. 
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Table 4.4: The overall average costs (public and private sectors) in three stages of BC during the 
follow-up period. Results after applying nonparametric bootstrapping.  
Costs as of 20.03.2014 (1€=34,000 rials) 
  
Early BC 
Loco-regional 
BC 
Advanced BC 
Number of patients  802 125 218 
Average follow up period (Days [SD])  397 [198] 349 [234] 318 [204] 
 Provided 
by public 
sector* 
Mean € (SE) Mean € (SE) Mean € (SE) 
 
95%CI 95%CI 95%CI 
Trastuzumab NA 
9,018 (233) 6,009 (591) 12,985 (648) 
8,566-9,452 4,975-7,296 11,745-14,340 
Medications (Others) NA 
1,838 (44) 1,642 (125) 3,547 (127) 
1,764-1,944 1,422-1,906 3,274-3,858 
Specialists visit 0.54 
79 (4) 86 (7) 119 (11) 
76-82 74-98 107-132 
Chemotherapy 
administration# 
0.61 
135 (46) 145 (42) 220 (16) 
122-149 129-161 201-239 
Radiotherapy 0.46 
440 (32) 243 (61) 121 (48) 
382-507 137-385 57-298 
Laboratory tests 0.16 
57 (2) 51 (6) 54 (5) 
54-61 42-65 46-64 
Medical imaging 0.24 
55 (2) 77 (7) 91 (10) 
51-60 64-91 75-118 
Inpatient services 0.83 
174 (49) - 335 (102) 
105-243  215-456 
Total (95%CI)  
11,796 8,253 17,742 
9,356-12,498 6,843-10,002 15,720-19,505 
CI Confidence Interval; NA Not Applicable; SE Standard Error; 
* This column shows the proportions of healthcare utilization in the public sector. (Number of services in 
public sector/Total number of services (private + public). 
# The data obtained from the questionnaire [76] 
Abbreviation: SD: Standard Deviation, SE: Standard Error 
Discussion 
BC is a costly illness throughout the world in general. When monoclonal antibodies like 
trastuzumab or pertuzumab are used and included for treatment of BC, then it would 
be a very costly illness with a significant budget impact specifically in MICs. We 
performed a real-world cost analysis using a large claims database and a validated 
patient classification algorithm to estimate stage-specific healthcare utilization and 
costs in associated with HER2-positive BC in Iran.  
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Our findings show that total direct medical costs per patient averaged €11,796 for early 
BC, €8,253 for loco-regional BC and €17,742 for advanced BC. The largest share of the 
total cost is spent on trastuzumab. Other medications like chemotherapy and hormone 
therapy are the second most important cost drivers in BC. The relative costs of other 
medications associated with advanced BC were dramatically higher compared with 
early and loco-regional BC (Figure 4.3). This was due to the use of other expensive 
medications to manage the effects of cancer metastasis to other organs or other 
medications to control the side-effects of chemotherapy. In early BC, the most common 
regimens of chemotherapy were the combination of an anthracycline antibiotic like 
doxorubicin and cyclophosphamide followed by a taxane like docetaxel. This was also 
in accordance with the results of a previous study [76]. In contrast to costly outpatient 
services, inpatient medical cares had only a minor impact on total costs. It should be 
noted that BC treatment in Iran is mostly provided on an outpatient basis, something 
that has been emphasized in studies in other countries [88]. For example, Vera-Lionch 
et al showed that inpatient costs of BC care, even for metastatic BC, accounted for 
approximately 20% of total BC costs in the United States [88]. These results (Table 4.1) 
reveal that the average age of BC is lower than the average age seen in other countries. 
Fifty years has been considered as the average age for early HER2-positive BC based on 
the majority of trials [30,89,90]. These results also correspond with the findings of 
previous Iranian epidemiological studies [91,92].  
The direct costs of treating patients with BC have been already estimated based on 
patients referred to one hospital in Iran [22]. Although that study examined the costs in 
different disease stages, its study population was small, which limited the precision of 
the results, and only one hospital was included, which limited the generalizability of the 
findings. In addition, that study did not report the costs of patient subgroups with tumor 
receptor expression. In contrast, our study provides more details concerning different 
treatment patterns and cost components on a national level, although it focused only 
on HER2-positive BC. Another recently published study of the economic burden of BC 
in Iran estimated the direct medical costs of BC using a societal perspective [23]. 
However, comparisons between their results and our results are not possible since the 
authors did not report resource use and unit costs separately [82]. 
Like any study, our study also has its limitations. The first limitation relates to our study 
population. That is, one could argue that the claim data covers approximately 50% of 
the population and therefore may not represent the whole Iranian population. 
However, our results can be generalizable to the whole population because the four 
main payers in Iran have the same benefit package and because the SSO covers the 
insurees from different socio-economic classes in all provinces [6]. Secondly, we 
focused on BC patients treated with trastuzumab limits the generalizability of the cost 
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estimates to other BC patients. While this is certainly true for trastuzumab costs, this 
selection is likely to have only a limited effect on other costs since trastuzumab use does 
not affect the choice of drug combinations or decisions about dose adjustment of 
chemotherapy. Therefore, our findings can cover direct medical costs in both patient 
populations by including or excluding the costs associated with trastuzumab. Thirdly, 
since inpatient data from two hospitals was used, our cost estimates of inpatient care 
might not reflect the average costs across all hospitals in Iran. However, this limitation 
has no major impact on the overall results since BC management is mainly performed 
on an outpatient basis in Iran and the outpatient costs were based on data from more 
than 45,700 (~100%) healthcare providers [58]. Fourthly, while data mining achieved a 
high accuracy rate of 84% (of classifying patients into the correct stage of BC), it was 
not perfect, meaning that some patients were incorrectly classified. Cost estimates 
using the verification results led to an increase in total costs for loco-regional BC (i.e., 
€10,161, 23% higher than the €8,253 from data mining) and a slight decrease in total 
costs for advanced BC (i.e., €17,402, 2% lower than the €17,742 from data mining), 
respectively. Therefore, total costs in loco-regional BC should be used with caution. The 
accuracy of classification can be improved by adding electronic results of diagnosis tests 
to the patient classification algorithms. Finally, the cost estimates in our study do not 
include illegal and informal payments [93] by patients to health care providers. 
Authorities in the Ministry of Health currently claim that they were able to reduce 
improper payments significantly over the past three years as a result of president 
Rouhani’s health care reform implementation [94]. However, due to lack of information 
we are not able to determine its impact on the final results of this study. The importance 
of excluding these costs may not be significant if the perspective of the health care is 
taken in estimating costs but could be important if a societal perspective is taken. 
This study shows that if relevant data are available, data-mining techniques can provide 
cost estimates that are invaluable in performing real-world cost-effectiveness analyses 
in MICs. National level cost-effectiveness analyses can use these cost estimates to 
determine if these costs are justified from a health economic viewpoint. For example, 
policymakers can reduce uncertainties about the cost-effectiveness of trastuzumab by 
performing a cost-effectiveness analysis using the results of our real-world cost analysis. 
The quality of reimbursement decision-making can be improved by using information 
about actual healthcare utilization and costs. One option in high-income countries 
would be an extensive cost analysis supported by patient registry data and electronic 
health records. However, implementation of comprehensive patient registries is costly 
and sometimes logistically infeasible in many MICs. If integrated electronic records are 
unavailable, researchers may have to rely on small sample sizes or expert opinion (e.g., 
[22], [23]) to estimate the medical direct costs of an illness. Both of these methods have 
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their shortcomings, which might affect the internal validity and generalizability of the 
results. Claims databases would be useful sources for cost analyses in MICs as long as 
the disease status of patients is known or adequately predicted. 
Conclusion 
This study estimated the stage-specific direct medical costs associated with HER2-
positive BC in Iran using a large claims database and data mining with validated patient 
classification algorithms using data from a patient registry. The findings show that the 
largest component in overall costs in all stages of BC is medication and that trastuzumab 
is the major cost driver. These real-world data can support cost-effectiveness analyses 
of implementation new technologies for HER2-positive BC management and thereby 
help to optimize reimbursement decision-making in an MIC.  
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Abstract 
Introduction: Clinical guidelines have recommended a one-year trastuzumab regimen 
as standard care for early HER2-positive breast cancer. However, this recommendation 
can have a dramatic impact on total drug expenditures in middle-income countries 
(MICs). We performed a cost-effectiveness analysis from the Iranian healthcare 
perspective to find an optimum duration of trastuzumab use in Iran. 
Method: We compared four treatment strategies comprising chemotherapy and 
varying durations of trastuzumab use (no-trastuzumab, 6-month, 9-month, and one-
year). A Markov model and probabilistic sensitivity analysis were used to estimate the 
costs and effects of the strategies. We then examined the cost-effectiveness of the 
strategies at different willingness-to-pay (WTP) thresholds, and ages at the onset of 
treatment.  
Results: Incremental costs (vs. no-trastuzumab) were €8,826 (6-month), €13,808 (9-
month) and €18,588 (12-month) while incremental QALYs were 0.65 (6-month), 0.87 
(9-month) and 1.14 (12-month). At a threshold of 3×GDP/capita (€21,000/QALY) and 
for patients younger than 59 years, the 6-month protocol was most likely to be cost-
effective (probability of 42%). At a threshold of 4×GDP/capita (€28,000/QALY), the 6-
month and one-year regimens were essentially equal in cost-effectiveness (37% and 
35%, respectively). At this WTP threshold, the 6-month and one-year regimens were 
optimal strategies only for patients up to 66 and 44 years respectively. 
Conclusion: In contrast to clinical guidelines, 6 months of trastuzumab may be the most 
cost-effective option for Iran. The lower absolute WTP threshold and lower life 
expectancy compared to high-income countries are two crucial parameters in cost-
effectiveness of interventions in MICs. It is therefore necessary to strive a balance 
between maximum population health and maintain affordability in these countries. 
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Introduction 
Trastuzumab is a monoclonal antibody that is used in the management of breast cancer 
(BC). It has mostly been used as adjuvant treatment for patients in the early stage of BC 
who overexpress human epidermal growth factor receptor 2 (HER2). Trastuzumab’s 
huge share of total drug expenditure, particularly in middle-income countries (MICs), 
has raised concerns among policymakers regarding efficient resource allocation in their 
countries [76]. To date, one year of trastuzumab use is considered as the optimum 
duration of therapy for the adjuvant treatment of the early stage of HER2-positive BC 
[28,89,95] based on the results of various randomized controlled trials (RCTs).  
Iran, as an MIC, provided a national guideline that recommends a 9-week period of 
trastuzumab use [50] due to unaffordability of one year trastuzumab therapy [76]. 
However, clinical evidence suggests that very short durations of trastuzumab therapy 
cannot provide significant efficacy [28]. Therefore, the main question in this regard is 
“What is the maximum obtainable level of health in an MIC when we are dealing with 
an expensive intervention?”  
The aim of this study is to provide a model-based cost-effectiveness analysis (CEA) of 
adjuvant trastuzumab for patients with early HER2-positive BC from the Iranian 
healthcare perspective. Subsequently, we undertake a scenario analysis to determine 
the optimum duration of trastuzumab use in Iran.  
Methods 
In our study, we compared two treatment approaches (chemotherapy with and without 
trastuzumab) to managing early HER2-positive BC. A Markov model was used to 
estimate the marginal differences in clinical outcomes and healthcare costs. We 
designed a cohort for patients with HER2-positive BC and included the necessary 
information in this model to estimate the incremental cost-effectiveness ratio (ICER) of 
using trastuzumab for these patients with a lifetime horizon in Iran. Afterward, a 
scenario analysis was conducted to compare the cost-effectiveness of different 
strategies of trastuzumab therapy in an MIC.  
Model structure 
We designed a model structure based on three sources of information (Figure 5.1). 
Firstly, the routine practice of treating HER2-positive BC in Iran was understood based 
on a previous study of clinical practice using a claims database and clinician survey [76]. 
Then, we discussed our interpretations of the results through a number of interviews 
with two Iranian academic oncologists and based on our final decision on data 
availability. The model was designed to be able to compare two main arms 
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(trastuzumab versus no-trastuzumab). It included six main health states: 1) early BC, 2) 
loco-recurrence BC, 3) advanced BC, 4-5) two progression-free health states after 
treatment in early BC and loco-recurrence BC, and 6) death. We also included other 
health-state subgroups for loco-recurrence (loco-regional and second primary BC), and 
advanced patients (central nervous system (CNS), visceral, bone, and soft tissue 
metastasis). Moreover, we incorporated long-term cardiotoxicity in all states in which 
patients use trastuzumab. A three-month cycle length was used in the model [76].  
In the model, patients with early HER2-positive BC received chemotherapy with or 
without trastuzumab. After treatment, patients moved to a follow-up state and could 
progress to local or advanced BC. Patients stayed in the follow-up state until the 
occurrence of progression (local or distance recurrence) or second primary BC. We 
assumed that patients in both arms were equally likely to receive all other medical 
services. Patients who had progressed to loco-recurrence after receiving the treatment 
could move to the disease-free state after the local-recurrence state or progress to 
advanced BC. Patients who progressed to advanced BC stayed there until they died from 
BC or other causes. Some of the patients who received trastuzumab developed 
reversible cardiac toxicity. Patients in all health states could die due to background 
mortality.  
Patient characteristics 
We set the age at onset of treatment at 45 years in accordance with the results of a 
variety of current claims database [96] and epidemiological [97-99] studies in Iran.  
  
Figure 5.1: The summary model structure 
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Transition probabilities 
The following items describe the input parameters used in the model as well as their 
sources. Various transition probabilities used in the model are shown in Table 5.1. 
- Treatment effect 
Effectiveness of trastuzumab was derived from a Cochrane review [28], which was a 
comprehensive systematic review and meta-analysis of eight RCTs regarding disease-
free survival (DFS) of trastuzumab. Due to our study design, we relied on a DFS hazard 
ratio based on the results of the meta-analysis of those trials (5 of 8) that investigated 
the effects of more than 6 months of trastuzumab therapy. To include the treatment 
effect duration in the model, we used an assumption that was used in a CEA of 
trastuzumab in the United Kingdom (UK) [31], based on discussions with experts.   
- Cancer progression  
For the first 4 years, the recurrence rate in the no-trastuzumab arm was obtained from 
the latest HERceptin Adjuvant (HERA) trial [30] report after 4-year patient follow-up 
[100]. For years 5-10, the recurrence rates were taken from the anthracycline-treated 
HER2-positive subgroup of the national surgical adjuvant breast and bowel project 
protocol (NSABP) B-15 trial [90]. Since the (NSABP) B-15 trial only focused on lymph 
node-positive patients, we applied a relative risk of 0.815 based on a study reporting 
that 63% of Iranian patients have node-positive BC at the time of diagnosis [19] and the 
assumption that node-positive patients have a recurrence rate that is two times greater 
than node-negative patients [101]. We also assumed no chance of recurrence after 10 
years based on expert opinion. The ratio of loco-recurrences to distant recurrences was 
obtained from the results of the HERA trial [102]. Two hazard ratios were applied to 
represent the increased risk of distant metastases after local recurrence. These hazard 
ratios were 3.22 (95% CI 2.02, 6.55) and 6.14 (95% CI 2.02, 6.55) for years 1-4 and 5-10, 
respectively [103].  
- Cardiac toxicity 
The results of a systematic review and meta-analysis of the Cochrane review [28] were 
used to estimate the probabilities of decline in left-ventricular ejection fraction (LVEF) 
and congestive heart failure (CHF) occurring during one-year of trastuzumab therapy 
and other chemotherapy drugs. The time of onset and toxicity duration for patients who 
suffered from reversible cardiac toxicity were taken from the HERA trial [104]. 
Moreover, patients suffer from CHF based on an age-specific background and these 
probabilities were obtained from a cohort study of 6,504 individuals in one province of 
Iran [105].   
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Table 5.1: Transition probabilities. 
Parameter 
Base-case 
estimate 
Distribution 
Distribution 
parameters 
Source 
Trastuzumab effectiveness     
DFS hazard ratio (12 M vs 0 M) 0.62 Log-Normal µ = -0.49,  = 0.13 Moja et al. [28] 
DFS hazard ratio (6 M vs 12 M) 1.28 Log-Normal µ = 0.23,   = 0.16 Pivot et al. [89] 
DFS hazard ratio (9 M vs 12 M) 1.14 Log-Normal µ = 0.13,   = 0.08 Assumption 
Treatment effect duration 48 M Log-Normal µ = 3.87,   = 0.31 Hall et al. [31] 
     
Disease progression     
Recurrence without trastuzumab     
Months 1-48 0.28 Beta α = 472,   β = 1226 Gianni et al. [100] 
Months 49-60 0.23 Beta α = 35,     β = 116 
Paik et al. [90] 
Months 61-120 0.10 Beta α = 11,     β = 94 
Beyond 120 0 Fixed  Expert opinion 
Loco vs distant recurrences      
Without trastuzumab 0.355 Beta α = 100,   β = 182 
Gianni et al. [100] 
With trastuzumab 0.372 Beta α = 79,     β = 133 
Distance recurrence pattern     
Without trastuzumab     
Bone  0.25 
Dirichlet 
α1 = 38 
Piccart-Gebhart  
et al. [102] 
Soft tissue 0.12 α2 = 19  
Visceral 0.53 α3 = 82 
CNS 0.10 α4 = 15 
With trastuzumab     
Bone  0.28 
Dirichlet 
α1 = 24 
Piccart-Gebhart  
et al. [102] 
Soft tissue 0.07 α2 = 6  
Visceral 0.40 α3 = 34 
CNS 0.25 α4 = 21 
Second primary or contralateral 
breast cancer 
   
 
Year 1-4 0.019 Beta α = 33,    β = 1698 Gianni et al. [100] 
Year 5-10 0.026 Beta α = 10,    β = 359 Metzger-Filho et al. 
[106] 
Increased risk of distant metastasis 
after local recurrence (hazard ratio) 
    
Years 1-4 3.22 Log-normal µ = 1.16,    = 0.14 
Tanis et al. [103] 
Years 5-10 6.14 Log-normal µ = 1.68,    = 0.52 
     
Cardiac toxicity      
Trastuzumab-induced decline in LVEF  0.112 Beta α = 466,  β = 4147 
Moja et al. [28] Trastuzumab-induced CHF  0.025 Beta α = 135,  β = 5471 
CHF due to chemotherapies 0.004 Beta α = 20,     β = 4810 
Duration of reversible cardiac toxicity 3 months Fixed  
Suter et al. [104] 
Time of onset during treatment  3-6 months Dirichlet αs=8,69,14,27 
Population back ground level of CHF 
among Iranian females 
Age specific Normal  Talaei et al. [105] 
     
Mortality     
Background mortality for Iranian 
females 
Age specific Fixed 
 
NOfCR [107] 
Breast cancer specific mortality for 
Iranian females 
Age specific Fixed 
 Vostakolaei et al. 
[97] 
Mortality from heart failure for Iranian 
females (one-year - age adjusted) 
0.263 Beta α = 727  , β = 2042 Talaei et al. [105] 
Mortality due to metastatic BC      
Bone (over 5 years) 0.63 Beta α = 17    , β = 10 
Dawood et al. [108] Soft tissue (over 5 years) 0.77 Beta α = 12    , β = 4 
Visceral (over 5 years) 0.78 Beta α = 28    , β = 8 
Brain (over 9 months)  0.50 Beta α = 54    , β = 54 Niwinska et al. [109] 
Abbreviations: CHF: congestive heart failure; DFS: disease-free survival; LVEF: left ventricular ejection fraction; 
M: months 
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- Mortality 
Age-specific background mortality rates were obtained from online data by the national 
organization for civil registration (NOCR) [107] which included data on all causes of 
death in Iran. We used another study of BC mortality rates in three different age ranges 
[97] to subtract the BC mortality rate from the NOCR data. Data on the age-specific 
congestive heart failure (CHF) mortality rate in Iran was obtained from an Iranian cohort 
study [105]. Other parameters regarding BC mortality rates in various metastatic states 
were extracted from international studies.  
Outcomes 
Life-years (LYs) and quality adjusted life years (QALYs) were estimated for both arms. 
Table 5.2 shows the utility values used in this study. We used the results of a study that 
provided the utility weights for various health states, based on the EQ-5D questionnaire 
in Sweden [110]. Another study that used the EQ-5D was selected to find the utility 
weight for patients who suffer from symptomatic heart failure in the UK [111]. Finally, 
the utility value (EQ-5D) for patients with brain metastases was obtained from a CEA 
study in the UK [31].  
Costs 
Direct medical costs were calculated from an Iranian healthcare perspective. We 
assumed 100% coverage for all healthcare services by payers. It helps policymakers to 
examine the cost-effectiveness of complete coverage of all services. We used a recent 
study that investigated healthcare costs and resource use in both the public and private 
sectors in Iran which covers approximately 50% of all Iranians (~40 million) [96]. Due to 
the varieties of health insurance coverage in Iran [51], out-of-pocket payments were 
already included in cost calculations [96]. Therefore, the costs shown in Table 5.2 
comprise the total costs of medical services. The average patient weight must be known 
to calculate the cost of trastuzumab. Therefore, we used data from a 3-year 
observational period [76] to estimate the average weight based on the average dose of 
trastuzumab per patient who used trastuzumab. The average dose per patient per 
prescription was 420mg (95% CI: 415-424) (n=1,295) which corresponds with an 
average weight of 70kg (69-71). While this may not represent the true average weight 
of the patients, these real-world data represent the total amounts of trastuzumab used 
and wasted in reality. Patients received trastuzumab in a 3-week cycle until the end of 
therapy.  
The annual national healthcare tariff [112] was used to inflate or adjust the costs 
attained from years other than the 2014 to 2017 values.  
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Table 5.2: Utilities and costs (year 2017).  
Parameter Mean 
Standard 
error 
Distribution Source 
Health utilities 
Baseline (Disease free) 0.779 0.017 Beta Lidgren et al [110] 
Treatment of early stage 0.779 0.017 Beta Assumption 
Symptomatic cardiac toxicity 0.600 0.010 Beta Calvert et al [111] 
     
Loco-recurrence 0.780 0.040 Beta 
Lidgren et al [110] Second primary breast cancer (first year)  0.700 0.032 Beta 
Advanced (Bone, Visceral and Soft tissue) 0.690 0.033 Beta 
     
Advanced (Brain) 0.600 0.120 Beta Hall et al. [31] 
Costs (€)(1euro=34,000 rilas) 
Treatment     
Trastuzumab (1st cycle) 6,123  Fixed 
SSO [113] 
Trastuzumab (2nd, 3rd and 4th cycles) 5,623  Fixed 
     
Early treatment first year 3,689 245 Log-Normal 
Ansaripour et al 
[96] 
Trastuzumab administration (6-month)* 188 194 Log-Normal 
Trastuzumab administration (9-month)* 329 359 Log-Normal 
Trastuzumab administration (One-year)* 471 485 Log-Normal 
Follow-up annual cost 370 34 Log-Normal 
     
Cardiac toxicity     
Symptomatic heart failure annual cost 
584 140 Log-Normal Ansaripour et al 
[96] 
     
Cancer recurrence costs     
Second primary breast cancer 1st year 
6,024 228 Log-Normal Ansaripour et al 
[96] 
Second primary breast cancer annual cost 
As follow-up  
annual cost 
Log-Normal Assumption 
Loco-recurrence 1st year 3,922 177 Log-Normal 
Ansaripour et al 
[96] 
Loco-recurrence annual cost 2,238 357 Log-Normal 
Advanced treatment 1st year 18,151 1,394 Log-Normal 
Advanced treatment annual cost 8,324 2,027 Log-Normal 
     
* The cost of trastuzumab administration in the first 9 weeks is excluded here due to administration of 
trastuzumab with other chemotherapy drugs in the same sessions. The cost of trastuzumab administration 
in the first 9 weeks is included in the cost of early treatment in first year.   
 
Analysis  
In the absence of a national guideline for economic evaluations in Iran, both costs and 
effects were discounted by 3.5% per annum as suggested by the World Health 
Organization’s choosing interventions that are cost-effective (WHO-CHOICE) project 
[114]. A half-cycle correction was also applied.  
Adjuvant trastuzumab therapy for early HER2-positive breast cancer in Iran | 87 
5 
The influence of specific input parameters on the ICER of CEA was examined using 
deterministic sensitivity analysis (DSA). The ranges in values were determined based on 
the literature or expert opinion.  
A probabilistic sensitivity analysis (PSA) was performed in order to quantify the overall 
uncertainty in the expected output measures [115,116]. The log-normal distribution 
was applied for relative risks, hazard ratios, and costs. The Dirichlet distribution was 
used for multinomial proportions and the beta distribution was used for binomial 
proportions and utility weights. The analysis used 10,000 iterations obtained via Markov 
Chain Monte Carlo simulation.  
Based on WHO-CHOICE, the willingness-to-pay (WTP) threshold in Iran would be 
3×GDP/capita, which is equal to 21,000 euros per QALY (1€=34,000 rials) [117]. Because 
widespread international economic sanctions on Iran began in 2012, we used gross 
domestic product (GDP) per capita in 2011, as reported by the World Bank [118], to 
avoid the effects of these sanctions on the Iran’s GDP. 
The building of the model, calculations, and statistical analysis were performed using R 
software for Microsoft Windows (Version 3.2.2) [119].  
Estimation of the optimum duration and the max-age threshold for trastuzumab 
use 
Three scenarios of 6-month, 9-month and one-year of trastuzumab use were designed 
to compare their cost-effectiveness. We used the results of PHARE (a randomized non-
inferiority trial) [89], which compared six months versus one year of adjuvant 
trastuzumab therapy, and the results of a meta-analysis [28], which compared one year 
of trastuzumab versus no-trastuzumab therapy. For nine months of trastuzumab use, 
we assumed that the effectiveness hazard ratio which was half of the non-inferiority 
hazard ratio in PHARE trial (Table 5.1). The ICERs of the three strategies were calculated, 
and, eventually, their probability being cost-effectiveness were compared with that of 
the no-trastuzumab arm. Furthermore, due to the importance of patient age, we 
investigated how the age threshold for treatment can affect the optimal duration of 
trastuzumab use. Multiple PSAs were performed with various ages (40-70) as the age at 
onset of treatment to determine the ‘max-age threshold’ for the best-case scenario. 
The ‘max-age threshold’ represents the maximum age at onset of treatment that still 
results in the strategy being optimal versus other strategies included in the comparison 
at a particular WTP threshold. 
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Model validation 
Internal validation was performed to assess how well the model’s results for DFS and 
overall survival (OS) corresponded with the no-trastuzumab and one-year trastuzumab 
arms from the HERA trial. Similarly, the results of the PHARE trial were used to validate 
the model’s results for the one-year and 6-month trastuzumab strategies.  
Results 
Over a lifetime horizon, all trastuzumab strategies were cost-effective versus no-
trastuzumab at a WTP of 3×GDP (Figure 5.2). The results of CEA, shown in Table 5.3, 
show that at the WTP threshold of 3×GDP, and a 42% probability, the 6-month protocol 
was the most cost-effective strategy, while other strategies showed lower rates of being 
cost-effective. The acceptability curves representing the probabilities that various 
strategies are cost-effective across various WTP thresholds in the base-case scenario 
can be found in Figure 5.3. The one-year trastuzumab strategy was cost-effective in only 
21% of simulations, and the 9-month and no-trastuzumab strategies were cost-effective 
in 21% and 17% of cases respectively. When the WTP threshold was increased to 
4×GDP, the 6-month and one-year regimens were essentially equal in cost-effectiveness 
(37% and 35%, respectively). The 9-month regimen had a 20% probability of cost-
effectiveness. However, the chance the no-trastuzumab strategy was cost-effective fell 
to 8% when a WTP threshold of 4×GDP was applied.  
Table 5.3: The results of cost-effectiveness analysis 
 Cost QALYs LYs ICER (QALY) ICER (LY) 
No-trastuzumab €14,541 11.1 14.41 NA NA 
6-month trastuzumab 
€22,442 11.71 15.18 
14,625 11,664 
 = €8,901  = 0.61  = 0.76 
9-month trastuzumab 
€28,410 11.95 15.48 
16,370 13,037 
 = €13,869  = 0.85  = 1.06 
One-year trastuzumab 
€33,160 12.22 15.82 
16,695 13,279 
 = €18,619  = 1.12  = 1.40 
 = Incremental values for costs and effectiveness of trastuzumab therapy strategists versus no-trastuzumab. 
Abbreviation: ICER: Incremental cost-effectiveness ratio, LY: Life years, QALY: Quality-adjusted life-year 
 
The base-case and DSA of the model yields ICERs for 6-month, 9-month and one-year 
were €15,108, €16,800, and €17,086 per QALY versus no-trastuzumab respectively. 
Subsequently, deterministic one-way sensitivity analysis (summarized in Table 5.4), 
revealed that the key drivers were the acquisition cost and clinical effectiveness of one-
year of trastuzumab use versus no-trastuzumab. Additionally, probabilistic one-way 
sensitivity analysis showed that when the cost of trastuzumab was changed from -30% 
to +30% in the base case, the probability of the one-year regimen being cost-effective  
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Figure.5.2: Cost-effectiveness plan for trastuzumab use scenarios vs no-trastuzumab (a 
sample of 7000 results of PSA for every strategy). The ellipses represent 95% confidence 
intervals. 
 
Figure 5.3: Acceptability curves of the base-case scenario. 
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Figure.5.4: The impact of life expectancy on the probabilities being cost-effective 
among different treatment strategies.  
*max-age threshold: represents the maximum patient age at onset of treatment that for 
those patients strategy remains optimal at a particular WTP threshold. 
 
Figure 5.5: The impact of price reduction on max-age threshold at willingness-to-pay 
3×GDP in Iran.  
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decreased from 41% to 8% (Appendix 1). However, 6 months of trastuzumab therapy 
showed less of a change (9% (34%-43%)) at the threshold of 3×GDP. In contrast, changes 
in the HR of DFS for 6-month trastuzumab vs no-trastuzumab showed a range of 16% 
(54%-38%) in the lower (0.50) and upper (0.74) limits (Appendix 2). At a threshold of 
3×GDP, the 6-month regimen was the most cost-effective strategy (54%) for the lower 
limit of HR. The no-trastuzumab strategy was the cost-effective strategy for the upper 
limit of HR. Finally, our results (Figure 5.4) show that the 6-month strategy is only cost-
effective when treated patients are not older than 59 years (the max-age threshold). At 
this age and a WTP threshold of 3×GDP, the two strategies of 6-month of trastuzumab 
and no-trastuzumab had almost equal chances of being cost-effective (39.5% vs 40%, 
respectively). However, this age threshold can change if the WTP is increased or 
decreased. At the WTP threshold of 4×GDP, one-year of trastuzumab use is cost-
effective only for patients who are younger than 44 years, and 6-months of trastuzumab 
use may be the best strategy for patients between 44 and 66 years old (Appendix 3). 
Finally, the impact of various ages (40-70) on cost-effectiveness of different strategies 
are shown in Appendix 4.  
Figure 5.5 illustrates the effect of price reductions on max-age threshold. Our analyses 
revealed that trastuzumab is cost-effective only if the price were to be reduced by 30%. 
However, this reduction would make one year of trastuzumab the optimal strategy only 
if it was given to patients younger than 49.5 years. As the Figure 5.5 shows, a 10% 
reduction in price increases the max-age threshold by three and six years for 6-month 
and one-year treatment regimen respectively. 
The internal validation results for the three strategies including no-trastuzumab, one-
year and 6 months trastuzumab use revealed no significant differences between the 
results of the model and the results of the trials used to perform this study (Table 5.5). 
Table 5.5: The results of internal validation  
 
No-trastuzumab 
(HERA trial vs Model) 
6-month trastuzumab 
(PHARE trial vs Model) 
One-year trastuzumab 
(HERA trial vs Model) 
Overall survival P-value=0.489 P-value=0.388 P-value=0.424 
Disease-free survival  P-value=0.395 P-value=0.319 P-value=0.267 
 
Discussion 
The use of monoclonal antibodies such as trastuzumab is a hotly debated topic among 
policymakers, patients, and healthcare professionals in MICs due to their considerable 
impact on these nations’ healthcare budgets. For example, in Iran, trastuzumab alone 
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accounts for roughly 93-140 million euros (~4%-6%) of total pharmaceutical 
expenditure [76]. Trastuzumab is an effective but very expensive drug for patients with 
HER2-positive BC. Therefore, policymakers in MICs can neither ignore it because of its 
effectiveness, nor reimburse it with the same duration as clinical guidelines have 
recommended in high-income countries (HICs) due to its cost. Specifically, more money 
spent on trastuzumab means less money for other treatments [55]. The questions that 
healthcare professionals and policymakers in these countries must answer include: 
“What is the optimum duration of trastuzumab use to provide an efficient and 
affordable treatment?” and “How can we balance population health and affordability?” 
In response to these questions, our study provides valuable information regarding the 
cost-effectiveness of various trastuzumab strategies in Iran, which may also be useful 
for other MICs. Moreover, to our knowledge, this is the first CEA that examines age 
heterogeneity of patients and explores the impact of life expectancy on the cost-
effectiveness for various trastuzumab strategies in an MIC. 
The effectiveness of shorter durations of trastuzumab therapy has been studied in 
various RCTs. FinHER (Finland Herceptin) trial [120] investigated the clinical outcomes 
in 9 weeks of trastuzumab use and reported an HR=0.42 (95%CI: 0.21-0.83, p=0.01) for 
the DFS of trastuzumab use versus no trastuzumab. This study, however, was faced with 
some limitations such as small sample size and the results of other trials (SOLD [121] 
and SHORT-HER [122]) that also focused on 9-week trastuzumab use have not yet 
published. As a result, therefore, we excluded the 9-week strategy as a comparator in 
this study. The clinical outcomes of 6-month trastuzumab use were the subject of two 
RCTs (PHARE [89] and PERSEPHONE [123]). Since only the results of PHARE are currently 
available, we used the PHARE results in this study. Our assumption regarding the DFS 
HR in the 9-month strategy was not supported by a real RCT. Assumptions were 
therefore necessary to make to investigate a potentially cost-effective strategy 
between 6 months and one year of trastuzumab use. Finally, the model was internally 
validated based on the results of the aforementioned RCTs. 
A previously published CEA reported that one year of trastuzumab use is not cost-
effective in Iran [124]. However, this study has some methodological inconsistencies 
when assessed using the Drummond economic evaluation checklist [82] and also used 
an inappropriate trastuzumab cost. The cost of one-year of trastuzumab use by a 70-
kilogram woman was estimated at $48,850, which is inconsistent with the public price 
of trastuzumab dosage forms (€500 and €1,294 for 150mg and 440mg vials, respectively 
(€22,992) [125]). Consequently, it was necessary to conduct a new study using 
appropriate methods and more reliable input parameters. For this purpose, we 
attempted to design a standard economic evaluation using country-specific information 
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such as the results of a real-world cost analysis that exclusively investigated HER2-
positive direct medical costs in Iran [96]. 
Our results show that the most cost-effective strategy in the treatment of early HER2-
positive BC in Iran is 6 months of trastuzumab as an adjuvant therapy. This strategy 
remains optimal, even if the price of trastuzumab is reduced by almost 30% (Appendix 
1). The one-year strategy is cost-effective only at higher WTP thresholds. Since, the 9-
month strategy was dominated by the 6-month and one-year strategies, from an 
efficiency perspective, the 6-month and one-year strategies are the two best strategies. 
If the 6-month protocol is considered the standard of care and doctors continue to 
adhere to this strategy, Iran can save €40 million/year compared to a one-year 
trastuzumab strategy. It is worth noting that all these results can be vary if the age of 
patients at onset of treatment is changed and that these various strategies for 
trastuzumab use would not be cost-effective in patients older than 59 years (Figure 5.4). 
In other words, in addition to a lower absolute WTP threshold for expensive drugs in 
MICs, life expectancy in these countries (e.g. 76.6 years for Iranian women) is also 
generally lower than in HICs. These two issues can affect the results of a CEA in MICs.  
We compared our results with the results of model-based CEAs [31,126-129] in other 
countries that used the same study perspective (healthcare), time horizon (lifetime), 
and trastuzumab use duration (one-year). Two studies (in China [126] and Belgium 
[129]) calculated ICER values that were lower than that in our study ($8,041 and 
€10,315 respectively) while four CEAs (in the USA [127,128], Australia [130], and the UK 
[31]) estimated higher ICERs ($39,982; $26,417; $A22,793; and £25,803, respectively). 
Regardless of this variation, in all studies, including our study, ICERs were primarily 
affected by the cost of trastuzumab. Despite the methodological similarities between 
this study and other studies, we cannot easily compare our results with other CEAs 
because of differences in various parameters such as costs of trastuzumab, prices for 
healthcare services, discount rates, background mortality rates, and sources of 
estimation of the effectiveness of trastuzumab. On the other hand, a CEA in Colombia 
using a shorter time horizon (20 years) concluded that trastuzumab is not cost-effective 
even though trastuzumab was cheaper (US$4,219 vs €22,992) and advanced stage 
treatment (downstream costs) was more costly (US$52,093 vs €16,926) compared to 
costs in Iran[131]. However, comparisons between that study and our study are difficult 
not only because of differences in time horizon and cost components, but also because 
of differences in the sources of clinical effectiveness and utility values that were used. 
This means that comparisons between CEAs of trastuzumab between MICs are also 
prone to the same problems that arise when comparisons between CEAs in HICs are 
performed. 
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Our study faced four notable limitations. Firstly, we had to use the results of studies 
performed in HICs due to the lack of country-specific health-related quality of life 
(HRQoL). In fact, there are no good-quality publications on HRQoL in Iran. This 
limitation, however, has no major impact on the overall results since our one-way 
sensitivity analysis showed ±30% changes on utility values caused less than ±8% on the 
estimated ICER. Secondly, the HERA trial has recently reported 11 years of median 
follow-up and data from this could have been used to update the parameter estimates 
in our model [132]. However, the updated estimate of effectiveness of trastuzumab 
after 11 years was lower than the effectiveness after two years (i.e., an increase in the 
hazard ratio for disease-free survival from 0.62 to 0.73). However, the results of one-
way sensitivity analysis (Appendix 2) that any reduced effectiveness of trastuzumab 
would not change the conclusion that the price of trastuzumab must be reduced 
significantly in order for it to have any chance of being cost-effective for even a 
subgroup of the patient population (i.e., younger patients). Thirdly, the cost-
effectiveness of 9-month strategy was estimated based on an assumption of 
effectiveness because of lack of data. Despite its low impact on overall results as 
demonstrated by sensitivity analysis (Table 5.4), our CEA can be updated when the 
results of SOLD [121] and/or SHORT-HER [122] become available. Finally, while it is 
known that women with hormone receptor negative tumors have an increased risk of 
recurrence and death we did not examine the cost-effectiveness of treatment decisions 
based on hormone receptor status [133]. This is something that should be examined in 
the future. 
New drugs launched in MICs do not necessarily have the same effectiveness or 
affordability as in HICs. Policymakers and other primary stakeholders, such as 
healthcare professionals and patient communities, should focus on a strategy that will 
help to create a balance between the highest attainable level of health and affordability 
of the new drug. However, if there is a desire to implement widely accepted clinical 
guidelines in MICs, concessions are unavoidable. There are four approaches that would 
lead to recommending one-year trastuzumab use in Iran: 1) price reduction, 2) use of a 
higher WTP threshold, 3) combination of these two methods, and 4) 'watchful waiting' 
for a generic product. Our results showed that the first two options, either price 
reduction (by -30%)(Figure 5.3) or the use of a higher WTP threshold (4×GDP), cannot 
achieve a new balancing point between population health and affordability to switch to 
a longer course of trastuzumab therapy (Appendix 3). The third option could be a 
potential solution, however due to changes on price of trastuzumab and WTP threshold, 
the max-age threshold for one year of trastuzumab use should be re-estimated. 
Moreover, the use of a higher WTP would set a precedent for other treatments. The 
‘watchful waiting' approach can indeed enhance affordability in MICs. However, this 
would mean waiting many years before drugs like trastuzumab would be reimbursed in 
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MICs. In many cases, ‘watchful waiting’ would mean a large amount health loss. 
Therefore, a more equitable solution would involve revamping pharmaceutical pricing 
systems to make new drugs more affordable for lower income countries. For example, 
a 75% price reduction would be needed to make one year of trastuzumab, the strategy 
recommended in clinical guidelines in HICs, cost-effective for all patients younger than 
76.6 years (the average life expectancy) in Iran (Figure 5.5). 
Effectiveness and affordability are not the only two factors to consider when 
policymakers make reimbursement decisions. Other factors, such as budget impact and 
equity analysis, are also important to consider. In fact, using multi-criteria decision 
analysis (MCDA) that includes various factors, is likely the best way to help policymakers 
reach a satisfactory conclusion [7].  
Conclusion 
Most clinical guidelines prepared in HICs have recommended one-year trastuzumab use 
due to the efficacy of the drug. However, this treatment strategy would not be an 
affordable recommendation in MICs due to the lower absolute value of WTP threshold 
and the lower life expectancy as compared with HICs. Our study showed that 6-month 
trastuzumab use is the most cost-effective option for the Iranian healthcare setting at 
a WTP threshold of 3×GDP and a max-age threshold of 59 years. Policymakers and other 
stakeholders in MICs must find the best way to balance population health and 
affordability of an expensive intervention. 
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Appendixes 
 
Appendix 5.1: Acceptability curves at the lower and upper limits of cost of trastuzumab as the 
results of one-way sensitivity analysis. 
 
Appendix 5.2: Acceptability curves at the lower and upper limits of effectiveness of 
trastuzumab as the results of one-way sensitivity analysis. DFS HR: Disease-free survival hazard 
ratio. 
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Appendix 5.3: The impact of WTP thresholds and life expectancy on the probabilities being cost-
effective among different treatment strategies at two WTP thresholds of 2×GDP and 4×GDP. 
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Appendix 5.4: Acceptability curves of various patient age at the onset of treatment as the 
results of one-way sensitivity analysis 
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Abstract 
Introduction: The results of cost-effectiveness analyses (CEAs) are often generalized 
between countries. However, the accuracy of their results is remaining uncertain when 
these countries have important differences in their economies and healthcare systems. 
The aims of this study are firstly to investigate compatibility between the results of 
transferred CEAs from high-income countries (HICs) with a previously published CEA in 
Iran (a middle-income country (MIC)). Secondly to identify bias factor(s) affected 
transferability from HICs to MICs, and finally to propose a method for estimating cost-
effectiveness of a drug in MICs. 
Method: We systematically searched and selected model-based CEAs in HICs which 
were based on the same method with an original country-specific CEA in Iran. The 
transferability of these studies to Iran was assessed using the Van Haalen method. 
Incremental quality-adjusted life-years (QALYs) were adjusted based on differences in 
life expectancy from age at treatment onset. Two methods were used to estimate 
incremental costs. In the conventional method, costs were corrected using consumer 
price indices and transferred to the Iranian setting using purchasing power parities 
(PPP). The proportional method involved estimating initial trastuzumab costs and 
combining them with the incremental downstream costs. Cost-effectiveness results 
using these methods were then compared with the results of an Iran-based CEA. 
Results: Five of the nine CEAs identified were considered transferable. The transferred 
incremental costs of the conventional method (€21,419(USA); €5,115UK); 
€12,550(USA); €9,170(Portugal); €10,187(Belgium)) did not match the incremental 
costs of the Iranian CEA (€19,056). However, we could estimate closer incremental costs 
(€19,988(USA); €19,742(UK); €19,320(USA); €19,497(Portugal); €19,361(Belgium)) with 
the proportional method. 
Conclusion: This study introduces a method to facilitate transferring the results of CEAs 
from HICs to MICs which is more efficient than the current methods. When there is a 
major economic gap between countries and external price referencing has a major 
impact on pricing in MICs, costs of expensive drugs should not be transferred using 
relative PPPs. The proportional method may be a solution to estimate a rough ICER in 
MICs while a country-specific CEA is recommended for a reimbursement decision-
making. 
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Introduction 
Cost-effectiveness analysis (CEA) is an important and valuable part of knowledge in 
health technology assessment (HTA) which is a prerequisite for pricing and 
reimbursement decision-making. The first CEAs of any new intervention are usually 
conducted in high-income countries (HICs) due to its preliminary market release and 
their results are used for initial pricing in these countries.  
CEAs are time-consuming studies, need detailed information, and require an adequate 
research capacity. These factors mean that CEAs are not always possible to perform, 
particularly in middle-income countries (MICs). Using methods that help to transfer the 
results of CEAs in other countries may be a solution to overcome above limitations in 
MICs. Previous studies have focused on different methods to transfer the results of 
CEAs from a study country to a target country. The feasibility of transferring (due to lack 
of information) and accuracy of the results of a transferred CEA, however, remain 
uncertain, specifically when study and target countries have important difference in 
their economies and healthcare systems. To our knowledge, there is a lack of 
appropriate solution for transferring CEA when there is a lack of necessary information. 
Moreover, no study investigated the accuracy of the results of a CEA that has been 
transferred from a HIC to an MIC, even though this type of transferability is more 
complex than transferability between HICs. Therefore, the aims of this study are firstly, 
to investigate the transferred results of CEAs performed in HICs to an MIC. Secondly, to 
identify what potential bias factor(s) affected transferability from HICs to MICs, and 
finally to propose a method to estimate of cost-effectiveness of a drug considering the 
limitation of necessary information in MICs. We used the results of a previously 
published cost-effectiveness analysis in Iran as the gold standard [134].   
Methods:  
We searched and used all model-based CEAs which assessed the cost-effectiveness of 
trastuzumab in early stage HER2-positive breast cancer in HICs. Subsequently, the Van 
Haalen method [135] was used to select transferable health economic evaluation 
models. In the next step, incremental QALYs and costs of selected CEAs were 
transferred to the Iranian setting. We used and compared the results of transferring 
costs to estimate the incremental cost-effectiveness ratios (ICERs) with the results of an 
Iranian-specific CEA, which was considered the “reference” study [134].  
The recommendation from the World Health Organization’s choosing interventions that 
are cost-effective (WHO-CHOICE) project [114] was used to determine cost-
effectiveness of transferred ICERs. On this basis, the highest willingness-to-pay (WTP) 
threshold in Iran is 3×GDP/capita (€21,000) [134]. 
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Search methods 
A systematic literature review was conducted in PubMed in December 2016. The search 
strategy is shown in Table 6.1. Two MeSH terms (“Cost-Benefit-Analysis” and “Breast 
Neoplasms”) were searched first, after which the term “trastuzumab” was included. As 
Table 6.1 shows, we then combined the above terms to find CEAs of trastuzumab in 
breast cancer and then added the term “early” in the search strategy to select studies 
in early-stage breast cancer. The search strategy was not limited to any publication year 
and language.  
Diagnosing the transferability 
The three-step approach by Van Haalen et al was used to select transferable CEAs to 
Iran. In the first step and due to our aim, we selected CEAs of trastuzumab in HICs. 
Moreover, only those studies were included that used the same method as the method 
used in the reference CEA. Therefore, we included model-based CEAs that used a 
healthcare perspective, a lifetime horizon and calculated direct medical costs and 
quality-adjusted life-years (QALYs) of one-year trastuzumab use among patients with 
an average age of 45-50 years. Studies were excluded if incremental costs and QALYs 
were not reported. In the second step of the Van Haalen method, Welte’s specific 
knock-out criteria [136] were used to indicate for which criteria the results of CEAs are 
biased and need to be adjusted. Finally, Drummond’s checklist [82] was used to assess 
the quality of CEA in the third step of the Van Haalen method. All studies that passed 
the Van Haalen method were then analyzed as the studies which were considered to be 
transferable between study and target country.  
Analysis of included studies 
We first checked whether patient-level cost estimates, including patient-level resource 
use data, were reported in sufficient detail. Lack of this level of detail meant we would 
be unable to estimate the cost for the Iranian setting. This was important because of 
differences in relative healthcare costs between study countries and Iran. Alternatively, 
we applied the following methods to transfer the utilities and costs: 
Transfer of QALYs 
In the five CEAs in HICs, there was a wide range of incremental QALYs across CEAs 
(Table 6.2), which was due to difference on source of effectiveness data. However, 
due to lack of good-quality publications on health-related quality of life in Iran, it was 
not possible to map the utilities between countries and therefore we assumed that 
trastuzumab lead to same QALY gains in Iran compared to other countries. However, 
the differences in discount rates and life expectancies need to be adjusted between 
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counties. The following steps describe how incremental QALYs adjusted from the 
selected CEAs to the Iranian setting 
- Adjusting the discount rates: 
We converted the incremental QALYs from those CEAs that used different discount 
rates than 3.5%, using the discount factors of the study country and target country. We 
also assumed that the main effectiveness appears in the first four years of treatment. 
This assumption was made based on the same approach which was used in the 
reference study [134] and also the CEA in the UK [31]. Then, the following formula used 
to adjust the incremental QALYs based on a 3.5% discount rate. 
𝐼_𝑄𝐴𝐿𝑌𝑆3.5% = 𝐼_𝑄𝐴𝐿𝑌𝒮 ×  
𝐷𝐹𝒮4
𝐷𝐹𝑖4
 
Where 𝐼_𝑄𝐴𝐿𝑌𝒮 is the incremental QALYs of the study country, 𝐼_𝑄𝐴𝐿𝑌𝑆3.5% is the 
adjusted incremental QALYs of the study countries based on a 3.5% discount rate and 𝐷𝐹𝒮 
and 𝐷𝐹𝑖 are discount factors in the study countries and Iran, respectively. 
- Adjusting incremental QALYs based on the difference in life expectancies 
between study countries and Iran: 
The incremental QALYs calculated in the previous step, were adapted based on the ratio 
of the overall life expectancy of Iranian women at age 45 [137] compared to the life 
expectancy of the average age used in the study country, using the following formula. 
𝐼_𝑄𝐴𝐿𝑌𝑖 = 𝐼_𝑄𝐴𝐿𝑌𝒮3.5%  ×  
𝐿𝐸𝑖
𝐿𝐸𝒮
 
Where 𝐼_𝑄𝐴𝐿𝑌𝑖 is the incremental QALYs in Iran and 𝐿𝐸𝑖 and 𝐿𝐸𝒮 are life expectancies 
among women in Iran and the study countries at a given age, respectively. 
The overall life expectancies of European countries were obtained from the European 
health and life expectancy information system [138] and data from the USA Social 
Security were used for the life expectancy of American women [139].  
Transfer of costs 
Two methods were used to transfer costs in absence of patient-level resource use data.  
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- Conventional method  
In the conventional method, the costs for both arms (trastuzumab and no-trastuzumab) 
reported in CEAs performed in other countries were adjusted to the costs in 2015 using 
country-specific consumer price index (CPI) data. After that, costs were converted to 
the currency of Iran using purchasing power parity (PPP) data.  
- Proportional method 
The basis of this method is a comparison of two simplified treatment strategies to treat 
HER2-positive breast cancer (Figure 6.1). As figure 6.1 shows, in this model, a 
combination of chemotherapy and trastuzumab is compared to chemotherapy alone. 
The chemotherapy regimens (Chemo) in two main stages of breast cancer (early and 
progressive) were assumed to be similar in both arms. Patients whose disease 
progressed, move to the progressed stage. Since the costs of trastuzumab can have an 
important impact on the incremental costs [96], we assumed that the incremental costs 
in the early stage could be estimated by calculating the costs of trastuzumab and its 
relative components using in this model. This meant cost components included 
trastuzumab acquisition costs, administration costs and the costs of trastuzumab-
induced cardiac toxicity. These were defined as ‘Incremental costs in early stage’ that 
were incurred by adding trastuzumab to routine care. However, it is possible that 
trastuzumab can reduce the risk of disease progression and thereby reduce 
‘downstream costs’. We estimated the difference in downstream costs by combining 
the absolute difference in risk of progression (between trastuzumab and no-
trastuzumab) with the costs of progression.  
 
Figure 6.1: The model structure was used in the proportional costing method 
Incremental costs (𝐼𝐶) are equal to the sum of the incremental costs in the early stage 
(𝐼𝐶𝜖) and the difference in downstream costs (𝐷𝐶): 
𝐼𝐶 = 𝐼𝐶𝜖 + 𝐷𝐶 
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Therefore, 𝐷𝐶 was calculated by multiplying the reduction in risk of progression by the 
cost difference between the two arms. 
𝐷𝐶 = (1 − 𝐸𝑓𝑓[𝐶ℎ𝑒𝑚𝑜𝜖 + 𝑇]) × 𝐶𝑝 − (1 − 𝐸𝑓𝑓[𝐶ℎ𝑒𝑚𝑜𝜖]) × 𝐶𝑝 
𝐷𝐶 = (−𝐸𝑓𝑓[𝐶ℎ𝑒𝑚𝑜𝜖 + 𝑇] + 𝐸𝑓𝑓[𝐶ℎ𝑒𝑚𝑜𝜖]) × 𝐶𝑝 
Where 𝐷𝐶 represents the downstream costs, 𝐸𝑓𝑓[𝐶ℎ𝑒𝑚𝑜𝜖 + 𝑇]  and 𝐸𝑓𝑓[𝐶ℎ𝑒𝑚𝑜𝜖] are 
the probability of progression-free survival in trastuzumab and no-trastuzumab arms in 
early stage of breast cancer respectively, and 𝐶𝑝 is the costs of treatment in progression 
stage.  
In this study, we used the results of a cost analysis study [10] to estimate ICϵ in Iran and 
used the results of the HERA trial to estimate 𝐸𝑓𝑓[𝐶ℎ𝑒𝑚𝑜𝜖 + 𝑇] = 0.790 and 
𝐸𝑓𝑓[𝐶ℎ𝑒𝑚𝑜𝜖]= 0.725 [11]. We assumed that Iranian policymakers can only estimate 
the extra costs relating to trastuzumab use and do not have sufficient data on other 
costs relating to current breast cancer treatment. To calculate an Iran-specific 𝐶𝑝, we 
first calculated the ratio between the costs of advanced breast cancer (𝐶𝑝𝒮) and 
Incremental costs in the early stage (𝐼𝐶𝜖𝒮) in each of the five CEAs in HICs. Using the 
𝐼𝐶𝜖 in Iran, we then estimated 𝐶𝑝 using the following formula.  
𝐶𝑝 = 𝐼𝐶𝜖 × (𝐶𝑝𝒮 ÷  𝐼𝐶𝜖𝒮) 
Where 𝐶𝑝𝒮 and 𝐼𝐶𝜖𝒮 are the costs of progression and Incremental costs in the early stage 
in HICs respectively. 
Eventually, we calculated the discounted incremental costs during first four years 
(Based on our assumption that the main effectiveness appears in this period) with 
yearly discount rate of 3.5% in correspond with the Iran-specific CEA.  
Results 
 Selection and transferability check of CEAs 
Nine CEAs were found through the literature search (Table 6.1), and five of these 
fulfilled our criteria in the first step of van Haalen’s method. Two of these studies were 
from the USA (Garrison et al [128] and Kurian et al [127]), while the other three were 
from the UK (Hall and et al [31]), Portugal (Macedo et al [140]) and Belgium (Van 
Vlaenderen et al [129]). Table 6.2 provides a summary of the methods and results of 
these five CEAs and the Iran-specific CEA [134]. As Table 6.2 shows, all six studies used 
the same overall methodology, although there were some differences regarding factors 
like age at onset of treatment, discount rate, and time horizon. The results of the second 
step showed that two main groups of costs and effectiveness need to be adjusted based 
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on Iran specifications (Table 6.3). Finally, the results of the third step of Van Haalen’s 
method showed that all five studies passed Drummond’s checklist and were considered 
as transferable CEAs to Iran. 
Table 6.1: The search strategy and the number of founded publications at every step.  
Search Query Items found 
#1 Search cost-benefit-analysis [mesh] 66,909 
#2 Search Breast Neoplasms [mesh] 243,752 
#3 Search trastuzumab 8,238 
#4 Search (#1 and #2) 1,440 
#5 Search (#4 and #3) 95 
#6 Search (#5 and early) 38 
#7 Selected 9 document(s) 9 
 
Table 6.2: A summary of the methods and results of CEAs in five high-income countries and Iran 
Study Kurian Garrison 
Van 
Vlaenderen 
Marcedo Hall Ansaripour 
Country USA USA Belgium Portugal UK Iran 
Year of costing 2005 2006 2007 2007 2008 2015 
Perspective  Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare 
Modelling method  Markov Markov Markov Markov Markov Markov 
Time horizon Lifetime Lifetime Lifetime Lifetime Lifetime Lifetime 
Duration of 
trastuzumab use 
One year One year One year One year One year One year 
Measure of 
effectiveness  
QALYs QALYs QALYs QALYs QALYs QALYs 
Average age at 
start 
50 50 50 50 50 45 
Duration of time 
horizon (Years) 
50 50 45 45 50 55 
Discount rate 
(Costs - effects) 
3% - 3% 3% - 3% 3% - 1.5% 3% - 3% 3.5% - 3.5% 
3.5% - 
3.5% 
Incremental cost US$76,669 US$44,923 €30,878 €21,280 £12,629 €19,056 
Incremental QALYs 0.53 1.70 2.98 2.01 0.49 1.14 
ICER (Cost/QALY) US$144,658 US$26,417 €10,315 €10,595 £25,803 €16,773 
 
Results of transferring QALYs 
The results of transferred incremental QALYs in all studies ranged widely between 0.46 
and 2.54 (Table 6.4).  
 Transfer of CEAs using the conventional method of transferring costs  
Table 6.4 shows the results of transferring costs using the conventional method. None 
of the incremental costs corresponded well with the reference incremental costs (based 
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on the Iranian CEA), usually because of an underestimation of incremental costs in most 
studies. Only the converted incremental cost obtained from the study by Kurian et al. 
(USA) estimated a higher incremental cost and a very different ICER compared to the 
results of the Iranian CEA. Figure 6.2A shows the dispersion of results obtained using 
the conventional method. Except for the transferred ICER from Kurian’s study, the other 
transferred ICERs suggest that trastuzumab is cost-effective in the treatment of early 
breast cancer in Iran. Moreover, the transferred ICERs from two European studies 
(Macedo et al and Van Vlaenderen et al) suggested that trastuzumab is a very cost-
effective intervention in Iran, since they were lower than the 1×GDP threshold.  
Table 6.3: Transferability of the results of CEAs in HICs to Iran based on the Welte’s specific 
knock-out criteria.   
Transferability criteria Impact on 
Relevance for 
transferability  
HICs and Iran 
Correspondence 
between HICs 
and Iran 
Need to 
be 
adjusted 
Perspective Costs and effects High High No 
Discount rate Costs and effects High High Yes 
Medical cost approach costs High Low Yes 
Productivity cost approach NA NA NA NA 
Absolute and relative prices Costs High Low Yes 
Practice variation Costs and effects High High No 
Technology availability Costs High High No 
Disease incidence / prevalence Costs and effects High High No 
Case mix Costs and effects High ? ? 
Life expectancy Costs and effects High Low Yes 
Health status preferences Effects High ? ? 
Acceptance, compliance and 
incentives for patients 
Costs and effects ? ? ? 
Productivity and absenteeism NA NA NA NA 
Disease spread NA NA NA NA 
Abbreviation: NA: Not applicable, ?: Unknown 
 Transfer of CEAs using the proportional method of transferring costs 
Based on the reference CEA, the 𝐼𝐶𝜖 was €24,046 in Iran. The results of ICϵ and 𝐶𝑝 
obtained from study countries are shown in Table 6.4. The ratios between 𝐼𝐶𝜖𝒮 and 
𝐶𝑝𝒮 was ranged from 0.71-1.20. Using the proportional method, transferred 
incremental costs based on the five HIC-studies shifted to a narrow range (€18,828-
€19,478) in Iran (Table 6.4). Figure 6.2B shows the distribution of the transferred 
incremental costs using the proportional method versus €19,056 in the Iran-specific 
CEA. According to three of the five results, trastuzumab was cost-effective in patients 
with HER2-positive breast cancer in Iran. In contrast, the transferred results from two 
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studies (Kurian et al, Hall et al) showed that trastuzumab was not cost-effective using a 
willingness-to-pay threshold of 3xGDP (Figure 6.2B). 
Table 6.4: The results of transferring of CEAs in five HICs compared with the results of CEA in 
Iran. 
 
Study Kurian Garrison 
Van 
Vlaenderen 
Marcedo Hall Ansaripour 
 Country USA USA Belgium Portugal UK Iran 
C
o
n
ve
n
ti
o
n
al
 
m
et
h
o
d
 
PPP 1 1 0.82 0.59 0.69 8,120 
Incremental costs €21,419 €12,550 €10,187 €9,170 €5,115 €19,056 
Incremental QALYs 0.49 1.58 2.54 1.74 0.46 1.11 
ICER (Cost/QALY) €43,390 €7,926 €4,013 €5,261 €11,077 €16,773 
P
ro
p
o
rt
io
n
al
 m
et
h
o
d
 
Incremental costs in 
early stage (ICES) 
US$64,185 US$56,066 €49,482 €49,619 £24,262 €24,046 
Costs of progression 
(CpS) 
US$45,792 US$50,000 €59,616 €53,481 £28,434 - 
Ratio (CpS/ICES) 0.71 0.89 1.20 1.07 1.17 - 
Incremental costs in 
early stage (ICE) 
€24,046 €24,046 €24,046 €24,046 €24,046 €24,046 
Costs of progression 
(Cp)  
€17,073 €21,401 €28,855 €25,729 €28,134 - 
Downstream costs (DC) -€1,110 -€1,391 -€1,876 -€1,672 -€1,829 - 
Incremental costs (IC) €22,936 €22,655 €22,170 €22,374 €22,217 - 
Incremental costs (IC) 
(Discounted) 
€19,988 €19,724 €19,320 €19,497 €19,361 €19,056 
Incremental QALYs 0.49 1.58 2.54 1.74 0.46 1.11 
ICER (Cost/QALY) €40,491 €12,469 €7,611 €11,187 €41,929 €16,773 
Abbreviations: DC: Downstream costs in Iran; Cp: costs of progression in Iran; CpS: costs of progression in 
study country; IC: Incremental costs in Iran ICE: Incremental costs in early stage in Iran; ICES: Incremental 
costs in early stage in study country; QALY: Quality-adjusted life-year 
Discussion  
Methods to transfer the results of CEAs between countries have enabled policymakers 
to obtain estimates of the cost-effectiveness of new technologies faster and more easily 
and they help to circumvent any lack of country-specific information and research 
capacity. However, the accuracy of these methods can be questioned when the study 
country and target country have important differences in their economies and/or 
healthcare systems. We aimed to examine and compare the compatibility of the results, 
which were obtained from transferring methods with the results of a previously 
published CEA in Iran. 
To our knowledge, this is the first study that investigates the accuracy of transferring 
the results of multiple CEAs from HICs to an MIC and proposed a simple solution for 
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transferring the results of CEAs in case of lack of information. We used standardized 
methods to search and select CEAs, and later to verify the possibility of transferring the 
results of these CEAs. This ensured comparability of methodology with other similar 
studies that transferred the results of a CEA between countries. However, the Van 
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Figure 2: The comparison of the results of two methods that were used for transferring the 
results of CEAs in five high-income countries to Iran (the conventional method (A) and the 
proportional method (B)) with the results of an Iran-specific cost-effectiveness analysis as the 
gold standard.   
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Haalen method needs to be revised for transferring CEAs between HICs and MICs. 
Because it would not be easy to assess the quality of a CEA when the model and patient 
level data are not accessible. Different studies used various data sources to estimate 
costs and outcomes and it can result in a wide range of ICERs across countries, which is 
evident in this study. Therefore, in case of our study, it is difficult to select one of the 
five CEAs as the most accurate CEA when their results were transferred to an MIC 
setting. Perhaps one says that none of five CEAs are perfectly fitted to transfer in an 
MIC due to lack of patient level-cost and effectiveness estimates both in study and 
target counties. However, from a policymaking point of view in MICs, CEAs in HICs are 
probably the only information that they have access and this study tries to find a 
solution to overcome this gap of knowledge. 
During our study, we had to address the lack of access to the patient-level costing 
information in all five studies. We used two methods in this study to calculate 
incremental costs. The conventional method was a naïve approach to transfer the 
results of CEA between HICs using PPP conversion factor after adjusting reported costs 
to 2015 costs. The proportional method was a more sophisticated approach where we 
divided costs into two general categories of incremental costs in the short term (𝐼𝐶𝜖) 
and the long term (𝐷𝐶), based on a method applied by Redekop et al in a study [141] 
which was not aimed at transferring the results of a CEA. This alternative method 
bypassed the need for various calculations regarding cost adjustment, such as using CPI 
and PPP conversion factor, which meant that we only need to transfer the ratio 
between 𝐼𝐶𝜖𝒮 and 𝐶𝑝𝒮 from any study country. More explanations may make our 
strategy more clear. We all know that treatments strategies are basically identical 
throughout the world based on the results of the main randomized controlled trials. For 
example, a recent study showed that the different patterns of treatment HER2-positive 
breast cancer in Iran [96] were similar to the patterns that clinical guidelines were 
recommended in HICs [15,52,72]. Therefore, from a cost point of view, we can expect 
the same resource use and different unit costs across countries. For example, we have 
already determined a high correspondence in practice variation (resource use) between 
HICs and Iran in the Welte’s specific knock-out criteria checklist (Table 6.3). 
Subsequently, if we assumed that the difference of unit costs for different healthcare 
services proportionally equal between HICs and MICs (regardless of the absolute values 
of service tariffs), then, our strategy seems to be reasonable because of same main cost 
drivers (the highest impact on ICER) for managing early and downstream health states 
in study and target countries. We used this method to estimate the downstream costs. 
However, this approach would not be relevant if there is a difference between the main 
cost drivers of the two health states. In this case, empirical data are needed to transfer 
the results of CEAs.  
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Our results showed that first method yielded estimated incremental costs that were 
highly influenced by the PPP conversion factor between countries and led to 
underestimates of the incremental costs and ICERs. Moreover, the transferred results 
from two of five studies suggested that trastuzumab was ‘very cost effective’ (<1×GDP) 
in Iran, which is not logical for an expensive drug in an MIC. In contrast, the proportional 
method was very easy to conduct and led to more accurate results compared to the 
first method. Interestingly, this method resulted in a narrow range of incremental cost 
estimates even though these studies originally reported widely disparate incremental 
costs. For example, two studies (Kurian et al, Garrison et al) from the USA originally 
reported incremental costs of US$76,669 and US$44,923. When these two were 
transferred to the Iranian setting, the incremental costs were almost equal (€19,478 
versus €19,240).  
Regarding the causes of the differences between the results of the conventional and 
the proportional cost approach, we would like to point out the impact of external price 
referencing (EPR) on transferring the results of the CEAs from HICs to MICs. In many 
MICs, the price of expensive drugs is determined based on EPR. In this approach, 
external prices are converted based on currency exchange rates and not based on 
country-specific PPPs. While PPP is strongly correlated with GDP per capita, different 
studies have shown a poor correlation between drug prices and GPDs per capita across 
countries [78-80]. Moreover, another study which exclusively investigated trastuzumab 
price differentiation across 19 HICs and MICs showed that there was no association 
between price of trastuzumab and GDP per capita across countries [81]. Therefore, 
transferring costs, specifically costs of expensive drugs, using PPP conversion factors 
may cause a major underestimation of costs which is evident in the first method. 
Moreover, applying EPR means that the costs of medication accounts for a large share 
of the total health expenditure (due to imports from HICs) compared to other 
healthcare services such as hospitalization, surgery or diagnostic tests in MICs. A study 
on economic burden of cancer across the European Union showed that drug costs 
represented the highest share of total health expenditure in breast cancer (€3.07 
billion, 46%) [142]. However, this proportion of cost in lower-income European counties 
was significantly higher than the European average. For example, this study reported 
that the share of drug costs was 81%, 79% and 76% in Cyprus, Hungary, and Malta, 
respectively (three MICs) [142]. Likewise, another study showed that trastuzumab alone 
accounts for almost 76% of total costs in early HER2-positive breast cancer in Iran [96]. 
Therefore, the EPR renders the PPP conversion factor essentially unusable in 
transferring of the results of CEAs and also causes heterogeneity in the absolute and 
relative cost components of an illness. According to reasons mentioned above, 
transferring the ratio between 𝐼𝐶𝜖𝒮 and 𝐶𝑝𝒮 from a study country would not be an 
appropriate approach if a) the key cost drivers were different between HICs and MICs 
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and b) the key cost components in MICs were not affected by the external reference 
pricing (e.g. personnel wages or hospitalization costs).  
Our study has some limitations worth noting. First of all, we had no access to patient-
level cost estimations in all five CEAs and it was not possible to transfer CEA results in 
HICs by replacing prices of healthcare services in HICs with the healthcare services 
prices in Iran. Access to this information would have enabled us to compare the results 
of three methods instead of two. This is something that should be looked at more 
carefully in the future. While this might be interpreted as a major limitation of our study, 
the reality of reimbursement decision-making in MICs is that policymakers have to 
make decisions without access to sufficient and good-quality information. Another 
limitation might be the generalizability of our findings to other diseases and health 
technologies. Trastuzumab is used as an adjuvant therapy in breast cancer and does not 
affect the choice of drug combinations or decisions about dose adjustment of 
chemotherapies. While this made our calculations easier, it is important to examine 
how the proportional method, an approach of using simple formulas rather than 
complex cost-effectiveness models, could be applied in studies of other drugs.  
This study showed that applying the conventional methods using PPP conversions, 
which are mostly used in transferring the results of CEAs between countries, may not 
be an appropriate approach when there is a notable difference between the economies 
of these countries. A proportional method which skips PPP conversions yielded 
incremental costs that came closer to the results of the Iran-specific CEA than the PPP 
conversion method. However, additional studies regarding the external validation are 
necessary to further develop the proportional method. For the time being, the 
preferred method for an MIC remains a country-specific CEA, despite the fact that 
transferring methods may be able provide reasonable cost-effectiveness evidence 
quickly.  
Conclusion: 
The transfer of CEAs between countries raises concerns regarding the accuracy of the 
transferred results, specifically when there are large economic gaps between the study 
and decision countries. The results of this study showed that the PPP converting factor 
should be used with caution when a CEA is transferring between HICs and MICs. Our 
proposed sophisticated method can be considered as an option in a preliminary-HTA 
analysis.  
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Abstract 
Introduction: The WHO has included several expensive drugs in the essential drugs 
package while middle-income countries (MICs) cannot afford them as equally as high-
income countries (HICs). We investigated the importance of price differentiation in 
enhancing drug affordability and provided recommendations to improve pricing 
systems in MICs. 
Method: Using trastuzumab (Herceptin®) for treatment of HER2-positive breast cancer 
as a case study, we compared prices across 14 HICs and 5 MICs. We estimated the 
budget impact of trastuzumab on total health expenditure assuming equal access 
across all countries. Two scenarios were used to reflect relative affordability of 
trastuzumab: one where prices were estimated using purchasing power parity (PPP) 
conversion rates and one where assumptive prices were calculated using PPP 
conversion rates (with the US trastuzumab price as an external reference price). 
Results: The relative budget impact of trastuzumab on total health expenditure was 
two times higher in MICs compared to HICs. There was no association between price 
and GDP/capita across countries (R2 = 0.004). However, trastuzumab was three times 
less affordable in MICs compared to HICs (p-value=0.02). Using assumptive prices 
resulted in equal affordability in both MICs and HICs (p-value=0.31). 
Conclusion: Current pricing systems do not facilitate access to expensive drugs in MICs. 
Equal affordability across countries can be improved by using price differentiation. 
Policymakers in MICs should base their price on national economic and social priorities. 
Implementation of value-based pricing using performance-based and finance-based 
risk-sharing arrangements is a critical need in lower income countries. 
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Introduction 
Equal drug affordability for patients all over the world is a global aim spelled out in the 
constitution of the World Health Organization (WHO) [143]. The possibility of 
establishing equal affordability worldwide is totally dependent on the possibility of 
implementing price differentiation across countries based on their GDP/capita. In other 
words, people in high-income countries (HICs) should pay more for any particular drug 
than people in lower income countries so that patients or payers can afford (expensive) 
drugs equally throughout the world. However, multiple studies have found a poor 
correlation between drug prices and per capita GDP across countries [78-80]. Therefore, 
the aim of equal drug affordability worldwide does not seem to be easily attainable for 
expensive drugs due to current pricing systems.  
For new pharmaceuticals, the majority of countries take into account prices of products 
in other countries where the product has already been launched. Consequently, the 
price in the country in which a new product was first launched is the most important 
price signal. This initial list price arises from a conflict between two interests upon initial 
market launch, namely the pharmaceutical manufacturer’s desire to maximize profit 
and the payer’s ability to pay. The target country of the first market launch is most 
certainly a HIC, followed by other HICs in the early phase [144]. The established list price 
in HICs is widely used as a reference price in lower-income countries, perhaps due to 
inadequate price negotiation with manufacturers. Consequently, people in lower 
income countries are ‘condemned’ to pay a high price based on HICs’ ability to pay. This 
phenomenon is likely to be more evident with expensive drugs as their high budget 
impact is not easily affordable in low and middle-income countries.  
Trastuzumab (Herceptin®) is an example of an effective and expensive drug and is used 
in targeted therapy for patients with HER2-positive breast cancer. It is a monoclonal 
antibody that can significantly improve both quality of life and survival and there are no 
other drugs with the same pharmacological effects. The therapeutic importance of 
trastuzumab is such that it was included in the WHO model list of essential medicines 
[145]. However, this does not guarantee access to the drug since countries also need to 
consider affordability. Therefore, price differentiation is an important and essential 
instrument for optimization of resource allocation and improvement of affordability. 
Many issues in healthcare systems may be related to how effectively policymakers use 
pricing instruments.  
This study aimed to a) investigate the role of current pharmaceutical pricing in 
enhancing drug affordability in middle-income countries (MICs) and HICs and b) provide 
recommendations on how to improve the pricing system and thereby achieve more 
equal drug affordability worldwide.  
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Methods 
To investigate affordability and accessibility, we focused on the price of trastuzumab a 
widely used expensive drug, in 19 countries (14 HICs and 5 MICs). Table 7.1 shows their 
ranges of per capita GDP, total healthcare expenditure, and breast cancer incidence 
rates. We used this information to perform different analyses. 1) The relative budget 
impact of trastuzumab on total health expenditure across countries and 2) the relative 
affordability of trastuzumab across countries.   
Relative budget impact of trastuzumab on total health expenditure across 
countries 
To investigate budget impact of trastuzumab on total health expenditure, public list 
prices of 10mg trastuzumab in 19 countries were derived from internet or obtained 
from experts [125,146-159] and were converted using exchange rates against the US 
dollar (USD) [160]. Using the recommendations of the ISPOR 2012 Budget Impact 
Analysis Good Practice Task Force [3], we estimated the impact of trastuzumab on total 
healthcare expenditure using country-specific per capita GDP% spend on health care (in 
USD) in these countries, based on a 2014 report from the World Bank [118]. We 
assumed the same patient population and treatment regimen in all countries (i.e., 
patients with early HER2-positive breast cancer and a 52-week treatment regimen). 
Incidence rates for early HER2-positive breast cancer across different countries were 
obtained from GLOBOCAN 2012 [75]; the proportion of HER2-positive patients was 
assumed to be 25% [161,162]. The average weight was assumed to be 70kg 
[31,128,134,163], except from Chinese patients (they were assumed to weigh 57kg 
[126]). Using the above information, public list prices, and actual exchange rates against 
the USD [160], we calculated the country-specific budget impact of trastuzumab per 
million people. We, then, calculated the effect of the country-specific budget impacts 
of trastuzumab on total health expenditure and their relatively impacts compared to 
the budget impact of this drug in the US.  
Relative affordability of trastuzumab across countries.  
Two scenarios were performed to investigate inequality in affordability across different 
countries. In scenario I, list prices of trastuzumab (2015) were converted using country-
specific purchasing power parity (PPP) [164] against PPP in the US. Scenario II addresses 
affordability and accessibility across countries by applying Ramsey pricing [165], which 
relates to the principle that the price of a drug should be varied based on differences in 
the income of a group of people or countries [166]. Assumptive prices were calculated 
using PPP conversion rates and the US trastuzumab price as an external reference price. 
Trastuzumab prices were considered as a sample of optimal price differentiation based  
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Table 7.1: Basic information of the target countries 
Category Country 
Population 
2015S1 
GDP per 
capita 
2014S2 
GDP per 
capita 2014, 
PPPS3 
Total health 
expenditure 
(% of GDP) 
2014S4 
PPP 
conversion 
factor, GDP 
2014S5 
Breast 
cancer 
incidence 
rate per 
100,000S6 
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Denmark 10,510,566 60,770 47,848 10.80 7.59  105 
Greece 10,919,459 21,498 26,454 8.08 0.63  44 
Germany 80,889,505 41,726 47,100 11.30 0.79  92 
Hungary 9,861,673 12,958 25,517 7.40 132.00  55 
Ireland 4,612,719 47,904 51,311 7.78 0.84  92 
Italy 61,336,387 35,878 36,294 9.25 0.76  91 
Netherlands 16,979,729 50,341 49,055 10.90 0.83  99 
Oman 4,654,471 19,921 39,678 3.55 0.19  26 
Poland 37,995,529 12,530 25,730 6.35 1.83  52 
Saudi Arabia 32,157,974 18,754 52,268 4.68 1.74  30 
Spain 46,064,604 29,767 33,688 9.03 0.68  67 
Sweden 9,851,852 52,076 46,446 11.93 8.95  80 
UK 65,111,143 38,362 40,745 9.12 0.71  95 
USA 318,857,056 48,374 54,540 17.14 1.00  93 
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Brazil 209,567,920 11,124 16,045 8.32 1.69  60 
China 1,382,323,332 4,515 13,440 5.55 3.53  22 
Iran 78,143,644 7,669 17,388 6.89 8,411.74  28 
Tunisia 11,375,220 4,212 11,358 7.00 0.63  32 
Turkey 79,622,062 10,530 19,654 5.41 1.20  39 
S1: Data were obtained from The World Bank - Population, total [167]; 
S2: Data were obtained from The World Bank - GDP per capita (current US$) [118];  
S3: Data were obtained from The World Bank - GDP per capita (current international $) PPP [168]; 
S4: Data were obtained from The World Bank - Health expenditure, total (% of GDP) [169]; 
S5: Data were obtained from The World Bank - PPP conversion factor, GDP (LCU per international $) 
[164]; 
S6: Data were obtained from the GLOBOCAN 2012 [75];  
S7: The World Bank classification method. Upper middle-income economies are defined as those with a 
GNI/capita between (US$4,036 - US$12,475) and high-income economies are those with a GNI/capita of 
US$12,476 or more. [170] 
 
Abbreviation: GDP: Gross Domestic Product; GNI: Gross National Income; LCU: Local Currency Unit; PPP: 
Purchasing Power Parity 
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on country-specific PPP. The relative prices of trastuzumab across countries in the two 
scenarios were calculated by dividing the different trastuzumab prices by the reference 
price of trastuzumab in USD ($85.73) [158,159]. 
In both scenarios, an ‘inability to purchase’ variable was calculated for trastuzumab and 
then compared across countries using the relative budget impact of trastuzumab on 
total healthcare expenditure based on country-specific PPPs. Inability can be defined as 
inequality in both affordability and accessibility of trastuzumab.  The formula for 
inability to purchase was defined as: 
𝐼𝑛𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑡𝑜 𝑝𝑢𝑟𝑐ℎ𝑎𝑠𝑒 =
𝐶𝑜𝑠𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔𝑃𝑃𝑃
𝑇𝑜𝑡𝑎𝑙 ℎ𝑒𝑎𝑙𝑡ℎ 𝑒𝑥𝑝𝑒𝑛𝑑𝑖𝑡𝑢𝑟𝑒𝑃𝑃𝑃
=  
𝑁 × 𝑃𝑟𝑖𝑐𝑒𝑃𝑃𝑃 × 𝐷𝑜𝑠𝑎𝑔𝑒 𝑟𝑒𝑔𝑖𝑚𝑒𝑛
𝐺𝐷𝑃/𝑐𝑎𝑝𝑖𝑡𝑎𝑃𝑃𝑃  × 𝑇𝐻𝐸% 𝑜𝑓 𝐺𝐷𝑃 × 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
 
Where 𝑁=number of patients; 𝑃𝑟𝑖𝑐𝑒𝑃𝑃𝑃, =price of the drug after conversion using PPP and 
GDP (Local currency unit (LCU) per international $) [164]; 𝐷𝑜𝑠𝑎𝑔𝑒 𝑟𝑒𝑔𝑖𝑚𝑒𝑛=total 
required amount of the drug. 𝐺𝐷𝑃/𝑐𝑎𝑝𝑖𝑡𝑎𝑃𝑃𝑃 =per capita GDP (current international $) 
based on PPP [168]; 𝑇𝐻𝐸% 𝑜𝑓 𝐺𝐷𝑃=total health expenditure as a percentage of GDP [169]; 
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛=total population of a given country.  
The relative inability to purchase trastuzumab in a particular country was calculated by 
dividing the inability to purchase it in that country by the inability to purchase it in the 
US. 
Results 
Relative budget impact of trastuzumab on total health expenditure  
Table 7.2 shows the budget impact in the 19 countries. In absolute terms, the budget 
impact per million people of trastuzumab use is the greatest in the US (USD: 
$10,951,362) and the lowest in Turkey (USD: $1,897,728). However, when the budget 
impact of trastuzumab is expressed as a percentage of total health expenditure, the 
impact is greatest in Tunisia (1.13%) and lowest in Sweden (0.08%). In fact, trastuzumab 
on average has a lower impact on total health expenditure in HICs than in MICs (0.21% 
vs. 0.68%, respectively). Figure 7.1 shows the relationship between relative public price 
of 10mg trastuzumab and GDP across the countries; the size of the bubbles reflects the 
relative budget impact. This figure shows that the budget impact of trastuzumab is 3.18 
times greater in countries with a lower GDP than in countries with a higher GDP.  
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Table 7.2: The results of budget impact analysis and its impact on total health expenditure in 
different two scenarios. 
Category Country 
Trastuzumab budget impact Inability to purchase trastuzumab 
per million 
people (US$) 
Health 
expenditure  
Relatively 
impact1 
Scenario 
I2 
Scenario 
II3 
Scenario 
II – 
scenario 
I 
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Denmark 8,576,263  0.13% 0.99 1.25 2.31 1.05 
Greece 1,948,163  0.11% 0.85 1.11 1.44 0.33 
Germany 7,640,025  0.16% 1.23 1.40 1.52 0.12 
Hungary 3,353,781  0.35% 2.65 3.21 1.37 -1.84 
Ireland 7,748,453  0.21% 1.57 1.40 2.75 1.35 
Italy 5,649,868  0.17% 1.29 1.70 2.31 0.60 
Netherlands 6,306,813  0.11% 0.87 1.09 1.72 0.62 
Oman 3,047,722  0.43% 3.26 3.75 0.91 -2.84 
Poland 3,546,824  0.45% 3.37 3.82 1.55 -2.27 
Saudi Arabia 2,706,249  0.31% 2.33 2.04 0.56 -1.47 
Spain 4,644,827  0.17% 1.31 1.73 1.68 -0.05 
Sweden 5,142,610  0.08% 0.63 0.75 1.55 0.80 
UK 5,421,251  0.16% 1.17 1.15 2.79 1.64 
USA 10,951,362  0.13% 1.00 1.00 1.00 0.00 
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Brazil 4,641,343  0.50% 3.80 5.85 2.27 -3.58 
China 2,601,139  1.04% 7.86 5.26 1.69 -3.58 
Iran 1,954,183  0.37% 2.80 4.80 0.68 -4.11 
Tunisia 3,342,792  1.13% 8.58 11.19 1.29 -9.90 
Turkey 1,897,728  0.33% 2.52 3.46 1.63 -1.83 
Average (HICs) 5,477,444 0.21% 1.61 1.81 1.68 -0.14 
Average (MICs) 2,887,437 0.68% 5.11 6.11 1.51 -4.60 
P-value (HICs vs MICs) <0.01 0.03 0.03 0.02 0.31 0.02 
 
S1: The World Bank classification method. Upper middle-income economies are defined as those with a 
GNI/capita between (US$4,036 - US$12,475) and high-income economies are those with a GNI/capita of 
US$12,476 or more. [170]  
1- A comparison of the relative budget impact of trastuzumab on the total health expenditure across countries versus the 
USA. (The relative budget impact of trastuzumab on the total health expenditure in USA=1), 2- A comparison of the current 
relative inequality in affordability of trastuzumab in target countries versus to the USA. (Inability to purchase trastuzumab in 
USA=1), 3- A comparison of the relative inequality in affordability of trastuzumab in target countries versus to the USA using 
the assumptive prices. (Inability to purchase trastuzumab in USA=1), 4- A pair comparison between inability to purchase 
trastuzumab in the first scenario versus the second scenario 
Abbreviation: GDP: Gross Domestic Product; GNI: Gross National Income; HIC: High Income Country; N: 
Number of patients; MIC: Middle Income Country; PPP: Purchasing Power Parity; THE: Total Health 
Expenditure  
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Relative affordability of trastuzumab across countries.  
Figure 7.2 shows the results of scenario I, where list prices of trastuzumab were 
converted using country-specific PPP against PPP in the US. Here we see that the price 
of trastuzumab decreases as per capita GDP increases (R2 = 0.510). This figure reveals 
that the inability to purchase trastuzumab, reflected by the size of the bubbles, is higher 
in countries with a lower GDP. Table 7.2 shows that the greatest inability to purchase 
trastuzumab (in Tunisia) was 11.19 times larger than the inability to purchase 
trastuzumab in the US (1.00). Comparing Tunisia with Sweden, the country with the 
lowest relative inability to purchase trastuzumab, trastuzumab was almost 15 times less 
affordable in Tunisia than it was in Sweden (Table 7.2). Overall, trastuzumab was 3.37 
times less affordable in MICs compared to HICs (p-value=0.02); the mean ratio of 
inability to purchase in MICs versus in HICs was 3.37 (Table 7.2), which indicates 
inequality in affordability and accessibility. 
Figure 7.3 presents the results of the scenario II which is a simulation of Ramsey pricing 
(price differentiation). The assumptive prices and per capita GDP increased 
simultaneously, indicating a significant price differentiation (p-value<0.01) across 
countries. Moreover, Table 7.2 shows that the ratio of inability to purchase trastuzumab 
in MICs versus in HICs was on average 0.91 in scenario II. This ratio is lower than the 
ratio of 3.37 seen in scenario I, which means that the inability to purchase trastuzumab 
in MICs improved 4.60 times in scenario II compared to scenario I (Table 7.2, final 
column, scenario II - scenario I). This change can also be seen in the smaller bubbles in 
Figure 7.3 in MICs compared to those in Figure 7.2. Scenario II also results in a 
nonsignificant difference in affordability and accessibility of trastuzumab between MICs 
and HICs (p-value=0.31). This approach affects countries differently. As Table 7.2 shows, 
the greatest loss in affordability and accessibility of trastuzumab was observed in the 
UK, where inability to purchase trastuzumab increased from 1.15 in scenario I (current 
situation) to 2.79 in scenario II. In contrast, the greatest gain in affordability and 
accessibility of trastuzumab was observed in Tunisia (change in inability to purchase= 
−9.90). However, in general, using scenario II resulted in improved equality of 
affordability and accessibility even in HICs (a 0.14 reduction in inability to purchase 
trastuzumab).  
Discussion 
Pricing is an instrument that policymakers can use to improve affordability of drugs in 
a healthcare system. This instrument is particularly valuable when an expensive drug is 
being considered for reimbursement in a lower or middle-income country. This study 
highlights the current differences in affordability and accessibility of trastuzumab, 
which is an expensive and important drug in HICs and MICs. We estimated the (relative)  
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Figure 7.1: GDP per capita (US$) 2014 world bank versus price ratios for trastuzumab. Real 
relative price of 10mg trastuzumab (Herceptin®) among some HICs and MICs based on the 
average currency exchange rate against USD in 2015[160] (price in USA=1)  
 
Figure 7.2: GDP per capita (US$) 2014 World Bank versus price ratios for trastuzumab. 
Comparison of converted prices of 10mg trastuzumab based on the PPP conversion factor, GDP 
lowest unit cost (LUC international $) obtained from the World Bank [164] (PPP in USA=1) 
 
Figure 7.3: GDP per capita (US$) 2014 world bank versus price ratios for trastuzumab: An 
assumptive comparison price of 10mg trastuzumab when price of this drug in USA directly 
converted based on PPP conversion factor for each country.  
Note: Using the size of 
bubbles, Figure 7.1 
represents a comparison of 
the relative budget impact of 
trastuzumab on the total 
health expenditure across 
countries versus the USA. 
(The relative budget impact 
of trastuzumab on the total 
health expenditure in USA=1) 
Note: Using the size of 
bubbles, Figure 7.2 illustrates 
a comparison of the 
inequality in affordability of 
trastuzumab in these 
countries versus to the USA. 
(Inability to purchase 
trastuzumab in USA=1) 
Note: Using the size of 
bubbles, Figure 7.3 illustrates 
a comparison of the 
inequality in affordability of 
trastuzumab in these 
countries versus to the USA. 
(Inability to purchase 
trastuzumab in USA=1) 
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budget impact of trastuzumab and inability to purchase trastuzumab in order to draw 
some conclusions about differences in affordability and accessibility between HICs and 
MICs.  
External price referencing is a widely applied method to control pharmaceutical prices. 
If differences between the economic status of reference countries are not taken into 
account, this will limit the ability of individual MICs to adjust drug prices to their 
affordability constraints, because it will result in a fairly narrow international price 
corridor [171]. Since the potential price indicated by this narrow price corridor is usually 
too high for lower income countries, it may reduce affordability and patient access to 
new pharmaceuticals in MICs.  
HICs often have a greater degree of negotiation power when setting pharmaceutical 
prices due to their larger market potential (4). However, because they often apply 
performance-based and finance-based risk-sharing arrangements (PFRSA), which are 
not publicly available due to confidentiality agreements [144], reference prices are 
most likely higher than actual paid prices. If other countries base their drug prices on 
publicly available reference prices in other countries, this will only increase inequality 
in affordability. In addition, external price referencing using prices of HICs results in 
other issues in MICs. For example, one of the main consequences is that the budget 
impact of expensive drugs account for a larger share of total health expenditure in MICs 
than in HICs. As an example, a study on economic burden of cancer in the European 
Union showed that on average €3.07 billion (46%) in total health expenditure were 
allocated to medication in treatment of breast cancer [142]. However, the proportion 
of pharmaceutical expenditure was much higher in several lower European income 
countries, such as Cyprus (81%), Hungary (79%), and Malta (76%), than the European 
average [142]. This means that money must be shifted away from other healthcare 
services to finance expensive drugs. This phenomenon may cause health and efficiency 
loss, and lead to compression elsewhere in the healthcare system. Illegal and informal 
payments [93,172] by patients to underpaid healthcare providers for difficult to access 
health care services due to insufficient budget allocation in MICs may be an example of 
this issue.   
From a pharmaceutical point of view, the domino effect is an undesirable consequence 
of external price referencing. If the lowest price is always considered a benchmark for 
other countries, this may result in a ‘race to the bottom’ and lower prices in many 
countries. To solve this issue, most countries keep their real price confidential. 
However, due to confidential price discounts specifically for expensive drugs in HICs, 
policymakers in MICs may not know actual paid prices of drugs in the reference 
countries. Therefore, uncertainty about the real price of drugs in reference countries is 
an additional issue associated with external price referencing [144].  
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Ramsey pricing is a method which enables pharmaceutical companies to price their 
products according to a country’s ability to pay [165]. If Ramsey pricing is implemented, 
pharmaceutical prices are lower in MICs compared to HICs, which improves affordability 
and accessibility, as illustrated in our study. However, it creates additional policy 
problems related to parallel trade between countries and domino effect of reducing the 
floor price of the pharmaceutical price corridor. Therefore, Ramsey pricing is not a 
reasonable strategy for pharmaceutical companies as long as there are deficiencies in 
external price referencing [166]. The companies, hence, may lose interest in launching 
their products in MICs at lower prices. On the other hand, Ramsey pricing should be 
considered by payers in MICs as the target price or starting point for price negotiations. 
Therefore, implementation of only one of these two methods may affect patient access 
to drugs in different countries (Figure 7.3 vs Figure 7.1).  
Policymakers in MICs must improve their pricing and reimbursement policies in order 
to ensure access to essential treatments. Our study shows that this means 
differentiating prices across countries based on the ability to pay. MICs should work 
towards establishing a value-based pricing system instead of only applying external 
price referencing. Furthermore, if MICs aim at implementing price differentiation, they 
have to solve issues related to parallel trading and the domino effect. Some procedures, 
such as a confidential rebate mechanism for MICs and restrictions on selecting 
reference countries with a similar GDP, may provide feasible opportunities for price 
differentiation. However, an improvement in capability for price negotiation would be 
a significant milestone in MICs.  
The capability to negotiate prices can be improved by using two strategies. The first 
strategy is to maximize the power for price negotiation in the pharmaceutical market. 
Different approaches could be used here. For example, one approach is to establish 
regional health technology assessment (HTA) bodies (like the collaboration among 
Belgium, Netherlands, Luxemburg and Austria [173]) to organize the pharmaceutical 
market in multiple countries with the same economic power. Another approach is to let 
brands launch in the market only under a regional brand name using a different 
package. This may reduce parallel trading and facilitate the implementation of price 
differentiation. The second strategy is to improve HTA knowledge in MICs. With more 
knowledge, MICs can improve their price negotiations based on the expected (value-
based) and assessed (real-world) value of a drug in a particular market and provide 
country-specific pricing standards rather than rely on the price of drugs in other 
countries. This would help policymakers to combine price negotiations with 
performance-based and finance-based arrangements (PFRSAs) [174,175].  
The implementation of PFRSAs is an approach to allocate the healthcare resources 
efficiently and based on our finding, it may be highly important in MICs. MICs may use 
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the experience of other countries to improve their pricing system. The UK may be a 
good example of this as instead of using external price referencing [144] they have a 
strong PFRSA system [175] based on HTA and fairly low explicit thresholds compared to 
their GDP per capita. The greatest price increase of trastuzumab between scenarios I 
and II was in the UK (Table 7.2). This means that the UK has the cheapest list price based 
on PPP conversion factor across the target countries. Moreover, due to some 
confidential rebates, it can be expected that trastuzumab is likely to be even cheaper in 
the UK. This price balance between payers and manufacturer is made based on ability 
to negotiate on price and/or measure the real-world effectiveness of drugs. An ability 
to negotiate price can be obtained by improving the knowledge production 
infrastructure in different areas of HTA analysis such as cost-effectiveness analysis and 
multiple criteria decision analysis. Moreover, the healthcare governance structure 
should be such that it can facilitate implementation of PFRSA. The UK has successfully 
implemented these two prerequisites to achieve value-based pricing. The power of 
pricing system in the UK is such that policymakers in many countries consider the NICE 
recommendations as an important document in reimbursement decision-making 
process. Therefore, manufacturers are willing to offer huge discounts to the UK for a 
positive NICE recommendation which can facilitate a successful international 
marketing. In summary, implementation of PFRSA can support a pricing system 
independent from other countries. However, PFRSA would not be easy to implement in 
countries that have not yet established a strong knowledge production infrastructure, 
and their healthcare governance would need to be upgraded to improve capacity for 
implementing PFRSAs.  
This study has two limitations worth noting. Firstly, the price of trastuzumab has only 
been studied in a limited number of countries, which may affect the generalizability of 
the results. Secondly, GDP per capita of Hungary and Poland - two HICs in Eastern-
Europe - is closer to MICs than to other HICs. Listing these two countries among HICs 
may reduce the power of our conclusions. However, it would have been difficult to 
justify an arbitrary 15,000 USD per capita GDP threshold to distinguish lower-income 
from higher-income countries. Regardless of these limitations, our result show that 
there is no correlation between price and per capita GDP across countries, which 
corresponds with results of other studies [78-80]. Therefore, we expect that our 
limitations do not affect the calculated inability to purchase.  
Our main message is a strong recommendation for MICs to improve their healthcare 
infrastructures with the goal of implementing innovative policies which facilitate 
establishing an independent pharmaceutical pricing system. International organizations 
such as the WHO can help lower income countries to improve their healthcare 
infrastructure in favor of implementation of price differentiation. An implemented 
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strong pricing system will improve patient access to (new) essential drugs, including 
expensive drugs, in MICs. 
Conclusion 
Equal drug affordability is an important aim emphasized by the WHO but current pricing 
methods result in affordability and accessibility issues in MICs. Population health and 
quality of care are both affected by limited access to essential drugs. Trastuzumab, an 
essential drug according to the WHO, is less affordable and accessible in MICs than in 
HICs. Equal affordability across countries can be improved by using price differentiation. 
Specifically, PFRSA can relieve inequality in affordability and accessibility and may help 
in price differentiation in MICs. 
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Abstract 
In the coming years, performance-based and finance-based risk-sharing arrangements 
(PFRSA) are expected to be more prominent in middle-income countries (MICs). This 
study examined the pharmaceutical pricing and reimbursement in one MIC (Iran) to 
identify prerequisites for the implementation of PFRSAs.  
In the first step, a SWOT (strengths, weaknesses, opportunities and threats) analysis 
was used to compare the current pharmaceutical pricing and reimbursement decision-
making system in Iran with the PFRSA governance and infrastructures in six reference 
countries (England, Germany, Hungary, Italy, Poland and Turkey) that have 
implemented PFRSA policies. We then developed recommendations to improve system 
capacity for implementing PFRSA policies in Iran.  
The SWOT analysis showed that distributed responsibilities, conflicts of interest, a lack 
of post-decision market monitoring, and time-consuming procedures are important 
weaknesses of the current system in Iran. The results of country comparisons showed 
that four important phases of PFRSA process (i.e., evaluation, negotiation, resolution, 
and observation) were not implemented continuously and consistently. Moreover, to 
improve performance of the current process, improvement in two areas of reorganizing 
healthcare governance and improving infrastructure and process would be 
instrumental in Iran.  
In conclusion, Iran can strengthen its pricing and reimbursement system by centralizing 
governance duties and responsibilities. The current process must be improved by using 
a cyclic and dynamic pricing and reimbursement process. Subsequently, implementing 
finance-based arrangements would be a good start point to implement PFRSA policies 
in Iran. Implementation of performance-based schemes needs more efforts on 
improvement of post-decision market monitoring and real-world evidence. 
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Introduction 
Performance-based and finance-based risk-sharing arrangements (PFRSA) between 
payers and manufacturers have been widely implemented in high-income countries 
(HICs) [32] to achieve an optimal balance between ensuring timely access and managing 
affordability. PFRSA is an overarching term that includes various policies related to price 
negotiation, post-decision-making monitoring of costs and outcomes, and evaluation of 
the cost-effectiveness of new technologies in a real-world setting [175]. These policies 
have been given a variety of names, including outcomes-based schemes, patient access 
schemes, and pay-for-performance [175]. They share, however, one main aim, which is 
to base reimbursement on real-world outcomes by addressing both value for money 
and cost containment.  
Implementation of PFRSA in middle-income countries (MICs) is of utmost importance 
to achieve equal affordability of a drug [81]. In countries where PFRSA is not 
implemented, payers and patients must endure possible finance and performance-
based risks [81]. Iran, as an MIC, is facing the consequences of its lack of implementation 
of such policies. Tracking the story of one drug can illustrate the shortcomings of the 
current Iranian pharmaceutical pricing system. The drug trastuzumab, used for early 
breast cancer treatment, is a good example as historically, the price of trastuzumab 
remained mostly stable over the years even though its use continued to increase (Figure 
8.1). This means that all of the finance-based risks have been aggregated for payers. 
Moreover, from a cost-effectiveness point of view, a recently published article studying 
different strategies of trastuzumab therapy [134] showed that with the current price of 
trastuzumab in Iran [176], a six-month course of trastuzumab is an optimal strategy only 
for patients who are younger than 59. In contrast, most clinical guidelines recommend 
a one-year treatment regimen for trastuzumab use. This means that the price of 
trastuzumab should be significantly reduced in Iran. In other words, if payers only want 
to cover six months of trastuzumab use and the manufacturer does not reduce the 
price, performance-based risks such as lower quality-adjusted life year (QALY) gains are 
imposed on the patient. Therefore, Iran needs to upgrade its pricing and 
reimbursement system to improve its capacity to implement policies like PFRSA.  
The implementation of PFRSA in MICs will, however, encounter serious issues. Some of 
these issues relate to a country’s limited infrastructure to produce health economic 
data or its inefficient healthcare governance [51], but there are also issues of patients 
already having a lower life expectancy than HICs and insufficient health care budget 
[134]. To move forward, it is important to know how policymakers in MICs can both use 
and improve their current available knowledge and how to strengthen their systems to 
ensure a better decision-making in order to get better health outcomes. This raises the 
question of how MICs can establish an appropriate process and infrastructure to 
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implement PFRSA. As there are many similarities in healthcare systems and above 
mentioned issues between Iran and other low- and middle-income countries [177], we 
will focus on the situation in Iran. 
 
Figure 8.1: The trend of trastuzumab use and changes in average price per mg over three years since the 
reimbursement date (01/2013) in Iran. The average price obtained from the prices of both 150mg and 440mg 
vials over a 3-years period [125].  
Abbreviation: IRR: The Iranian rial, USD: The United states dollar 
The aim of this study is to investigate the prerequisites for improving pharmaceutical 
pricing and reimbursement in Iran. Firstly, the shortcomings and successes of the 
current drug pricing and reimbursement system are explained using an analysis of the 
relevant strengths, weaknesses, opportunities, and threats (SWOT analysis). The SWOT 
analysis helps create a framework to identify and analyze the internal and external 
factors that can have an impact on the pricing and reimbursement system [178] in Iran. 
Then, using the experiences of six other countries (England, Germany, Hungary, Italy, 
Poland, and Turkey) regarding their implementation of innovative policies such as 
PFRSA, recommendations for policymakers in Iran are outlined. These 
recommendations may also be relevant for other MICs.  
The current drug pricing and reimbursement system in Iran 
The pharmaceutical pricing is managed by the Iranian Food and Drug Organization 
(FDO), under the supervision of the Ministry of Health (MoH) [179]. The pricing method 
for domestic pharmaceutical products is based on a “cost-plus” pricing strategy, which 
means that the pricing is based on the final cost of drug production plus marginal 
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8 
benefits in various layers of wholesale and pharmacy retail. Prices in other countries 
(Greece, Spain, and Turkey [14]) and currency exchange rates are considered in order 
to set the prices of imported drugs [179]. The prices of branded and generic drugs are 
different; however, four main payers [51] which cover more than 95% of Iranian 
population, mostly cover the price of the generic form. Although prices for expensive 
drugs are negotiated before reimbursement decisions [51], the implementation of 
finance-based risk sharing arrangements is uncertain because of three main issues. 
Firstly, in the case of rapid changes in the currency exchange rate [117], the agreed price 
may change if the currency exchange rate changes significantly. Secondly, the 
regulating body for drug pricing (FDO) is not sensitive to the budget impact of drugs in 
Iran [51] because payers are responsible for healthcare expenditures. Finally, although 
payers are responsible for the pharmaceutical budget [51], they do not participate in 
the pricing commission [179] and are not allowed to negotiate directly with 
manufacturers. However, the pharmaceutical companies have a representative on the 
pricing commission.  
The drug reimbursement decision-making process in Iran can be described as a shared 
responsibility process as it is divided between two different ministries, the MoH and the 
Ministry of Welfare (MoW) [51]. New drugs must first be approved by the MoH. Once 
a drug is approved, patients can have access to them even though the reimbursement 
phase of the process is still incomplete. Next, pharmaceutical firms must apply for 
reimbursement of expenses by payers at the MoW. Ultimately, the Iranian Cabinet 
approves a drug when they get a positive reimbursement recommendation from the 
MoW. In addition, other stakeholders are involved in the reimbursement process, 
including the Iranian Medical Council and two members of the Iranian Parliament. 
Under the supervision of the MoW, payers are also involved and mostly focus on 
economic considerations [51].  
To identify ways to improve the reimbursement decision-making process, both internal 
and external factors that may impact the current drug pricing and reimbursement 
system in Iran need to be analyzed. Therefore, a SWOT analysis was performed by 
reviewing the administrative rules and interviewing experts and policymakers in Iran. 
SWOT analysis; shortcomings and success of the pricing and reimbursement system 
in Iran 
Table 8.1 shows the results of the SWOT analysis. In terms of strengths, Iran’s strong 
generic market and universal health insurance coverage are the most important 
strengths of its pharmaceutical system. These strengths help reimbursed drugs to be 
affordable to all patients. Moreover, Iran has an existing pharmaceutical pricing and 
reimbursement system and drugs must undergo a formal process of assessment and 
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appraisal to be reimbursed. On the other hand, the system has some weaknesses such 
as the fact that two ministries share the responsibility for the drug pricing and 
reimbursement system, which leads to inefficient management. The fact that the 
process is non-transparent and time-consuming is another important weakness that 
causes unequal affordability among patients. Moreover, Iran has not been defined any 
correction methods on the previous decisions and also flexibility on the process of 
reimbursement decision making for drugs with different specifications. There are many 
opportunities to overcome the weaknesses, such as Iran’s large population size, that 
can bolster the price negotiating power of Iranian policymakers, and Iran’s generally 
strong health information infrastructure that can facilitate post-market monitoring. In 
contrast, there are important threats to improving the system. For example, 
pharmaceutical firms may be unwilling to reform the system and to implement of 
PFRSA. Another major threat that policymakers are face is a decrease in social 
accountability of payers due to budget constraints.  
Based on the results of the SWOT analysis, the main challenges seen in the Iranian 
pricing and reimbursement process are the inconsistency between the two ministries, 
the time-consuming and opaque process, and the lack of process dynamism (flexible 
process execution to improve performance) [51]. Therefore, policymakers should try to 
consolidate the strengths and eliminate the weaknesses through the proper use of their 
opportunities. They also should try to turn threats into opportunities by creating new 
policies. Furthermore, to improve the performance of the pharmaceutical pricing and 
reimbursement decision-making process, Iran may benefit from the experiences of 
other countries. That is, a careful examination of the systems in other countries could 
help Iranian policymakers recognize how weaknesses can be improved using the 
current strengths and opportunities of the Iranian system.  
What can Iran learn from the experiences of other countries?  
The experiences of HICs regarding the implementation of PFRSA provide a useful 
resource when considering how to implement these policies in MICs. Due to the results 
of SWOT analysis (Table 8.1), this study focused on two main aspects which affect the 
pricing and reimbursement system: healthcare institutions and governance and 
infrastructure and process.  
A comparison of healthcare institutions and governance  
Table 8.2 presents an overview of the pharmaceutical pricing and reimbursement 
institutions and governance seen in six HICs and one MIC (Iran), including information   
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Table 8.1: SWOT analysis of the pharmaceutical pricing and reimbursement process in Iran. 
 Strengths  Weaknesses 
Type of 
issue 
1. Long-established generic drug market 1. Pharmaceutical governing bodies distributed across 
two ministries 
HG 
2. Universal health insurance coverage policy 2. Non-transparent drug registration and 
reimbursement decision-making process  
HG, IP 
3. National basic package for all Iranians 3. Conflicts of interest in the pricing and reimbursement 
process 
HG 
4. Drug assessment and appraisal protocols for 
the drug reimbursement process 
4. Time-consuming procedure of reimbursement 
decision-making 
HG, IP 
5. Existence of national level pricing and 
reimbursement policies 
5. Payers are not involved in the pricing process HG, IP 
6. Appropriate financial contribution 
particularly by payers for severe diseases 
with catastrophic costs (almost 100% of 
costs are covered) 
6. No correction method for previous pricing and 
reimbursement decisions 
IP 
7. Drugs are properly available in all regions of 
the country 
7. Inflexible process for drug reimbursement with 
different specifications such as administrative 
burden and budget impact. 
IP 
8. Price negotiation and budget impact 
analysis during the reimbursement process 
8. New and expensive drugs can be launched while they 
are not reimbursed and affordable 
HG, IP 
  
9. Risk aggregation is centered on payers and patients. 
There is a no-risk market for the manufacturers 
after the reimbursement decision-making process 
HG, IP 
  
10. Uncertainty regarding implementation of the price 
negotiation agreements  
HG, IP 
  
11. Lack of a systematic reimbursement revision process 
after a decision to health insurance coverage of 
drugs  
HG, IP 
  
12. Unwillingness of payers to reimburse new 
technologies, such as expensive drugs 
HG, IP 
  
13. Redundancy of information provided by applicants 
for the registration and reimbursement decision-
making processes  
HG, IP 
 
Opportunities  Threats 
 
1. Large population size, which can provide a 
stable market for manufacturers 
1. Scarcity of health and drug financing  HG, IP 
2. Strong general tendency for implementing 
strategic purchasing among the Iranian 
policymakers and governors 
2. Growth of expensive pharmaceutical products, 
medical devices, targeted therapies, and patient-
centered therapies in the global market  
HG, IP 
3. Strong HIT infrastructure for outpatient 
services and rapidly improving HIT 
infrastructure for inpatient services 
3. Decreasing social accountability of payers due to drug 
budget limitations. 
HG, IP 
4. Developing production of expensive drugs 
inside the country, which means lower 
costs for payers  
4. Increasing patient copayments HG, IP 
5. Developing health economy and outcome 
research 
5. Resistance of manufacturers to novel pricing and 
reimbursement policies 
HG, IP 
6. Increasing export rate of branded-generic 
products to other countries 
6. Insufficient research capacity for HTA studies HG, IP 
  7. High rate of fluctuation in the currency exchange 
rates  
Others 
  
8. Phenomenon of increasing intermediaries among 
drug import companies 
HG 
Abbreviations: HIT: Health Information Technology, HTA: Health Technology Assessment, HG: Healthcare 
Governance, IP: Infrastructure and Process.   
Can be handled by 
improvement in 
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about the main actors involved in the drug pricing and reimbursement decision-making 
process in these countries. The number of institutions that are involved in the process 
is remarkable. In most of the six HICs, pricing and reimbursement decision-making is 
centralized in the same body or in various institutions administered by a single 
governing body. In Iran, however, these processes are divided between two ministries 
with partly divergent missions [51]. 
In the six countries, the pricing authorities are also governing bodies for health 
insurance payers. Moreover, pharmaceutical companies do not appear to be directly 
involved in the process of price determination by the governing bodies in these 
countries. In contrast, pharmaceutical pricing in Iran are centralized in a non-finance-
related organization. Moreover, representatives of the manufacturers have been 
directly and legally involved in pricing decision-making since 1988 [180]. This can be 
seen as an example of conflict of interest in the Iranian drug pricing process.  
Within the hierarchical governance structure, Table 8.2 shows that the difference 
between the assessment-appraisal layers and the layer of final reimbursement decision-
making is greater in Iran compared to the six countries. In other words, a longer process 
can be expected in Iran. As European countries are committed to implementing the 
Transparency Directive regulation of the European Union [181], there is a maximum 
duration of their pricing and reimbursement decision-making process. With 2 layers and 
without a directive about maximum duration it is expected that the process in Iran will 
take longer [51].  
A comparison of infrastructure and process 
Table 8.3 shows the differences and similarities in infrastructure and process of 
pharmaceutical pricing and reimbursement between Iran and the six other countries, 
including information regarding drug pricing, reimbursement, and post-market 
monitoring. The first remark is that Iran, as in the other countries, has implemented 
some parts of the reimbursement infrastructure, such as having a national drug 
formulary and a national level pricing system. However, considerable differences in the 
current process exist as well. Iranian policymakers manage the demand side by using 
reimbursement restrictions (e.g. restrictions regarding indication or prescriber). In 
contrast, the other six countries use easy-to-implement risk-sharing policies to contain 
costs. Until now, Iranian policymakers have shown little interest in any of the PFRSA.  
In the six countries, the pharmaceutical market is monitored by governing bodies that 
investigate real-world drug utilization, adherence to treatment or guidelines, and long-
term clinical outcomes. However, the results of these systematic audits may lead to 
revision of reimbursement status. It means a cyclic process for the drug reimbursement   
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decision-making system. The situation in Iran is different; neither systematic nor ad-hoc 
reimbursement revision is possible in the current process unless important drug safety 
concerns arise later. Therefore, it seems that drug manufacturers operate in a secure 
market after reimbursement because all of the risks of low performance or high budget 
impacts are pushed onto the payer or patient, which leaves the pharmaceutical firms 
with no concern about revision of reimbursement decision-making.  
With this comparative analysis of the six target countries, four phases of drug pricing 
and reimbursement should be considered in order to implement PFRSA policy: 
evaluation of a new drug, negotiation of the price, resolution of the price and 
reimbursement of the new drug, and observation of the outcomes followed by a 
decision. These phases not only must be in line with the other phases, but also the 
results of the observation phase, based on real-world evidence (RWE), should be used 
for the next evaluation phase. A self-correcting system, like revision of reimbursement 
status which already discussed, is needed such that for each new decision to be made, 
it corrects what issues were found in the past. Therefore, to enhance reimbursement 
revision, as shown in Table 8.3, it is crucial to make the reimbursement process more 
cyclical (Figure 8.2) [182]. To achieve this proposed structure, policymakers need to 
provide some prerequisites.  
What is needed to move forward? 
A series of recommendations can be formulated based on a SWOT analysis of Iran’s 
system and a comparison of Iran’s system with the systems found in six other countries. 
Each recommendation has an impact on different components of the SWOT analysis 
and leads to consolidation of strengths and improvement of weakness. Table 8.4 shows 
the impact of the recommendations on each item of the SWOT analysis given in Table 
8.1.  
Eliminate conflicts of interest and maximize process transparency 
It is very important that healthcare governors identify and eliminate all current conflicts 
of interest. Otherwise, upgrading actions and the adoption of various recommendations 
will be affected by the multi-faceted characteristics of personal (member composition 
of the pricing commission) or organizational purposes (Inconsistency between MoH and 
MoW). Moreover, by increasing transparency, the risk of conflicts of interest can be 
decreased. If these two actions (eliminating conflicts of interest and maximizing process 
transparency) are not fulfilled, this will not only mean that the ultimate aims of PFRSA 
will not be achievable but it can also increase the risk of poor performance in the 
healthcare system.  
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Establish integrity in operation 
According to the experiences of other countries, the reimbursement decision-making 
and pricing process should operate as a unified process. Accountability, performance, 
and timeliness suffer if the process is fragmented. Some of the weaknesses of the 
Iranian pharmaceutical system exist because this process is shared between two 
ministries whose objectives are not necessarily (or perfectly) aligned (Table 8.1). 
Therefore, a reorganization is required to integrate the operation of the pricing and 
reimbursement system. The experiences of other countries show that the pricing and 
reimbursement process is mostly performed by the governing bodies that coordinate 
the payers. The FDO (MoH), as the drug price regulator in Iran, may not be sensitive to 
the actual impact on payers’ budgets or may not be the most appropriate organizer of 
risk-sharing agreements between producers and payers. Based on the experiences of 
other countries, price negotiations can be better implemented when the body 
responsible for price regulation is directly involved with healthcare financing. 
Ultimately, budget responsibility and the management of all pricing and reimbursement 
process components, including the final decision-making, should be centralized in one 
organization. Centralized responsibility will stimulate policymakers to establish and 
maintain a sustainable balance between healthcare resources and expenditures. In the 
case of Iran, the responsibility for the healthcare system should be centralized in the  
MoH, and its authority should be increased correspondingly. This transfer of 
responsibility would include shifting final reimbursement decisions from the cabinet to 
the MoH. The establishment of a health technology assessment (HTA) body as a 
department of the MoH is recommended in order to ensure cohesive management of 
the components of the proposed structure (Figure 8.2). Therefore, a reorganization of 
the MoH would be necessary to move all processes associated with the reimbursement 
system from various departments, such as the FDO, to the HTA body. Due to the country 
comparisons, in addition to the HTA body, it is highly recommended that another 
governing body, a health insurance administration (HIA) responsible for the pricing 
phase and coordination among payers (like the GKV-SV in Germany), be implemented 
in the MoH. The duties of these two main governing bodies (HTA and HIA) in 
collaboration with the MoH are shown in Figure 8.2. 
Start a PFRSA system with a finance-based scheme 
Finance-based schemes, such as market share or price-volume agreements, can help to 
contain costs quickly and create an appropriate context in which to introduce 
performance-based policies. Large population size, a rapid growth of health economics 
studies, and the use of a positive reimbursement list are important components of the 
current Iranian system (Table 8.1) that can lead to efficient price negotiation. When 
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finance-based schemes are extended, other pharmaceutical infrastructures should be 
simultaneously upgraded by improving skills such as post-decision monitoring, data 
management, value measurement, and the implementation of internal reference 
pricing. Moreover, improvements in the health information technology infrastructure 
are necessary for the implementation of health-outcome-based schemes (like PBRSAs). 
It is important to remember that the implementation of outcomes-based schemes is 
difficult, even in HICs. Missing data in electronic health records, administrative burden, 
and biases related to clinical outcome measurement and patients’ adherence to 
treatment are some of the implementation obstacles. This is probably why 
policymakers tend to focus on finance-based schemes, which are easier to implement. 
However, outcomes-based schemes seem optimal to ensure real value-for-money and 
should therefore be considered as a long-term goal by further developments in the 
generation of RWE. 
 
Figure 8.2: Schematic illustration of the proposed cyclic and dynamic reimbursement process. 
Abbreviations: HIA: health insurance administration; HTA: health technology assessment 
 
Improve real world evidence  
PFRSA could be implemented based on a platform of RWE generation. If this platform 
is stable, it will result in an efficient pay-for-performance system. Policymakers may use 
external reference pricing when they decide to negotiate a drug’s price and determine 
the national price, but they must monitor the actual consequences. Based on national 
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RWE, previous decisions ought to be re-evaluated and modified, if necessary, in a cyclic 
and dynamic reimbursement process (Figure 8.2).  
RWE generation requires the development of a health information technology (IT) 
infrastructure, but MICs may not be able to create the necessary infrastructure due to 
difficulties in its financing and implementation. There is, in fact, a vicious circle in MICs 
regarding PFRSA implementation and health IT infrastructure. PFRSA requires proper 
information flow through the health IT systems while health IT needs sufficient 
financing to be implemented. Thus, the lack of financing is the main obstacle to 
implementing a comprehensive health information technology system, but financial 
resources are currently wasted due to a lack of PFRSA policies. Therefore, a transitional 
action plan is necessary to improve health IT in MICs based on a priority-setting 
program. Moreover, the potential cost-savings derived from a finance-based 
arrangement can (partly) be shifted to improve the health information systems.  
Make the system more dynamic 
In order to improve the system, the assessment and appraisal of new evidence about a 
drug should lead to a change in the pricing and reimbursement (Figure 8.2). In some 
cases, however, policymakers can achieve cost savings using a fast-track price 
modification based on the results of monitoring the process or RWE (the shortcuts 
between monitoring or real-world evidence and pricing, as seen in Figure 8.2). In other 
words, a cyclic and dynamic reimbursement process produces an evidence-based 
pricing method. In this method, drug prices can be modified so as to correspond with 
the revised estimate of added-value. Modified prices should be considered as the new 
references for other drugs, which means that they can be applied to new drugs (within 
a therapeutic class) to estimate the initial prices when starting a new reimbursement 
decision-making process. Accordingly, an initial price will be determined by 
pharmacological similarity, differences in effectiveness, and other criteria that apply to 
national priority setting.  
Table 8.4: The impact of recommendations on different components of SWOT analysis.  
Recommendations 
Consolidation 
of strengths  
Addressing of 
weakness  
Use of 
opportunities 
Elimination 
of threats 
Eliminate conflicts of interest and 
maximize process transparency 
1, 3, 4, 5, 7, 8 2, 3, 4, 5, 8  2 3 
Establish integrity in operation 1, 3, 4, 5, 7, 8 1, 2, 3, 4, 5, 8, 12  5, 8 
Start a PFRSA system with the 
finance-based schemes 
5 
2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12 
1, 2, 3, 4 1, 2, 3, 4, 8 
Improve real world evidence 4, 8 2, 3, 4, 6, 7, 12, 13 1, 3, 6 
Improve dynamicity of the system 
1, 3, 4, 5, 7, 8 
3, 4, 6, 7, 9, 10, 11, 
12 
2 5 
The numbers represent the number of items for columns of strengths, weaknesses, opportunities and threats 
in Table 8.1. 
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Conclusion 
MICs face difficult challenges with their pricing and reimbursement decision-making 
policies while HICs have addressed similar challenges by improving their systems using 
innovative policies for better resource allocation. Using PFRSA schemes is a tested 
policy in HICs that it can improve timely access and affordability of an expensive drug.  
There are numerous barriers that prevent a PFRSA system from being implemented in 
Iran, such as dysfunctional healthcare systems, various conflicts of interest, and the lack 
of a comprehensive health information technology infrastructure. Iran can start 
improving its pharmaceutical pricing and reimbursement decision-making system by 
using various finance-based schemes. Most importantly, increased use of RWE will 
enable the implementation of various performance-based schemes (e.g. pay-for-
performance policy). Duties and responsibilities must be centralized in new HTA and 
HIA bodies that manage the tasks of the cyclic and dynamic reimbursement process 
under the leadership of the MoH. These changes will provide better functionality for 
pharmaceutical pricing and reimbursement decision-making system to make Iran ready 
for the implementation of PFRSA policies and ultimately to improve the affordability 
and accessibility of expensive drugs.  
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Introduction 
To discuss the results of this thesis, it would be appropriate to flashback to the overall 
goals of a drug reimbursement decision-making system which is described in the first 
chapter. It is noted that the best decision is made when the three goals relating to 
quality of care, population health, and affordability have been accomplished 
simultaneously. To make sure whether or not these goals are met at any decision, 
decision-makers need to reach maturity and wisdom on different areas of the subject 
of the decision. This chapter explains how Iran can move toward achieving the overall 
goals and improving its drug reimbursement decision-making system by using the 
findings of this thesis. The general discussion has been structured in three sections. In 
the first section, the main issues and subsequent consequences of the current drug 
reimbursement decision-making system in Iran are explained and then applying our 
findings in this thesis, some possible solutions are suggested. In the second section, 
some general recommendations are proposed to facilitate improvement of the drug 
reimbursement decision-making system. Finally, in the third section, studies’ limitations 
and general conclusion are explained followed by the final remarks.  
1. Dilemmas and Solutions 
1.1- The main issues of the current drug reimbursement decision-making system in 
Iran 
As outlined in chapters two and eight, the current drug reimbursement decision-making 
system in Iran has some important issues such as inconsistency among different 
stakeholders, lack of transparency, and a time-consuming process. As an example, using 
trastuzumab to treat breast cancer may help to illustrate these current issues. 
Trastuzumab was launched in 2007 after issuing a marketing license by the Ministry of 
Health in Iran while the reimbursement process started at the Ministry of Welfare was 
later on. As a result, patients had to pay the total costs of trastuzumab; consequently, 
trastuzumab was not affordable for many patients due to its high cost. Iranian health 
insurance organizations (payers) were not interested in reimbursing this drug due its 
significant budget impact. Therefore, trastuzumab was available but not affordable for 
many patients at least for 5 years after its market launch in 2007. Doctors and patients 
tried to force payers to reimburse trastuzumab in different ways that are explained in 
chapter three. Subsequently, Iranian policymakers decided to reimburse trastuzumab 
in 2012 with no reasons. This example clearly shows that there is an inconsistency 
between the two ministries of health and welfare in Iran. According to the Ministry of 
Health policy, patients should have access to all essential drugs and that any drug with 
no safety issues can be launched in Iran. However, the Ministry of Welfare and payers 
are not interested in covering all drugs approved by the Ministry of Health, due to 
economic issues. Therefore, payers try to postpone the reimbursement of expensive 
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drugs with high budget impacts. Consequently, these issues make the drug 
reimbursement decision-making system a non-transparent and time-consuming 
process in Iran. These main issues lead to lack of solidarity and mutual understanding 
between different stakeholders. For example, the Ministry of Health in Iran 
recommends nine weeks of trastuzumab for patients with HER2-positive breast cancer, 
since the high cost of this medication. Payers therefore covered only a nine-week 
treatment strategy. However, as described in chapter three, most Iranian doctors did 
not follow this recommendation and treat patients in longer periods. Therefore, those 
patients who use trastuzumab longer than nine weeks, should pay 100% of the costs of 
trastuzumab and incur the financial risks for the extra treatment. Due to the huge out 
of pocket payments caused by implementation of the national guideline, both doctors 
and patients argued against the decision made by payers regarding coverage of the 
short duration of trastuzumab therapy. This way resulted in one-year treatment 
strategy was reimbursed for trastuzumab. These events call into question the full 
dominance of policymakers on the pharmaceutical market in Iran. In other words, while 
payers are working under pressure of healthcare budget constraints, as chapter eight 
explains, drug manufacturers can release their product almost without taking any 
substantial financing or performance risks. Patients and payers, however, have to incur 
these risks. 
In summary, the performance of the current drug reimbursement decision-making 
system is affected by inconsistency between the two ministries. To solve the current 
problems, Iran has to prepare some new arrangements. 
1.2- Requirements to improve the drug reimbursement decision-making system 
As chapter eight recommends, to improve the system, Iran should eliminate conflict of 
interests and inconsistency throughout the healthcare system and increase 
transparency of the drug reimbursement processes. These two important 
recommendations should be viewed by the Parliament members and non-
governmental organizations as societal important needs. As chapter eight also explains, 
these two issues can be solved by improving health economics-related evidence and 
healthcare governance. Therefore, this section has focused on how to improve these 
two parts.  
Improving evidence for better decision making concurrently with eliminating conflict of 
interests would be an important step to achieving the overall goals of decision-making. 
This is possible only through a proper infrastructure which helps in providing proper 
knowledge for decision-making. In other words, the existence of a knowledge-
production infrastructure is a key item in moving forward to an optimal decision-making 
system. This infrastructure could manage the flow of data from the healthcare 
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environment to policymakers. However, the quantity and quality of necessary 
information are dependent on how well the infrastructure generates, collects and 
integrates the data (Figure 9.1). As Figure 9.1 shows, the healthcare system is composed 
of different layers, and various stakeholders are involved in each layer. Healthcare 
providers and patients are found in the environment layer and their activities generate 
patient level data. This data must be collected at a higher layer (data layer) by patient 
registry centers and payers. This layer is a source of many necessary patient-level data 
like observational and claims data. Researchers can use these data to generate valuable 
information such as the costs of illness and quality of life values. This information can 
then be used to support various cost-effectiveness and budget impact analyses of any 
intervention or be used to conduct priority setting studies such as multi-criteria decision 
analysis in the healthcare system. This knowledge is provided by researchers in the 
academic field or by governmental bodies like health technology assessment (HTA) 
agencies and can be used to help policymakers to obtain important insights in to the 
particular area of interest, which will prepare them to make a balanced decision. This 
infrastructure for reimbursement decision-making consists of two main parts in 
general. The first part is ‘Production of health economics-related evidence’ and the 
second part is an ‘Efficient healthcare governance structure’ that supports the 
continuity and quality improvement of the first part. These two parts are indispensable 
and are the main requirements of a proper decision-making system in healthcare, as 
concluded in chapter eight. If all components of this healthcare platform work perfectly, 
then we can expect perfect knowledge and an appropriate decision.  
1.2.1- Production of health economics-related evidence 
As stated in the previous subsection, knowledge production is a necessity to make 
better decision. Indeed, HTA studies yield an important part of the knowledge required 
for evidence-based decisions. Providing this part of knowledge, however, needs a 
strong platform based on health information technology to manage the flow of data 
and information. It is worth noting that implementation of a perfect infrastructure is 
costly and sometimes infeasible in many middle-income countries (MICs). Therefore, in 
parallel with the improvement of different components of the current infrastructure, 
we need to find solutions to overcome some missing elements. This subsection 
illustrates the knowledge gaps in the current Iranian healthcare system and provides 
some solutions to improve it. 
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1.2.1.1- Knowledge gaps in drug reimbursement decision-making 
Limitations of health information technology lead to various obstacles for HTA studies. 
Any platform for health information technology should be able to manage two 
important parts of patient level information including clinical and resource used data. 
In general, patient registries and claims databases are the two important sources of 
data for HTA studies. However, implantation of country-level patient registries is very 
costly and time-consuming [1] even in high income countries (HICs). Patient registries 
in HICs can be created and maintained through different potential sources of funding, 
including funding by governments and manufacturers [2] due to mutual interests in 
performing observational studies between pharmaceutical firms and HTA bodies in 
HICs. This collaboration, however, would not be possible in MICs and governments must 
mostly fund patient registries. Accordingly, a comprehensive and national patient 
registry is not available in Iran and various academic institutes track different clinical 
outcomes of treatments in a local population of patients. As explained in chapter four, 
the generalizability issues are explicitly expressed in most patient-level studies due to 
lack of patient registries. On the other hand, Iran has implemented universal health 
 
Figure 9.1: An appropriate infrastructure for a reimbursement decision-making system.  
Abbreviations: BIA: budget impact analysis, CEA: cost-effectiveness analysis, DBs: data bases, EA: equity 
analysis, EBM: evidence-based medicine, MCDA: multi criteria decision analysis, QoL: quality of life 
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insurance coverage that involves various payers. Chapter two notes that two payers 
(Social Security Organization (SSO) and Health Insurance Organization (HIO)) insure 
more than 85% of the Iranian population. This means that a good source of claims data 
potentially is available to provide important information such as patient level resource 
used and costing. However, despite the huge data collection from the health care 
providers by payers, Iran does not have a comprehensive database representing a 
country-level healthcare resource use data. Therefore, researchers should find a 
solution to deal with limitations of patient-level data in Iran. 
Another important knowledge gap is lack of reliable health-related quality of life data, 
both in the general population and in specific types of disease. This gap exists due to 
the lack of research capacity (human and finance resources) in the field of health 
economics in Iran. Lack of health-related quality of life data can influence the results of 
various HTA studies like cost-effectiveness analyses, as clearly discussed in chapters five 
and six of this thesis.  
In summary, there are different limitations to perform HTA studies and many country-
specific studies cannot easily be conducted in Iran. Therefore, short-term and long-term 
solutions are needed to improve knowledge production in Iran. In the next subsection, 
some possible solutions are presented based on the previous chapters of this thesis as 
the short-term solutions for dealing with the lack of necessary information. The long-
term solution, however, is to improve the knowledge-production infrastructure (Figure 
9.1) in general.  
1.2.1.2- Possible solutions to address the knowledge gaps 
This thesis described two solutions that were proposed and tested by researchers. The 
idea was that the knowledge gaps described above can be addressed through the 
appropriate use of available data sources. In other words, Iranian researchers and 
policymakers should use what is available to obtain what they need. For example, the 
strong claims databases in Iran may help researchers and policymakers to obtain the 
information that is vital for HTA studies. One possibility (first solution) is to produce the 
necessary information, which are normally obtained from patient registries, using 
various patient classification techniques on the claims databases. As this thesis shows 
in chapter four, validated patient classifications could support a real-world cost analysis 
in Iran. Data-mining techniques, in this case, facilitated the acquisition of valuable 
information to estimate health care utilization and understand the contribution of 
diverse cost components of treatment of HER2-positive breast cancer in Iran.  
Another solution is to use the results of economic evaluations performed in other 
countries. Iran may use these evaluations but should be careful with the interpretation. 
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This strategy may also introduce extra uncertainties regarding the outcomes, resulting 
in less reliable information for the drug reimbursement decision making. Simplifying the 
problems based on important factors with high impact on the results of a cost-
effectiveness analysis can be an option, as shown in chapter six. This strategy of 
transferring the results of cost-effectiveness analyses to Iran can facilitate the process 
of knowledge production and therefore decision-making. Chapter six shows how a 
relatively simple transfer method could lead to a good estimation of incremental costs 
of an expensive drug in Iran. There is a strong argument that the simplification 
technique may not provide an accurate estimation of ICER. That may be the case, 
however, there are always uncertainties around any estimations and the simplification 
technique is no exception to that rule. On the other hand, simplification method can be 
considered as an option to overcome various limitations such as time-limitation for a 
reimbursement decision-making, necessary detailed information, and adequate 
research capacity for economic evaluation studies. In other words, this technique can 
be used as a preliminary-HTA analysis. However, despite the fact that transferring 
methods may be able to provide reasonable cost-effectiveness evidence quickly, the 
preferred method remains a country-specific cost-effectiveness analysis which can be 
an important segment of a post-marketing analysis.  
Improving research capacity in Iran is a prerequisite for improvements in 
reimbursement decision making. Increased funding for research can provide incentives 
for researchers to improve the quantity and quality of HTA knowledge production by 
some fundamental studies. For example, some studies are essential like measuring 
utility weights and quality of life both in population and individual levels. These are very 
important studies which provide knowledge that is useful for many economic 
evaluations and financial contributions are needed to conduct. However, these studies 
may not be interesting enough to invest by some third party financial contributors such 
as pharmaceutical firms in middle-income countries. Therefore, knowledge production 
must be supported mostly by governing bodies in middle-income countries.  
1.2.2- Efficient healthcare governance structure 
To support the process of knowledge production an efficient healthcare governance is 
essential. From a governance perspective, chapters two and eight describe the 
structural deficiencies in the Iranian healthcare system. In fact, without an efficient 
healthcare governance, the process of knowledge production and application of this 
knowledge in decision-making would not be possible. The role of an efficient healthcare 
governance is to support the process of knowledge production and provide the 
connectedness among different stakeholders in healthcare system (Figure 9.1). Only a 
guaranteed and effective collaboration among the different stakeholders who are 
involved in different levels of healthcare system can help the decision-making process. 
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A strong healthcare governance can guarantee effective collaboration. This subsection 
explains the issues and provides solutions to improve healthcare governance. 
1.2.2.1- Healthcare governance issues in drug reimbursement decision-making 
Chapters two and eight explain how the responsibilities of drug reimbursement decision 
making are inappropriately split between two ministries. The Ministry of Health in Iran 
is trying to expand patient access to different medications without considering 
affordability of treatments and budget impact. This strategy may mean that expensive 
drugs are made available for patients with a high socio-economic status. However, 
other patients in lower socio-economic classes, who cannot afford easily the costs of 
unreimbursed expensive drugs are condemned to incur the catastrophic costs of 
expensive drugs [3]. On the other hand, a very time-consuming reimbursement process 
by the Ministry of Welfare can make it impossible for patients to obtain early access to 
effective in an affordable manner. This time-consuming decision-making process by the 
Ministry of Welfare and payers may be existing because of uncertainty about the 
potential consequences beyond reimbursement of expensive drugs. The payers try to 
postpone reimbursement until they have enough information about the financing of 
expensive drugs. However, as explained in chapter eight, it may not be possible to 
reduce the degree of uncertainty regarding reimbursement decisions due to lack of 
information and an inability to implement innovative policies like performance-based 
and finance-based risk sharing arrangements (PFRSAs). Therefore, payers are not 
enough active in reimbursement decision-making process [4] while they have to pay the 
costs of drugs with very high budget impact. In fact, in this governance structure, payers 
are not able to perform risk assessments and therefore try to shift the risks caused by 
reimbursing drugs to patients by increasing out-of-pocket payments [5] or delaying 
payments to healthcare providers such as pharmacies [6,7]. Both of these two 
strategies limit the ability to achieve the overall goals of a drug reimbursement decision-
making system (i.e., quality of care, population health, and affordability). Therefore, 
drug availability and affordability do not necessarily go hand in hand in Iran. While a 
drug may be available on the market, its purchase price may not be reimbursed and its 
high price may not make it easily affordable for the majority of patients. 
In recent years, many efforts have been made to reduce patients’ out-of-pocket 
payments since the first term of president Rouhani in 2014 [8-10]. Under the 
“Healthcare Reform Plan”, the state has allocated 1% of value added tax (VAT) to 
healthcare system in order to facilitate the achievement of the plan’s objectives 
including eliminate of informal payments [11]. However, improvements in financing 
alone may not be helpful in sustaining the reform plan. Sustainability and improvements 
in the performance of any plan are depend on how the decision-making bodies are well 
organized in healthcare system [12]. As chapter seven explains, use of external price 
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referencing can influence the costs of expensive drugs in Iran or other MICs and can 
lead to more waste of healthcare resources. Therefore, as chapter eight concludes, 
improvements in healthcare governance is necessary to optimize budget allocation. 
Otherwise, policymakers have to increase the healthcare budget to cover governance 
inefficiencies. This sounds like what is happening for the “Healthcare Reform Plan” in 
Iran. In other words, increase in healthcare budget without improvement in healthcare 
governance cannot necessarily lead to a better quality of care. 
1.2.2.2- Possible solutions to improve healthcare governance 
As chapter eight explains, integrity in operation is the most important solution to 
overcome inefficiencies. Centralizing responsibilities at the Ministry of Health will help 
to improve the overall performance of different organizations, which are involved in the 
healthcare system. To express this simply, when an organization is responsible for both 
healthcare resources and expenditure, its decisions will be based on a balancing act 
between various expectations and available resources. Policymakers then must focus 
to make an optimal decision considering budget constraints rather than trying to 
resolve the conflicts [13]. 
Chapter eight proposes a new structure for the reimbursement decision-making 
process in the Ministry of Health. Two important governing bodies are responsible for 
clarification about the various uncertainties about reimbursement and pricing of any 
new drug. A governing body for health technology assessment (HTA body) should 
provide a strong connection between different research institutes in the country to 
facilitate performing comprehensive researches. Real-world evidence of new 
interventions should be monitored by the HTA body. Another governing body which is 
responsible for health insurance administration (HIA body) should be a coordinator of 
various health insurance organizations and should be responsible for negotiating prices 
with pharmaceutical firms. Monitoring different financial consequences would be an 
obvious task for this governing body. Indeed, these two governing bodies must be 
completely synchronized to perform the cyclic and dynamic reimbursement process 
shown in Figure 8.2. The Minister of Health will be responsible for establishing 
coordination and management of these two governing bodies and must be an eligible 
figure for making and revising decisions regarding drug reimbursement and pricing. Due 
to this new reorganization, the current responsibilities found in different departments 
of the Ministry of Health should be centralized in the two governing bodies of HTA and 
HIA. Specifically, the process of registration, evaluation and pricing needs to be 
disconnected from the FDO. On the other hand, the process of reimbursement decision 
making in the Ministry of Welfare and the Cabinet should be transferred to the two 
governing bodies. Obviously, the final decision would be made by the Minister of 
Health.   
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The solutions explained in the first section of this chapter were based on the opinion of 
the researchers involved in this thesis. Other researchers may suggest alternative 
solutions to improve both knowledge production and healthcare governance. However, 
policymakers should understand that all of these possible solutions should lead to 
achieve the overall goals of a drug reimbursement decision-making system. Therefore, 
some important steps should be implemented in the Iranian healthcare system which 
are explained in the second section. 
2. Improvements needed in the drug reimbursement decision-making  
This section provides and explains general recommendations to achieve more effective 
drug reimbursement decision-making in Iran. In contrast with the first section that 
contains some solutions to improve the system, the second section provides key points 
suggested to implementing in Iran.  
Chapter eight shows that the drug reimbursement decision-making system should be 
designed as a cyclic and dynamic process. Policymakers should pay attention to the fact 
that pharmaceutical market is always changing; new products are launching 
continuously and new effective interventions are potentially available. Meaning that 
the previous reimbursement decisions would not be relevant forever and may if 
needed, be modified. Moreover, the healthcare market has its own complexities and 
the priorities of policymakers and other stakeholders in any healthcare system can be 
changed over time. Therefore, under this circumstance, a drug reimbursement 
decision-making process should not be considered like a one-way street and pros and 
cons of the decisions made should be monitored in the real world. In other words, the 
four main sections of the proposed cyclic and dynamic reimbursement process 
(evaluation, negotiation, resolution, and observation), as introduced in chapter eight, 
should be performed regularly. If the cyclic and dynamic process is implemented 
fundamentally, it can certainly help to achieve the overall goals of a drug 
reimbursement decision-making system in the long term. To improve the performance 
of the process, implementation of some actions is strongly recommended to 
policymakers in Iran. 
2.1- Development a country-specific guideline for economic evaluations 
As evident in chapters five and six, the WHO-CHOICE recommendations [14] were used 
to conduct these studies in the absence of Iran-specific guidelines for economic 
evaluations. The development of guidelines, that clearly define the framework of the 
economic evaluations, analytic approaches, input data, and reporting, is one of the 
requirements for improving quality and standardization of various economic 
evaluations.  
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A country-specific guideline for economic evaluation can reduce uncertainties around 
decision-making process. For example, the World Health Organization recommends a 
unique willingness-to-pay threshold of 3×GDP/capita for lower-income countries [14]. 
Implementation of this threshold does not help countries in their reimbursement 
decision-making process, due to the following weaknesses that it can potentially affect 
reimbursement decision-making. Firstly, it is changeable with fluctuations of the GDP 
over years and policymakers then cannot make a long-term decision based on a 
threshold at the year of study. Secondly, it does not necessarily reflect the total health 
expenditure which is allocated to healthcare system. And thirdly, it is relatively higher 
than the threshold in HICs (e.g.: 3×GDP/capita estimates almost £100,800 in the UK in 
2015 [15] while the reference threshold for the NHS is ranged between £20,000 and 
£50,000). Therefore, introducing a range of willingness-to-pay thresholds based on 
severity of disease can be more effective and operative in Iran. Similar to the 
willingness-to-pay threshold, other important parameters such as budget impact 
analysis, different perspectives and discount rates also need to be defined based on 
socio-economic specifications in Iran.   
2.2- Development a good governance standard for drug reimbursement decision-
making 
With respect to chapter eight, responsibilities of different governing bodies for health 
insurance administration, health technology assessment, and also the Minister of 
Health, should be clearly defined in the cyclic and dynamic process (Figure 8.2). It is 
necessary that Iranian policymakers design and implement principles of good 
governance like those standards for public services recommended by the Independent 
Commission on Good Governance in Public Services in the UK [16]. Six principles have 
been introduced in this guideline, which can be considered and adapted to improve the 
performance of the drug reimbursement decision-making system. These standards 
should help governing bodies to: a) being clear about their purposes and intended 
outcomes for patients and healthcare providers; b) being clear about their functions 
and roles; c) being attentive to transparent decisions in their governing bodies; d) 
Making sure that personnel have the skills, knowledge and experience they need to 
perform well; and e) engaging effectively with stakeholders in healthcare system [16].  
2.3- Development an independent pricing system 
Chapter four shows how the healthcare budget allocated for the treatment of breast 
cancer can quickly be consumed by an expensive drug in Iran. This is due to use of 
external reference pricing which has reduced the affordability of expensive drugs in 
lower income countries. Chapter seven, however, explains why a strong pricing system 
is necessary to improve affordability and accessibility of drugs. This thesis recommends 
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that payers should first improve their ability to negotiate the price of drugs through 
improvement of health economics-related evidence generation and then establish a 
value-based pricing. It would be understandable if payers wanted to reference the price 
of drugs in other countries for the first price determination. However, price 
modification might be necessary as soon as real-world evidence suggests an 
unpredictable risk on financial resources or improvement population health (Figure 
8.2).  
2.4- Implementing risk sharing arrangements 
Sharing risk between payers and pharmaceutical firms is an important missing piece in 
Iranian healthcare system. This is due to limitations in the current healthcare 
governance in Iran which hinders the implementation of risk sharing arrangements. This 
thesis provides some recommendations to distribute risks between payers and 
pharmaceutical firms and thereby improve accessibility to expensive drugs.  
Two main groups of risks should be taken into consideration. Firstly, financial risks, 
which have an impact on healthcare expenditures, will appear as an early consequence 
of any reimbursement decision-making. Therefore, financed-based risk sharing 
arrangements would be a necessity to reduce budget allocation uncertainties. It seems 
that implementation of this type of risk sharing policies would be easily feasible for both 
payers and pharmaceutical firms, due to existence of an adequate developed 
infrastructure for health information technology in Iran. The second group of risks are 
those that affect population health or quality of care. Therefore, implementation of a 
performance-based risk sharing arrangement can reduce uncertainties around 
improvements in population health and quality of care. Feasibility of implementing this 
policy, however, is uncertain due to a series of shortcomings and deficiencies in Iran 
that have already been mentioned in chapter eight. Indeed, such problems are not 
limited to Iran and even high-income countries are facing with difficulties and 
challenges [17,18]. Perhaps Iranian policymakers can take the first step by focusing on 
orphan drugs and some other expensive drugs administered in relatively low disease 
frequency. Because of a small number of patients, policymakers can easily prepare 
requirements for measuring and monitoring treatment responses. 
2.5- Pricing based on a max-age threshold 
Price determination based on a fair price that ensures a drug remains cost-effective for 
a large patient population might be among important goals for policymakers. In the 
absence of a performance-based risk schemes using max-age threshold may be a 
possible solution to improve affordability and accessibility of expensive drugs. As 
chapter five shows, an expensive drug might be cost-effective but only for a small 
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number of patients. We need to reach an optimal price to implement in a larger group 
of patients. This idea will be discussed more later.  
2.6- Improvement of post-marketing observations 
Post-marketing monitoring helps policymakers to check the accuracy (moving toward 
the overall goals) and precision (achieving the overall goals) of the conclusions derived 
in pre-decision steps (assessment, appraisal and pricing) (Figure 8.2). Chapter eight has 
explained that lack of post-marketing monitoring in Iran is one of the main issues 
leading to increase decisions uncertainties. Perhaps the most obvious part of post-
monitoring process is the monitoring of the actual budget impact of any new 
intervention and its deviation from the budget impact that was estimated before 
making the reimbursement decision.  
This thesis showed that post-marketing analyses are important to correct previous 
decisions by policymakers. Some of the research described in this thesis performed 
shortly after reimbursement of trastuzumab in Iran. Therefore, the results of some 
chapters can be considered as examples of post-marketing analyses. For example, 
chapter three showed that Iranian doctors did not adhere to the national guideline 
published by the Ministry of Health in Iran which recommended a very short duration 
of trastuzumab (9 weeks). The contribution of trastuzumab to medical costs of health 
care services associated with HER2-positive breast cancer in Iran was investigated in a 
real-world cost analysis described in chapter four. This analysis showed two things. 
Firstly, the average duration of 21 weeks trastuzumab therapy in patients was not 
consistent with the Iranian national guideline or the clinical guideline in HICs (52 weeks 
for trastuzumab therapy). Secondly, trastuzumab costs comprised the largest share of 
total costs in all three stages of breast cancer. Chapter five is an example of how 
policymakers should be aware about the updated evidence and then modify their 
previous decisions. This study used the results of PHARE trial [19], which compared six 
months versus one year of adjuvant trastuzumab therapy. The PHARE trial was 
published almost two years after reimbursement of trastuzumab in Iran. Consequently, 
using this updated evidence, it is possible to improve the affordability and accessibility 
of expensive drugs in MICs. Finally, chapter eight showed that trastuzumab use in Iran 
continually increased in the three years after the reimbursement date and discussed 
what steps should be taken to adjust budget impact of trastuzumab using different risk 
sharing schemes. Moreover, to make sure about the real-word effectiveness of 
trastuzumab, the real-world outcome in Iran could be compared with the results of 
different randomized control trials such as HERA and PHARE trials. However, we were 
limited to perform this comparative analysis. Despite this limitation, there is enough 
evidence to express the importance of post-marketing observations. All of the above 
evidence suggests that the current policies based on previous decisions do not 
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effectively improve quality of care, population health, and affordability simultaneously 
and lead to the conclusion that these decisions must be modified.  
Two proposed governing bodies in chapter eight (HTA and HIA) should be responsible 
for post-marketing monitoring and real-world evidence generation after drug 
reimbursement decision making. Specifically, these two institutions should make sure 
about the moving toward and achieving the overall goals at any decision. If there is a 
deviation from achieving the goals, as shown in Figure 8.2, these two governing bodies 
should provide an appropriate solution to fix the deviation. Depending on the issue, it 
may lead to a new evaluation phase or using two fast-tracks price modification (Figure 
8.2). 
2.7- Correcting former decisions  
New and updated evidence may present additional and important information. This 
provide an opportunity for policymakers to review their former decision and think 
about other options to improve quality of care, population health, and affordability at 
the same time. Therefore, an alert system is necessary to follow evidence and consider 
their potential impact on previous decisions. 
As chapter eight suggested, healthcare services costs and their impacts on healthcare 
budgets need to be monitored regularly after any decision. A higher than expected 
budget impact and off-labeling use of drugs may cause consequences on total health 
expenditure and, therefore, correction of the former decision need to be considered 
persistently. Chapter eight suggests a cyclic and dynamic reimbursement process 
(Figure 8.2) to monitor and correct the previous decisions. In the medium or long term, 
this process provides considerable knowledge and evidence on various pharmacological 
categories. Policymakers can use this knowledge and evidence not only to improve 
internal price referencing, but also to enhance predictability of an appropriate price for 
other new drugs in future. Ultimately, this structure helps countries to eliminate the 
use of external price referencing and ensure that their decisions are independent from 
the decisions which were made regarding the price of a drug in other countries. 
Pharmaceutical firms will then be faced with an efficient healthcare governance that 
can detect and measure various possible risks for reimbursing a drug. Therefore, they 
should convince policymakers by both reducing the possible risks (financial and 
performance-based risks) for healthcare system and asking a reasonable price.  
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3. General conclusions and policy implications 
Reimbursement and pricing decision-making is a complicated process and it is not very 
easy to find two similar cases in this process. The system should be designed in a way 
that policymakers are able to be flexible in applying the various techniques already 
mentioned in different chapters of this thesis. The main aim is to achieve all three 
overall goals for drug reimbursement decision-making. To manage uncertainties around 
the decision, policymakers can use different techniques to ensure that they achieve the 
goals. Figure 9.2 illustrates how and what techniques must be applied to improve 
decision-making regarding reimbursement of a drug in MICs. When drug 
reimbursement cannot help achieving all three goals simultaneously, policymakers 
should apply various strategies to reduce uncertainty. For example, if specific drug is 
effective and improves population health but it is not affordable, finance-based risk 
sharing arrangements need to be applied to help improving affordability. In another 
situation, if the drug improves quality of care but there are uncertainties about 
affordability and improvement of population health, both finance-based and 
performance-based risk sharing arrangements can be applied to achieve them. 
It is quite likely to not achieve the three overall goals of reimbursement decision making 
for any new drug despite using the various techniques explained in section two. 
Therefore, if the best decision (area number 1 in the figure 9.2) is not possible, 
policymakers should prioritize the three overall goals of reimbursement decision 
making. Due to severe budget limitations in MICs, affordability of a drug may be the 
most important goal; indeed, if drugs are not affordable, they cannot improve 
population health or quality of care. However, using an affordable drug is also useless 
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when it is not effective and cannot improve population health or quality of care. 
Therefore, affordability of a drug is an integral part of an optimal decision. In conclusion, 
when it is not possible to make the best decision, an optimal decision happens when an 
affordable drug can improve population health or quality of care.  
From a policymaking point of view, improving population health is more important than 
quality of care. The obvious reason is that a drug or intervention (such as vaccination) 
that saves lives is more important than any intervention that can only improve quality 
of care (such as robotic surgery). Moreover, as chapter five shows, it is likely that MICs 
have a lower overall population health [20] than HICs and a lower life expectancy can 
affect the cost-effectiveness of expensive drugs. Therefore, as much as life expectancy 
improves probability of being cost-effectiveness for expensive drugs will be improved 
as well.  Therefore, an optimal decision that covers affordability and population health 
is more preferable than a decision which covers affordability and quality of care. Figure 
9.2 shows the area of an optimal reimbursement decision making which is the green 
zone. As the figure shows, the priority of decision will decrease from the first to the 
third section of the green zone and a decision made in other areas cannot be considered 
as a proper decision and should be avoided by policymakers. 
To make these concepts clearer, as an example, we can consider our case study and 
explain three scenarios for decision-making on trastuzumab reimbursement in Iran. The 
first scenario is to make a decision on trastuzumab reimbursement with the current 
price in Iran. In this situation, chapter three explains that one year of trastuzumab is not 
an affordable strategy due to its huge budget impact, despite the fact that it can 
improve population health. On the other hand, chapter five showed that 6-month 
trastuzumab use is an optimal strategy that can improve both population health and 
affordability. However, this strategy is cost-effective only in patients younger than 59 
years. Based on what was explained before, both strategies cannot fulfill the overall 
goals of reimbursement decision making. Therefore, policymakers should not 
reimburse trastuzumab with the current price in Iran and should seek a price reduction 
(through finance-based or performance-based risk sharing arrangements) to make 
trastuzumab more affordable. The second scenario could be when policymakers reduce 
the price of trastuzumab in Iran using different strategies of risk sharing schemes. 
Supposing a 30% price reduction for trastuzumab has been achieved in Iran. In this 
situation, chapter five explains that with a 30% reduction in trastuzumab price, one year 
of trastuzumab can also be considered as an optimal strategy but only for patients 
younger than 49.5 years (Figure 5.5). One year compare to 6 months of trastuzumab 
duration may provide better individual quality of care, however, due to smaller group 
of patients for whom the strategy remains optimal (max-age 49.5 vs 68), it is less cost-
effective than the 6-month strategy. It looks like the one-year and 6-month strategies 
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can be assumed in areas number 3 and 2 in the figure 9.2 respectively. According to the 
above-mentioned, both strategies can be considered as the optimal strategies (green 
zone). However, from a healthcare point of view, 6-month trastuzumab use would be 
more preferable in Iran. The third scenario is a significant trastuzumab price reduction 
using the max-age threshold. Depending on how much the price of trastuzumab can be 
reduced, the one-year treatment regimen may be closer to the best decision area. For 
example, chapter five shows that if Iranian policymakers decide to consider the max-
age threshold for pricing and it should be equal to the average life expectancy of Iranian 
women (75.6 years), then the best decision happens when the price of trastuzumab is 
reduced by ~70% (Figure 5.5). In this situation, most women can undergo a cost-
effective and standard treatment regimen (one-year) of trastuzumab which is 
recommended by many clinical guidelines worldwide [21-29]. Subsequently, 
trastuzumab not only would be an affordable medication but also it improves both 
population health and quality of care. In other words, all three goals of a drug 
reimbursement decision-making system can be accomplished simultaneously.  
3.1- Limitations and recommendations for future research 
There are some limitations related to the fact that although different methods are used 
for improving evidence in the field of HTA in Iran; some other methods are missing in 
this thesis. Firstly, as it has been noted, quality of life measurement is one of the missing 
research areas in this thesis. Specifically, there is an important lack of information 
regarding generic utility weights that helps calculating quality adjusted life years 
(QALYs) in Iran. Utility measurement is one of the most important parts of HTA 
knowledge due to its significant impact on the results of cost-effectiveness analyses. In 
the absence of country specific information in this area, utility weights in other 
countries were used in different chapters of this thesis. The results of studies included 
in this thesis should be examined using Iran-specific utility weights in the future. 
Secondly, this thesis does not include a multi-criteria decision analysis (MCDA) [31] in 
Iran. This method may help policymakers to improve their decision regarding 
reimbursement of an expensive drug. Performing a MCDA, however, seems to be 
affected by budget impact (affordability) of an intervention. Therefore, it would also 
necessary to investigate the role of a MCDA approach in improvement of 
reimbursement decision-making in a middle-income country in the future studies. 
3.2- Final remarks 
This thesis opens a window toward a less well-known part of the HTA-related sciences. 
At first glance, the drug reimbursement and pricing system in an MIC may look like the 
same system in HICs. However, various studies in this thesis showed that improvement 
of the system in lower income counties is relatively more difficult than in counties with 
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more financial resources and more stable infrastructures. Although this thesis only 
focused on drug reimbursement and pricing system in Iran, we believe that other MICs 
can also use our findings to improve their system where the limitations on knowledge 
production and healthcare governance represent the most important obstacles to 
improve the system in these countries.  
Different chapters of this thesis show that the drug reimbursement decision-making 
system in Iran needs to be improved. The shortcomings of the current system are 
categorized into two main types: those that have impact on understanding to make a 
good decision and those that improve the connectedness among different stakeholders 
in this system (Figure 9.1). To overcome these shortcomings, two strategies should be 
used. Some solutions may be useful in the short term while others need some structural 
changes in the long term. Improving decision-making system for drug reimbursement 
in Iran is feasible but it is a tough task to provide necessary infrastructure for 
‘Production of health economics-related evidence’ and to achieve an ‘Efficient 
healthcare governance structure’. All changes must be targeted toward improving the 
ability to achieve the best decision through the accomplishment of the three goals of 
quality of care, population health, and affordability simultaneously.  
The final conclusion of this thesis is that good decision making happens when the 
pharmaceutical market can be controlled by monitoring and correcting previous 
decisions. A national commitment is needed to implement the recommendations 
provided in this thesis. We hope that this thesis helps Iranian policymakers in this way.  
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Introduction 
Reimbursement decision making in any healthcare system is an important process to 
ensure patient access to various healthcare services in an affordable manner. A proper 
reimbursement decision making happens when it can concurrently pursue three main 
goals including quality of care, population of health, and affordability. However, 
achieving the goals requires enough knowledge and proper healthcare governance. In 
middle-income countries (MICs) improving the three main goals is likely to be difficult 
due to weakness in the knowledge production infrastructure and healthcare 
governance. To investigate possible solutions for improving the drug reimbursement 
decision-making system in MICs, this thesis focuses on the drug reimbursement 
decision-making system in Iran. Subsequently, we focus on use of a monoclonal 
antibody in breast cancer. Trastuzumab (Herceptin) is widely used in the treatment 
of overexpressed human epidermal growth factor receptor 2 (HER2-positive) breast 
cancer. Trastuzumab, as an expensive drug, has continued to be a topic of conversation 
in many healthcare systems since its launch into the pharmaceutical markets.  
The overall aim of this thesis is to investigate how an MIC (in this case, focusing on Iran) 
can improve its drug reimbursement decision-making system. Therefore, this thesis 
provided important information on how an MIC can improve the drug reimbursement 
decision-making system in three parts. Firstly, we discussed the current situation and 
subsequent consequences of the drug reimbursement decision-making system in Iran. 
Secondly, we provided some solutions to improve limited health economics-related 
evidence in Iran. And finally, some recommendations are provided to improve the 
system. 
Part I: The current drug reimbursement decision-making system in Iran 
In chapter two, we focus on the current drug reimbursement process in Iran. The entire 
drug reimbursement process and the stakeholders are explained in this chapter. We 
reviewed the documents describing the administrative rules and directives of 
stakeholders. Moreover, we used published statistics and interviewed with experts and 
policymakers. The Food and Drug Organization and the Supreme Council of Health 
Insurance are two most qualified organizations in this process. Ultimately, the Iranian 
Cabinet approves and recommends a drug to all health insurance organizations. Despite 
its strengths, the system faces various issues. Important shortcomings in the system 
include out-of-pocket contributions due to lengthy decision-making, lack of 
transparency, and conflicting interests amongst stakeholders 
To obtain insight about routine practice of treatment HER2-positive breast cancer in 
Iran, chapter three assessed the extent to which current routine practice in Iran 
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matches the recommendations found in the national guideline published by the Iranian 
Ministry of Health. The Iranian national guideline recommends a nine-week 
trastuzumab regimen while most national standard therapeutic guidelines in the world 
recommend a 52-week trastuzumab regimen for breast cancer treatment. To 
investigate clinician adherence to the Iranian guideline for treating HER2-positive breast 
cancer, an online anonymous questionnaire was sent to 128 Iranian oncologists and 
asked them about their approach when they treat a patient with HER2-positive breast 
cancer. Moreover, a 3-year retrospective claims database analysis was conducted using 
data from the Social Security Organization, a health insurer which covers approximately 
50% of the Iranian population, to enable comparisons with the questionnaire results. 
Iranian doctors reported a low rate of absolute adherence (6%) to the guideline for 
duration of trastuzumab treatment. The general trends found in the survey were 
confirmed in the claims database analysis of 1,295 HER2-positive patients. Therefore, 
Iranian physicians appear to rely more on the medical literature than on national 
guidelines regarding trastuzumab use. 
Part II: Production of health economics-related evidence in Iran 
To fill the gap of knowledge to make better reimbursement and implementation 
decisions, chapter four explains how middle-income countries can use claims data and 
data mining to achieve a good understanding of real-world healthcare costs. This 
chapter examine the fraction of total costs related to trastuzumab use into three 
disease stages of HER2-positive BC in Iran. A retrospective analysis of claims data was 
performed from the Iran Social Security Organization, a health insurer which covers 
approximately 50% of the Iranian population (~40 million). We performed data-mining 
algorithms using R software. After validating the data-mining using patient dossiers in 
the Cancer Research Center, we identified 1,295 patients and divided them into the 
three main HER2-positive breast cancer stages (early, loco-regional and advanced). The 
number of women totaled 802 (early), 125 loco-regional and 218 (advanced). Average 
costs of direct medical care in early, loco-regional and advanced stages were €11,796 
(95%CI: €9,356-€12,498), €8,253 (95%CI: €6,843-€10,002) and €17,742 (95%CI: 
€15,720-€19,505), respectively. The results of chapter four show that wherever 
comprehensive patient registries are infeasible or costly, real-world costs can be 
estimated through claims databases and data-mining strategies. 
To investigate an optimum duration of trastuzumab use in Iran, a cost-effectiveness 
analysis was performed from the Iranian healthcare perspective in chapter five. We 
compared four treatment strategies comprising chemotherapy with different durations 
of trastuzumab use (no-trastuzumab, 6-month, 9-month, and one-year). A Markov 
model and probabilistic sensitivity analysis were used to estimate the costs and the 
effects of these strategies. The cost-effectiveness of these strategies at different 
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willingness-to-pay thresholds, and ages at the onset of treatment were examined. In 
contrast to the clinical guidelines in high-income countries, six months of trastuzumab 
may be the most cost-effective option to apply in Iran. As a result, this chapter showes 
that the lower absolute willingness-to-pay threshold and lower life expectancy 
compared to high-income countries are the two crucial parameters in cost-
effectiveness of interventions in MICs.  
Generalizing the results of cost-effectiveness analyses between countries is one of the 
solutions to overcome knowledge gaps in middle-income countries. However, the 
accuracy of their results is remaining uncertain when these countries have important 
differences in their economies and healthcare systems. To investigate accuracy of the 
results of a transferred cost-effectiveness analysis from high-income countries to a 
middle-income country, chapter six compared the results of five transferred cost-
effectiveness analyses with a previously published CEA in Iran. This chapter also 
identified bias factor(s) affected transferability from high-income countries to middle-
income countries, and finally it proposed a new method to estimate cost-effectiveness 
of a drug in middle-income countries. We systematically searched and selected model-
based CEAs in five high-income countries based on the same method with an original 
country-specific CEA in Iran. In this chapter, two methods were used to estimate 
incremental costs. In the conventional method, costs were corrected using consumer 
price indices and transferred to the Iranian setting using purchasing power parities. The 
proportional method involved estimating initial trastuzumab costs and combining them 
with the incremental downstream costs. Cost-effectiveness results using these methods 
were then compared with the results of an Iran-based CEA. The transferred incremental 
costs of the conventional method (€21,419(USA); €5,115UK); €12,550(USA); 
€9,170(Portugal); €10,187(Belgium)) did not match the incremental costs of the Iranian 
CEA (€19,056). However, we could estimate closer incremental costs (€19,988(USA); 
€19,742(UK); €19,320(USA); €19,497(Portugal); €19,361(Belgium)) with the 
proportional method. The results of this study showed that when there is a major 
economic gap between countries and external price referencing has a major impact on 
pricing in middle-income countries, costs of expensive drugs should not be transferred 
using relative purchasing power parities. However, the proportional method might be 
a solution to estimate cost-effectiveness of a drug in a middle-income country. 
Part III: Recommendations to improve the drug reimbursement decision-making 
system in Iran 
To investigate the importance of price differentiation in enhancing drug affordability 
and provide recommendations to improve pricing systems in middle-income countries, 
chapter seven compares prices of trastuzumab for treatment of HER2-positive breast 
cancer across 14 high-income countries and five in middle-income countries. We 
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estimated the budget impact of trastuzumab on total health expenditure. Two 
scenarios were used to reflect relative affordability of trastuzumab: one where prices 
were estimated using purchasing power parity conversion rates and one where 
assumptive prices were calculated using purchasing power parity conversion rates (with 
the US trastuzumab price as an external reference price). The relative budget impact of 
trastuzumab on total health expenditure was two times higher in middle-income 
countries compared to high-income countries. It means that trastuzumab was three 
times less affordable in middle-income countries compared to high-income countries. 
Therefore, current pricing systems do not facilitate access to expensive drugs in middle-
income countries. Equal affordability across countries can be improved by using price 
differentiation.  
Chapter eight examines the pharmaceutical pricing and reimbursement in Iran as a 
middle-income country to identify prerequisites for the implementation of 
performance-based and finance-based risk-sharing arrangements. As the previous 
chapter showed performance-based and finance-based risk-sharing arrangements 
facilitate implementation of price differentiation in different countries. Therefore, 
performing a SWOT (strengths, weaknesses, opportunities and threats) analysis, we 
compared the current Iranian pharmaceutical pricing and reimbursement decision-
making system with the performance-based and finance-based risk-sharing 
arrangements governance and infrastructures in six reference countries (England, 
Germany, Hungary, Italy, Poland and Turkey) that have implemented PFRSA policies. 
The results of SWOT analysis showed main weaknesses points of the Iranian system 
including distributed responsibilities, conflicts of interest, a lack of post-decision market 
monitoring, and time-consuming procedures. To improve performance of the current 
process, improvement in two areas of reorganization of the Iranian healthcare 
governance and improving infrastructure and process would be instrumental in Iran. In 
conclusion, a cyclic and dynamic pricing and reimbursement process should be used to 
improve the current process. Iran can start improving the system by implementing 
finance-based arrangements and concurrently provide necessary infrastructure 
(including post-decision market monitoring and real-world evidence) for 
implementation of performance-based schemes. 
Discussion 
Chapter nine, the general discussion, discusses the key findings of this thesis based on 
the results of different chapters. Previous chapters showed that the drug 
reimbursement and pricing decision-making is a complicated process. Improvement in 
knowledge production infrastructure and health governance are two main and 
important necessities in Iran. Iranian policymakers should be able to applying the 
various techniques already mentioned in different chapters of this thesis to achieve all 
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three overall goals for drug reimbursement decision-making. This thesis also 
recommends some key points that must be implemented in Iran including development 
a country-specific guideline for economic evaluations, development a good governance 
standard for drug reimbursement decision-making, development an independent 
pricing system, implementation of risk sharing arrangements, implementation of 
pharmaceutical pricing based on a max-age threshold, Improvement of post-marketing 
observations, and correcting former decisions. All changes must be targeted toward 
improving the ability to achieve the best decision through the accomplishment of the 
three goals of quality of care, population health, and affordability simultaneously. 
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Introductie 
De besluitvorming rondom geneesmiddelvergoeding is een belangrijk proces in 
elk zorgsysteem om betaalbare zorg voor patiënten te verzekeren. De 
vergoedingsbeslissing kan als goed worden bestempeld als het 
achtereenvolgend de volgende doelen nastreeft; kwaliteit van zorg, 
gezondheid van de samenleving, en betaalbaarheid van zorg. Om verbetering 
op deze drie punten te bereiken moet er voldoende kennis beschikbaar zijn en 
goed zorgbeleid uitgevoerd worden. Doordat midden-inkomenslanden een 
minder sterk zorgbeleid en een minder sterke infrastructuur hebben om deze 
kennis te vergaren ondervinden zij meer problematiek in het verbeteren van de 
drie punten. Deze thesis is opgezet om de mogelijkheden tot verbetering van 
het besluitvormingsproces rondom geneesmiddelenvergoedingen in midden-
inkomenslanden te onderzoeken. Het onderzoek is gedaan op basis van het 
besluitvormingsproces in Iran aan de hand van het geneesmiddel trastuzumab 
(Herceptin), een monoklonaal antilichaam dat veel gebruikt wordt bij de 
behandeling van borstkanker patiënten die een verhoogde aanwezigheid 
hebben van het humane epidermale groeifactor receptor type 2 (HER2 positief). 
Trastuzumab is een duur geneesmiddel, waarover vraagtekens bestaan over de 
hoogte van vergoeding sinds zijn intrede in de farmaceutische markt.  
Onderzoek naar de mogelijkheden tot verbeteren van het vergoedingsproces in 
midden-inkomenslanden (met focus op Iran) staat centraal in deze thesis. De 
thesis bestaat uit drie delen. In het eerste deel staat de huidige situatie rondom 
het Iraanse geneesmiddelvergoedingssysteem en zijn gevolgen centraal. Het 
tweede deel biedt verschillende oplossingen tot het verbeteren  van de  Iraanse 
kennis met betrekking tot gezondheidseconomie. Het derde en laatste deel 
doet verschillende aanbevelingen ter verbetering van het vergoedingssysteem 
in Iran.  
Deel I: Het huidige besluitvormingsproces rondom geneesmiddelvergoeding 
in Iran 
In hoofdstuk 2 ligt de nadruk op het huidige besluitvormingsproces rondom 
geneesmiddelvergoeding in Iran. Het gehele proces en alle betrokken partijen 
worden toegelicht in dit hoofdstuk. Om deze informatie in kaart te brengen zijn 
alle documenten die het huidige beleid beschrijven onderzocht. Daarnaast is er 
gebruik gemaakt van openbaar beschikbare statistieken en zijn er experts en 
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relevante beleidsmakers geïnterviewd. De Iraanse ‘Food and Drug 
Organization’ en de ‘Supreme Council of Health Insurance’ zijn de 
kernorganisaties in dit besluitvormingsproces, maar het Iraanse kabinet neemt 
uiteindelijk de beslissing of een geneesmiddel wordt goedgekeurd en dus wordt 
vergoed door de zorgverzekeraars. Ondanks dat het Iraanse systeem sterke 
kanten bevat, ondervindt het ook verscheidene problemen. Tekortkomingen 
van het systeem bestaan onder andere uit out-of-pocket-kosten voor patiënten 
(kosten gemaakt door patiënten zelf). Dit wordt  veroorzaakt door een 
vertraagde besluitvorming, gebrek aan transparantie en door tegenstrijdige 
belangen van de belanghebbenden.  
Om inzicht te krijgen in de dagelijkse praktijk van het behandelen van HER2-
positieve borstkanker patiënten in Iran, beschrijft hoofdstuk 3 de huidige 
praktijk in Iran en in hoeverre deze overeenkomt met de nationale 
behandelrichtlijnen van het Ministerie van Gezondheid. De Iraanse nationale 
richtlijnen adviseren een negen-weken trastuzumab regime aan, terwijl de 
richtlijnen van de meeste andere landen een 52-weken regime hanteren. Om 
de naleving van de Iraanse richtlijnen door Iraanse oncologen te onderzoeken 
is er een online-enquête ontwikkeld en gestuurd naar 128 oncologen. Zij zijn 
gevraagd naar hun aanpak in de behandeling van HER2-positieve borstkanker 
patiënten. De uitkomsten van deze enquête zijn vergeleken met data over een 
periode van 3 jaar afkomstig uit de retrospectieve claim database van de Social 
Security Organization, een Iraanse zorgverzekeraar die ongeveer 50% van de 
bevolking dekt. Slechts een klein deel van de Iraanse artsen (6%) rapporteerde 
absolute naleving van de richtlijnen omtrent de duur van trastuzumab-
behandeling. Deze uitkomst komt overeen met wat werd gevonden in de 
analyse van de claim database van 1295 HER2-positive borstkanker patiënten. 
Daaruit blijkt dat Iraanse oncologen zich meer berusten op de medische 
literatuur, dan op de nationale richtlijn wat betreft het gebruik van trastuzumab 
bij deze groep patiënten.  
Deel II: Ontwikkeling van farmaco-economische data in Iran 
Hoofdstuk 4 bekijkt  hoe het gebruik van de claims database en datamining het 
besluitvormingsproces omtrent  geneesmiddelenvergoeding in midden-
inkomenslanden kan ondersteunen, door middel van het verkrijgen  van meer 
kennis rondom de zorgkosten in de klinische praktijk. Een retrospectieve 
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analyse is uitgevoerd op basis de claims database van de Iraanse Social Security 
Organization (dekking 50% van de Iraanse bevolking; ~40 miljoen inwoners). 
Datamining algoritmes zijn uitgevoerd in R software. Patiëntendossiers van het 
Kanker Onderzoek Centrum (Cancer Research Center) zijn gebruikt om de 
datamining te valideren, resulterend in de identificatie van in totaal 1295 
patiënten. Deze patiënten hebben allen HER2-positieve borstkanker en zijn 
ingedeeld naar de volgende stadia, vroeg stadium (802 vrouwen), locoregionaal 
stadium (125 vrouwen) en geavanceerd stadium (218 vrouwen). De gemiddelde 
directe kosten in het vroege stadium, locoregionaal stadium en geavanceerd 
stadium zijn €11.796 (95% betrouwbaarheidsinterval (BI): €9.356-€12.498), 
€8.253 (95%BI: €6.843-€10.002) en €17.742 (95%BI: €15.720-€19.505), 
respectievelijk. De uitkomsten in dit hoofdstuk 4 laten zien dat in het geval dat 
het opzetten van patiëntenregistraties onmogelijk of te duur is, de kosten van 
de dagelijkse praktijk ook geschat kunnen worden op basis van claims 
databases en datamining. 
Om de optimale duur van trastuzumab gebruik in Iran te onderzoeken is er een 
kosteneffectiviteitsanalyse uitgevoerd vanuit het Iraanse zorgperspectief ( 
(hoofdstuk 5). Hierbij zijn vier behandelstrategieën onderzocht  en ingedeeld 
op basis van tijdsduur van trastuzumab behandeling , te weten geen 
trastuzumab, 6-maanden, 9-maanden, en 1-jaar trastuzumab. Een Markov-
model en een probabilistische sensitiviteitsanalyse werden toegepast om de 
kosten en effectiviteit van elk van de vier behandelstrategieën te schatten. Voor 
elk van deze  vier strategieën is de kosteneffectiviteit bepaald op basis van 
verschillende betalingsbereidheid grenzen (willingness-to-pay-thresholds), en 
de leeftijd van start van behandeling. In tegenstelling tot de behandelrichtlijnen 
in hoog-inkomenslanden, lijkt de  6-maanden trastuzumab behandeling de 
meeste kosteneffectieve optie te zijn in Iran. Dit hoofdstuk maakt inzichtelijk 
dat de lagere betalingsbereidheid grens en de lagere levensverwachting in 
midden-inkomenslanden cruciale factoren kunnen zijn in het bepalen van de 
kosteneffectiviteit van medische behandelingen.  
Het tekort aan kennis in midden-inkomenslanden kan overkomen worden door 
het generaliseren van resultaten van kosteneffectiviteitsanalyses tussen 
landen. Echter, verschillen in economie en zorgsystemen tussen landen maken 
dat het overdragen van deze resultaten mogelijk onbetrouwbaar en 
onnauwkeurig is. Hoofstuk 6 verdiept zich in het generaliseren van resultaten 
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van kosteneffectiviteitsanalyses van hoog-inkomenslanden door midden-
inkomenslanden. De resultaten van vijf gepubliceerde 
kosteneffectiviteitsanalyses zijn vergeleken met een eerder gepubliceerde 
Iraanse kosteneffectiviteitsanalyse. Daarnaast staan in dit hoofdstuk factoren 
die mogelijk een effect hebben op de overdraagbaarheid van de resultaten 
tussen de hoog- en midden-inkomenslanden, en presenteert het een nieuwe 
methode om de kosteneffectiviteit van een medicijn te bepalen in een midden-
inkomensland. Na een systematisch onderzoek zijn vijf modelgebaseerde 
kosteneffectiviteitsstudies uit hoog-inkomenslanden, die een eenzelfde 
methode toepasten, en een originele Iraanse kosteneffectiviteitsanalyse 
geselecteerd. Er zijn twee methoden gebruikt om de incrementele kosten te 
bepalen. In de gangbare methode zijn de kosten gecorrigeerd op basis van de 
consumentenprijsindex en vertaald naar de Iraanse situatie aan de hand van 
Iraanse koopkrachtpariteitsindices. In de proportionele methode zijn de initieel 
geschatte trastuzumab kosten gebruikt en gecombineerd met incrementele 
downstream kosten. De resultaten van deze twee methoden zijn vergeleken 
met de resultaten van de originele Iraanse kosteneffectiviteitsanalyse. De naar 
Iran-gecorrigeerde incrementele kosten op basis van de traditionele methode 
(€21.419 (Verenigde Staten, eerste studie); €5.115 (Verenigd Koninkrijk); 
€12.550 (Verenigde Staten, tweede studie); €9.170 (Portugal); €10.187 (België)) 
komen niet overeen met de incrementele kosten van de Iraanse 
kosteneffectiviteitsanalyse. Echter, de proportionele methode schatte de 
incrementele kosten nauwkeuriger (€19.988 (Verenigde Staten, studie 1); 
€19.742 (Verenigd Koninkrijk); €19.320 (Verenigde Staten, studie 2); €19.497 
(Portugal); €19.361 (België)). De resultaten van dit onderzoek laten zien dat in 
het geval dat er  grote economische verschillen zijn tussen landen, en in het 
geval dat externe prijsreferenties een grote rol spelen in midden-
inkomenslanden, de kosten van dure geneesmiddelen niet overgedragen 
kunnen worden op basis van de relatieve koopkrachtpariteiten. De 
proportionele methode biedt dan een uitkomst in het schatten van 
kosteneffectiviteit van een medicijn in midden-inkomenslanden. 
Deel III: Aanbevelingen voor het verbeteren van medicijnvergoeding 
besluitvorming in Iran 
Om het belang van prijsdifferentiatie in het verbeteren van de betaalbaarheid 
van medicijnen te onderzoeken  wordenin hoofdstuk 7 de prijzen van 
Samenvatting| 183 
 
trastuzumab in de toepassing bij HER2-positieve borstkanker patiënten 
vergeleken tussen  veertien hoog-inkomenslanden en vijf midden-
inkomenslanden. Tevens worden aanbevelingen gedaan tot  het verbeteren van 
de prijssystemen in midden-inkomenslanden en is de budget impact van 
trastuzumab op de totale zorgkosten geschat. Twee scenario’s zijn toegepast 
om de relatieve betaalbaarheid van trastuzumab te evalueren. In het eerste 
scenario zijn prijzen geschat op basis van koopkrachtpariteiten wisselkoersen. 
In het tweede scenario zijn de prijzen berekend op basis van 
koopkrachtpariteiten wisselkoersen, waarbij  de prijs van trastuzumab in de 
Verenigde Staten als referentieprijs diende. De relatieve budgetimpact van 
trastuzumab ten opzichte van de totale zorgkosten is twee keer groter in 
midden-inkomenslanden vergeleken met hoog-inkomenslanden. Dat betekent 
dat trastuzumab drie keer minder betaalbaar is in midden-inkomenslanden 
vergeleken met hoog-inkomenslanden. De huidige prijssystemen dragen 
daarom niet bij aan het toegankelijk maken van dure medicijnen in midden-
inkomenslanden. Gelijke betaalbaarheid tussen landen kan worden verbeterd 
aan de hand van prijsdifferentiatie.  
Hoofdstuk 8 onderzoekt het prijs- en vergoedingssysteem van Iran als midden-
inkomensland om de voorwaarden van het implementeren van prestatie-
gebaseerde en financieel-gebaseerde risicodeling (‘risk-sharing’) (PFRSA) 
regelingen. Het voorgaande hoofdstuk maakte inzichtelijk hoe deze prestatie-
gebaseerde en financieel-gebaseerde regelingen kunnen bijdragen aan de 
implementatie van prijsdifferentiatie in verschillende landen. Aan de hand van 
een SWOT-analyse (sterktes, zwaktes, kansen, en bedreigingen) is er een 
vergelijking gemaakt tussen het huidige Iraanse medicijnprijs- en 
vergoedingsbesluitsysteem en de prestatie-gebaseerde en financieel-
gebaseerde regelingen, beleid en infrastructuren van zes referentie landen met 
een PFRSA beleid, te weten Engeland, Duitsland, Hongarije, Italië, Polen en 
Turkije. Uit de SWOT analyses bleek dat verdeelde verantwoordelijkheden, 
tegenstrijdige belangen, een gebrekkig post-market monitorbeleid, en het 
tijdrovende proces de zwakke punten in het Iraanse systeem zijn. Om het 
huidige systeem te verbeteren, is een reorganisatie op twee terreinen van het 
Iraanse zorgbeleid, alsmede het verbeteren van de infrastructuur en van het 
proces, noodzakelijk. Concluderend wordt een cyclisch- en dynamisch prijs- en 
vergoedingsproces aangeraden om het huidige systeem te verbeteren. Deze 
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verbeteringen kunnen in gang gezet worden door het implementeren van 
financieel-gebaseerde regelingen en het opzetten van een juiste infrastructuur 
(inclusief post-market monitoren en het gebruiken van ‘real-world evidence’) 
voor het implementeren van prestatie-gebaseerde regelingen.  
Discussie 
Hoofdstuk 9 bespreekt de hoofdbevindingen van deze thesis op basis van de 
bevindingen van elk hoofdstuk. Voorgaande hoofdstukken concludeerden al 
dat het prijs- en vergoedingsproces met betrekking toelating van 
geneesmiddelen gecompliceerd is. Het verbeteren van de kennis infrastructuur 
en het zorgbeleid zijn de twee noodzakelijkheden in Iran. Iraanse beleidmakers 
moeten in staat zijn de verschillende technieken, besproken in deze thesis, toe 
te passen om de drie doelen voor een goed werkend systeem te behalen. Deze 
thesis biedt ook kernaanbevelingen voor Iran, waaronder het ontwikkelen van 
land-specifieke richtlijnen voor economische evaluaties, het ontwikkelen van 
beleidstandaarden voor besluitvorming omtrent het vergoeden van medicijnen, 
het ontwikkelen van een onafhankelijk prijssysteem, het implementeren van 
risicodeling regelingen, het verbeteren van post-market observaties, en het 
evalueren en aanpassen van eerdere beslissingen. Alle veranderingen moeten 
gericht zijn op het bereiken van de juiste vergoedingsbeslissingen door middel 
van het tegelijkertijd behalen van de drie doelen; kwaliteit van zorg, 
gezondheid van de samenleving, en betaalbaarheid van zorg. 
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